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ABSTRACT
Candida species are the fourth leading cause of nosocomial infection. The increased incidence of
drug-resistant Candida species has emphasized the need for new antifungal drugs. Histatin 5 is a
naturally occurring human salivary antifungal peptide and the first line of defense against
infections of the oral cavity. This research has focused on understanding the activity of histatin 5,
and subsequently designing novel peptides that may serve as models for the further development
of therapeutics to treat fungal infection. This objective has been achieved in three steps: studying
the structural requirement of histatin 5 involved in antifungal activity, the identification of a
short peptide sequence, referred to as KM motif, important for fungicidal activity, and finally,
the development of a novel antifungal peptide with potent activity. In the initial phase of this
work it was demonstrated that reversing the sequence of histatin 5 C-16 peptide to create a retro
peptide did not interfere with the fungicidal activity or secondary structure of the peptide. This
suggested that the spatial arrangement of amino acid residues was more relevant for fungicidal
activity than the actual peptide sequence. In the second phase of the work, we identified and
characterized a five amino acid sequence, termed the KM motif, within histatin 5 that maintained
fungicidal properties. Although this short peptide was less active than histatin 5, the data
suggested it was killing fungi via a mechanism similar to histatin 5. In the final phase, a novel
antimicrobial peptide, termed KM-12, was generated containing two KM motifs dimerized via
disulfide bonds. The activity of KM-12 on C. albicans was approximately fifteen times more
potent than the monomeric peptide and ten times more active than the native histatin 5. KM-12
was shown to have antifungal activity with several Candida species, including fluconazoleresistant species. In conclusion, KM-12 is promising antifungal peptide that will serve as a lead
candidate for the development of antifungals peptide for pharmaceutical applications.

ACKNOWLEDGMENTS
The achievement and final outcome of this project required a lot of guidance and assistance from
many people and in so different ways, and I am extremely fortunate that to have got this all along
the completion of my project work. Whatever I have done is only due to such guidance and
assistance, and I would not forget to thank them.
I owe a debt of gratitude to many people for the following pages. Above all I must thank my
advisors, the inimitable Dr. David McNabb and Dr. Suresh Kumar. Without their invaluable
guidance none of this tremendously hard work would be achieved.
Also, my deep gratitude and extended thanks go to Dr. Douglas Rhoads, who is the reason of
why I am here. I am profoundly grateful to him for his unfailing encouragement and many hours
of help.
Also at the University of Arkansas, my sincerest thanks go to Dr. Ralph Henry, Dr. Gisela Erf,
and Dr. Roger Koeppe who serve as my committee members and who have made my time here
such an intellectual and personal delight.
My thanks go also to Dr. Ines Pinto who kept both me and my work throughout my years here
interesting, thoughtful, and productive.
In addition, I would like to send my true thanks to the members of Dr.Koeppe lab, especially Dr.
Denise Greathouse for their time and guidance in peptide synthesis.
For their support and friendship, my unending thanks go to all members of Dr.McNabb and
Dr.Pinto Labs, especially Marsha Rhoads.

DEDICATION
I dedicate this dissertation to my family, especially my wife who has been fathering my three
riotous kids along five years. Their constant love, support, and encouragement have sustained me
throughout my career and life.

TABLE OF CONTENTS
ABSTRACT.......................................................................................................................ii
ACKNOWLEDGMENTS.................................................................................................iii
DEDICATION..................................................................................................................vi
TABLE OF CONTENTS ..................................................................................................v
CHAPTER 1. Introduction and literature review. ............................................................ 1
1.1 Candida Species ................................................................................................... 2
1.1.1 Candida albicans ................................................................................................. 2
1.1.2 Epidemiology and risk factors .............................................................................. 4
1.1.3 Candida and Human immunity ............................................................................. 5
1.1.4 Treatment of fungal infections .............................................................................. 6
1.1.4.1 Azoles ............................................................................................. 6
1.1.4.2 Polyenes ........................................................................................ 9
1.1.4.3 Echinocandins ............................................................................... 10
1.1.4.4 Antimetabolites ............................................................................. 11
1.2 Antifungal peptides (AFPs) ................................................................................ 12
1.2.1 Classification........................................................................................................ 13
1.2.1.1 Cationic ........................................................................................ 13
1.2.1.2 Anionic ......................................................................................... 20
1.2.1.3 Neutral ......................................................................................... 22
1.2.2 Post-translation modification in natural AFPs ..................................................... 23
1.2.3 Disadvantages of AFPs and proposed solutions ................................................. 26
1.3 Histatins .............................................................................................................. 29
1.3.1 Histatin 5 .............................................................................................................. 30
1.3.1.1 Unique features ............................................................................ 31
1.3.1.2 Antimicrobial activities ................................................................ 31
1.3.1.3 Secondary structure ...................................................................... 32
1.3.1.4 Amphipathicity and hydrophobicity ............................................ 32
1.3.1.5 Charge .......................................................................................... 33
1.3.1.6 Amino acids composition ............................................................. 33
1.3.1.7 Structure function relationship ..................................................... 34
1.3.1.8 Structural modifications ............................................................... 35
1.3.1.9 Mechanism of action .................................................................... 37
Figures .......................................................................................................................... 39
Tables ............................................................................................................................ 43
References ..................................................................................................................... 49
CHAPTER 2. Analysis of Wild-type ,enantio, retro and retroenantio derivatives of Histatin 5
16mer …….. ................................................................................................................. 77
2.1 Introduction ............................................................................................................ 78
2.2 Materials and Methods ........................................................................................... 81

2.3 Results .................................................................................................................... 86
2.4 Discussion .............................................................................................................. 93
2.5 Conclusions ............................................................................................................ 102
2.6 Tables ..................................................................................................................... 103
2.7 Figures .................................................................................................................... 107
2.8 References .............................................................................................................. 125
CHAPTER 3. Identification of a small domain within histatin 5 essential for fungicidal activity
........................................................................................................................................... 135
3.1 Introduction ............................................................................................................. 136
3.2 Materials and Methods ............................................................................................ 139
3.3 Results ..................................................................................................................... 142
3.4 Discussion ............................................................................................................... 148
3.5 Conclusions ............................................................................................................. 153
3.6 Tables ...................................................................................................................... 154
3.7 Figures..................................................................................................................... 158
3.8 References ............................................................................................................... 167
CHAPTER 4. The development and characterization of KM-12 as a potent antifungal peptide
........................................................................................................................................... 172
4.1 Introduction ............................................................................................................. 173
4.2 Materials and Methods ............................................................................................ 175
4.3 Results ..................................................................................................................... 183
4.4 Discussion ............................................................................................................... 192
4.5 Conclusions ............................................................................................................. 202
4.6 Tables ...................................................................................................................... 204
4.7 Figures..................................................................................................................... 208
4.8 References ............................................................................................................... 224
CHAPTER 5. Conclusions................................................................................................ 233
5.1 Conclusions ............................................................................................................. 233
5.2 References ............................................................................................................... 243

CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
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1.1-Candida species
The Candida genus represents a group of eukaryotic microorganisms belonging to the kingdom
of Fungi - phylum Ascomycota. The genus Candida contains about 150 species and
approximately 30 have been associated with human diseases 1, 2. Fungi differ from other
eukaryotes by the presence of a rigid cell wall and the presence of ergosterol instead of
cholesterol in the cell membrane 3. Normally, Candida species live in a commensalism
relationship with the host, including humans. However, this genus is also the most common
fungal pathogen of humans and the cause of several diseases including mucosal and bloodstream
infections 4. Vaginal candidiasis, for example, alone affects approximately 75 % of women
around the world

5, 6

. Furthermore, Candida infections can lead to significant mortality and

extended hospital treatment 7. In the United States, Candida species are the fourth leading cause
of nosocomial blood stream infection with up to 40% mortality 8. Candida infections are
dramatically increased in patients suffering from immunodeficiencies as several forms of
Candida can become invasive and cause systemic disease. For instance, research has shown
90% of HIV patients and 50% of AIDS patients had oral candidiasis. In terms of health care
costs, systemic Candida infections in the United States alone cost about 1.8 billion dollars and
that accounts for 70% of the costs of fungal infections 4. Candida species can be subdivided into
Candida albicans and non-albicans groups. The major non-albicans species include Candida
glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae,
Candida kefyr and Candida dubliniensis 9.
1.1.1 Candida albicans
Candida albicans is a dimorphic opportunistic fungal pathogen naturally found as a commensal
in the gastrointestinal tract and oral cavity, even though it is the most common isolated fungus in
2

clinical microbiology laboratories 2, 10, 11. Candida albicans has the ability to grow in two
distinct forms: budding yeast and hyphae. In vitro transitions between these two morphological
forms can be induced in response to several environmental factors such as pH, temperature, or
compounds such as N-acetylglucosamine or serum 12. Morphologically, Candida albicans can
be found in one of three forms: yeast, pseudohyphae and true hyphae. Yeast forms as rounded
cells and the daughter cells separate from the mother cell via budding. Pseudohyphae consist of
a chain of cells, which have different degrees of elongation but still have a constriction between
adjacent cellular compartments. True hyphae are tube-like as the sides are parallel along the
entire length without any constriction 13, 14.
The virulence of Candida albicans has been shown to be associated with their ability to switch
between the yeast and hyphal morphologies 15. Several observations have supported the role of
hyphae in virulence: the C. albicans hyphal form is usually found at sites of infection 14, hyphae
and pseudohyphae have been shown to be important for tissue invasion 16, and finally other
Candida species that do not form true hyphae are much less frequently isolated from humans 17.
The suggested virulence mechanism is that hyphal cells express cell-wall proteins which may
facilitate the adhesion to the human tissues, as well as the escape from phagocytosis 18. So while
the hyphae and pseudohyphae forms can promote tissue penetration at the early stages of
infection, the yeast form might be more appropriate for spreading in the bloodstream 16, 19, 20.
As mentioned previously, Candida albicans is the fourth most common hospital acquired
infection in the United States, the treatment of which is estimated to cost more than $1 billion
annually in the United States4. Candida albicans represents one of the major causes of mucosal
infection and systemic infection. Furthermore, it causes a range of complications including
superficial infections such as vaginitis in healthy women, severe mucosal infection in mouth and
3

esophagus of HIV patients (chronic mucocutaneous candidiasis), and systematic infections
among post chemotherapy and organ or bone marrow transplant patients, such as myocarditis
and Candida septicemia 12, 16, 21.
1.1.2 Epidemiology and risk factors
The major risk factors for Candida infections have changed dramatically in last 20 years since it
was prominently associated with patients having malignancy or neutropenia 22 . Currently, the
risk factors have changed with the growing number of immunocompromised individuals. New
risk factors include the suppression of the immune response, uncontrolled use of broad-spectrum
antibiotics and the exposure to pathogens and Candida 9. The suppression of immunity is not
limited to HIV and patients with malignancies, it also includes premature infants, patients over
70 years of age, post-chemotherapy patients, post-transplantation patients or those on steroid
medication, renal failure patients, patients with malnutrition or with another severe disease23, 24.
The uncontrolled usage of broad antibiotics promotes fungal colonization and encourages
development of antibiotic resistance bacterial strains. For example, research has shown that
post-surgery patients that received multiple different antimicrobial therapies were 800 times
more susceptible to Candida derived wound infections than other patients 8. Exposure to
Candida can happen through direct contact with patients via sexual intercourse or being in the
hospital for a prolonged stay. Moreover, direct contact with body fluids is another way to expose
patients to Candida, such as the bloodstream during catheterization during surgery and
hemodialysis, peritoneal fluid during peritoneal dialysis and in the lung during mechanical
ventilation 20.
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1.1.3 Candida and human immunity
The human immune response is a combination of innate and adaptive immunity. Innate
immunity is the first to be activated 25. Skin and mucosal membranes are considered as the first
line of innate immunity by forming a physical barrier and prevent microorganisms from passing
through. After the yeast passed the first barrier it will be detected by germ line-encoded
receptors (pattern recognition receptors) that recognize conserved molecular patterns common in
microorganisms (pathogen-associated molecular patterns)26. This recognition will activate
phagocytosis and initiate the production of chemotactic factors. The involved phagocytic cells
vary depending on yeast type. For example, the primary effector cells during Candida albicans
infections are neutrophils while macrophages are the primary cells that respond to Cryptococcus
infection 27. Chemotactic factors play an important role in human immunity as they are the link
between innate and adaptive immunity. Moreover, they attract more leukocytes to the site of
infection and activate several biological procedures including antigen presentation, Th cell
differentiation, and production of defense peptides. Activation of the adaptive immunity means
the activation of B-cells, T-cells and the general inflammatory responses 28. Some yeast has
succeeded in escaping from the recognition and later from the host defense. For example,
Candida albicans not only escapes recognition, it also suppresses host immunity by inducing the
production of TLR2-mediated anti-inflammatory cytokine (IL-10).
Antimicrobial peptides (AMPs) play important roles in host immunity. These peptides are able
to attack the yeast cells and inactivate them by direct contact via several mechanisms of action 29.
Moreover, the AMP killing activity does not always associate with the specific activation of the
host immune response, since some AMPs are produced constantly under normal conditions. For
example, the histatins , anti-fungal peptides produced by salivary glands, are constantly secreted
5

in human saliva at an average level of 3.33 microgram/ml, despite the absence of fungal
infection 30. Antimicrobial peptides also play an important role in activation and mediation of
adaptive immunity in response to inflammation 31. Their roles can be summarized as being
chemotactic for leukocytes and T-cells, and they activate the production of several immune
factors such as interleukin-1, Interferon-gamma and tumor necrosis factors 32.
1.1.4 Treatment of fungal infections
1.1.4.1 Azoles
The azole type of anti-fungal agents has been used to treat various fungal infections for more
than 30 years. The azoles can be divided into two groups, the imidazoles and the triazoles.
Imidazoles (i.e. miconazole and ketoconazole) have a two-nitrogen azole ring, while triazoles
(i.e. fluconazole, itraconazole, voriconazole and posaconazole) have 3 nitrogen azole rings. Both
the triazoles and imidazoles share a common mechanism of action. Imidazoles are mostly used
as topical agents to treat fungal infections and they have been essentially replaced by the
triazoles for systemic infection due to their pharmacokinetics and safety issues 33. Azoles inhibit
the cytochrome P450 enzyme-dependent 14-α-sterol-demethylase which is required for the
conversion of lanosterol to ergosterol. Thus, ergosterol is depleted and the sterol intermediate
(14α-methyl-3,6-diol) accumulates within the cell membrane, that leads to growth arrest 34.
Azoles are in general considered fungistatic; however, there have been some exceptions reported
with itraconazole and voriconazole, that have shown some fungicidal activity against Aspergillus
spp 35.
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Different azole compounds have different affinities for the 14-α-sterol-demethylase;
consequently, they have various antifungal activities, side effects and drug-drug interactions.
Imidazoles have a low affinity to the demethylase enzyme and as a result, a higher dosage is
required. Due to toxicity problems, imidazoles has been restricted to topical applications such
as creams, lotions, shampoos, vaginal suppositories, lozenges, and solutions for epidermal
candidiasis. In contrast, the triazoles can be found in several formulations that can be
administrated topically, orally and intravenously.
Several side-effects have been reported with azoles including events as simple as skin dryness
associated with fluconazole to as serious as hepatic failure with itraconazole 34, 36. Liver toxicity
is the main adverse reaction associated with all azoles 37. Azoles have several significant drug
interactions in humans due to the inhibition of liver oxidative metabolism via the binding to
cytochrome P450 enzymes. The inhibition of these enzymes interferes with liver metabolism,
and subsequently increases drug concentrations in blood resulting in drug toxicity. Azole
treatment can increase the overall blood levels of cyclosporine, calcium channel blockers and
warfarin 34, 38 due to negative drug interactions when taken together. Nevertheless, the azoles
remain the safest available anti-fungal agent. Aqueous solubility has been a significant barrier to
the development of new azole-based drugs and the lack of solubility has limited their systematic
use outside of a hospital environment.
The extensive use of azoles has resulted in an appearance of drug resistant Candida strains and
their incidence has increased dramatically since last decade 40-43. Moreover, a report has shown
AIDS patients may harbor azole resistant Candida in their oral cavities 40. However , the rate of
azole resistance among the most common Candida species remain low with the exception of C.
glabrata 44.
7

Four different mechanisms of azole resistance have been described in Candida spp. The first
mechanism decreases the azole concentration near the target enzyme via efflux pumps. Two
gene families that encoded efflux pumps have been defined, Candida drug resistance gene
(CDR), which encodes an ATP-binding cassette (ABC)-type transporter, and multi-drug
resistance gene (MDR),which encodes a major facilitator transporter 45. These genes have been
identified in different Candida spp.: C.albicans (MDR1, CDR1, CDR2) 45, 46, C.
glabrata (CDR1, CDR2)47, 48, and C. dubliniensis ( MDR1 , CDR1)49. The induction of the CDR
genes generates resistance to all azole drugs, while the MDR genes are selective for fluconazole
43

.

The second mechanism of resistance involves the alteration of the target enzyme. It has been
shown that mutations in ERG11, the gene encoding for the target enzyme (C14α-demethylase) ,
reduces or halts the azole-binding capability of the enzyme50. Furthermore, the mutations can
range from a single point mutation 51 to multiple mutation within the same gene 41, 52.
The third mechanism involves the overexpression of azole target enzyme. Increasing the
concentration of the target enzyme means more drugs are needed and the common therapeutic
concentration is no longer effective 41. The fourth mechanism of azole resistance in Candida
species involves the development of bypass pathways 43 . The alternative pathway prevents the
accumulation of steroid intermediates via replacing the ergosterol with a latter product. This
replacement keeps the membrane functionality and negates the action of azole on the ergosterol
biosynthesis pathway. Mutations in the ERG3 gene, an example of this class, avoids the
formation of 14α-methyl-3,6-diol from 14α-methylfecosterol 53. Finally, more than one
mechanism of resistance can be occurred within one strain and their effect will be additive.
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1.1.4.2 Polyenes
Polyenes are a group of antifungal drugs originally derived from Streptomyces species and they
have been widely used to treat systemic and oral fungal infections 54. Some examples of the
polyene drug family include amphotericin B (AmB), nystatin and natamycin. They are
macrocyclic molecules with multiple conjugated double bonds, in which a heavily hydroxylated
region of the ring is facing the conjugated system 55.
The mechanism of action for this class of drugs begins with the hydrophobic moiety binding to
ergosterol within the fungal cell membrane and producing an aggregate. This subsequently leads
to pore formation in cell membrane and leakage of vital cytoplasmic components, such as K+,
and ultimately inducing cell death

56

. Molecular modeling studies have suggested that AmB

creates aqueous pores consisting of eight molecules linked hydrophobically to ergosterol
embedded in yeast membrane phospholipids 57. In addition, AmB causes a direct membrane
damage in Candida albicans by the generation of oxidative reactions 58.
AmB is fungicidal against the majority of Candida species 59. Though AmB is the most
effective antifungal drug available, its narrow therapeutic index continues to limit its clinical
utility. AmB has the ability to bind cholesterol of mammalian cell membranes, which is
responsible for a major aspect of human toxicity60; however , studies have shown that AmB
exhibits a greater affinity for ergosterol-containing membranes versus cholesterol-containing
membranes60. Renal failure and nephrotoxicity are common toxic consequences of AmB
treatment, as several studies have reported the rate of acute renal failure in patients on AmB
range from 49% and 65% 61. To overcome the toxicity, several AmB formulations have been
evaluated and the best formulation was found to be AmB in liposomes as it permits higher doses
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with the lowest rate of nephrotoxicity 62. Currently, the lipid formulations have been used as
second-line of therapy since the liposome formulations cannot completely solve the mammalian
cell toxicity and the liposome formulations are considerably more expensive than other antifungal drugs 63.
Although polyene resistance has not been a major clinical problem to date, multiple cases have
been reported in Candida species, including C.albicans64, C. krusei65, C. lusitaniae66, C.
glabrata67 and C. tropicalis68. The exact mechanism of resistance is not clear but most of the
resistant strains shares a common feature, their ergosterol content was low compared to
susceptible strains 41. Proposed mechanisms of polyene resistance include alterations in
membrane ergosterol content via the accumulation of other sterols, alterations in the sterol to
phospholipid ratio or changing the ergosterol structure by reorienting or masking69. It is worth
mentioning that cross-resistance to azole and polyene classes of drugs have been reported in
Candida species 70. Furthermore, the efflux pump mechanism that functions with azole
compounds has not been identified, so far, in polyene resistance strains 71, 72.
1.1.4.3 Echinocandins
Echinocandins are the most recently discovered class of antifungal drugs that has been
introduced for clinical use. There are now three echinocandins approved for clinical use:
caspofungin, micafungin, and anidulafungin 73. Echinocandins are derived from semisynthetic
modifications of fungal lipoproteins: caspofungin from pneumocandin B0 from Glarea
lozoyensis74, micafungin from FR901370 (hexapeptide) from Coleophoma empedra75, and
anidulafungin from echinocandin B0 from A. nidulans76. Moreover, they are cyclic
hexapeptides N-linked to long acyl lipid side chains with a molecular weight of approximately

10

1,200 77. The enchinocandins have a unique mode of action in which they act as noncompetitive
inhibitors of the enzyme 1, 3-β- and 1, 6-β-D-glucan synthase. 1,3-β-D-glucan is an essential
carbohydrate component of all fungal cell walls which covers 30%–60% of the fungal cell wall
in Candida species. Inhibition of enzymatic activity leads to changes in the cell wall
components that result in osmotic instability and cell lysis 77. Compared to other antifungal
drugs, the echinocandins possess low human toxicities due to the fact that human cells lacks 1,3β-D-glucan78. The most common side-effects are urticarial, pruritus and elevation in
transaminase levels 79.
Echinocandins are fungicidal against a wide range of species and they are effective against
biofilms 80. In some cases, echinocandins are fungistatic. For example, caspofungin is
considered fungistatic against Aspergillus whereby they block hyphal tip growth 80. Since the
glucan composition varies between yeast species the echinocandins activity against these species
will vary. These agents are not recommended as the first line of treatment for fungal infections
76, 80

. Echinocandin resistance has been identified in C. albicans81, C. krusi 82, C. glabrata 83, C.

lusitaniae 84 and C. parapsilosis 85. The echinocandins resistance is mediated by point
mutations of FKS1 gene encoding a component of the β-1,3-D-glucan synthase complex 86 .
1.1.4.4 Antimetabolites
Flucytosine (5-FC), also known as 5-fluorocytosine, is a fluorinated analog of cytosine and one
of the oldest antifungal agents. Furthermore, it is the only antifungal agent that functions as an
antimetabolite. Flucytosine is considered a fungistatic agent and its activity comes from the
rapid conversion of 5-FC to 5-Fluorouracil (5-FU); therefore, 5-FC by itself has no antifungal
activity. 5-FC gets into the cell via a cytosine permease, which are also transports cytosine,
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hypoxanthine and adenine. Inside the fungal cell, 5-FC undergoes a deamination process via
cytosine deaminase to generate 5-FU 87.
There are two potential pathways for 5-FU fungistatic activity 88. The first pathway is 5-FU
undergoes further metabolism by uridine monophosphate pyrophosphorylase to generate 5fluorodeoxyuridine monophosphate (FdUMP). Then, FdUMP, an inhibitor to thymidylate
synthetase, halts thymidine biosynthesis, and accordingly DNA synthesis. The second pathway
starts with the transformation of 5-FU into 5-fluorouridine triphosphate (FUTP), then FUTP
replaces uracil in fungal RNA and later inhibits protein synthesis. 5-FC is highly selective
against fungi because mammalian cells lack the cytosine deaminase. Due to a high rate of
resistance, the use of 5-FU as a monotherapy is restricted. The compound is typically used in
combination with other antifungal agents such as amphotericin B 59.
The mechanisms of resistance to 5-FC in Candida is mediated by enzymatic modifications that
either impair 5-FC cellular uptake via a mutation in cytosine permease 89 or a defect in 5-FC
metabolism which can be achieved by mutations in the gene encoding either the cytosine
deaminase or uracil phosphoribosyl transferase 41, 90 .
1. 2 Antifungal peptides (APFs)
The major reservoir for generating new antimicrobial peptides (AMPs) is natural sources that
might be any living organism such as vertebrates, invertebrates, plants and bacteria 91. Besides
their roles in innate immunity, AMPs serve as promising candidates for new therapeutic
compounds. AMPs are attractive models because they possess unique features, such as broad
activity, rapid action, low microbial resistance and high selectivity. Thus, several synthetic and
semi-synthetic peptides have been synthesized for this purpose. Therapeutic peptides are
12

designed mainly after careful studies of the biophysical characteristics and structure-activity
relationship of naturally occurring AMPs 92.
The broad activity of AMPs makes it difficult to exclusively classify them as either antifungal or
antibacterial. There are relatively few examples where a peptide retains only antifungal or
antibacterial activities. In some cases, AMPs could be antibacterial; however, their antifungal
activities have not been tested yet, and Vice versa. This section will discuss antimicrobial
peptides that exhibit anti-fungal activities and they will be referred to as antifungal peptides
(AFPs).
1.2.1 Classification
The antimicrobial (AMPs) and antifungal peptides (AFPs) represent a diverse array of sequences
and there could be no perfect way to classify them. Several reviews have classified the AMPs
using different criteria: secondary structures 93, 94, source and the mechanism of action 94-96, cells
that produce the peptide 97, 98,99, post-translation modification 100 and the species (eukaryotic and
prokaryotic ) 101, 102. In general, there are around 700 AMPs with antifungal activity found in
the antimicrobial peptide database (http://aps.unmc.edu /AP/ main.php)103 . Peptide net charge is
an alternative way to categorize them. Consequently, the peptides could be divided into three
groups: anionic, neutral and cationic.
1.2.1.1 Cationic AFPs:
The vast majority of the AFPs are cationic and they display a positive net charge (Figure 1).
Cationic AFPs are gene-encoded peptides mainly derived from larger precursors via proteolytic
processing 104.
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1.2.1.1.1 Biophysical properties of cationic AFPs.
This section will discuss the main biophysical characteristics of AFPs in general and the cationic
peptides more specifically. The characteristics are: stereospecificity, conformation, charge,
amphipathicity, and hydrophobicity. It is important to note that some of these characteristics are
interdependent; therefore, modification of one character could lead to alterations in the other.
Stereospecificity. Stereospecificity means certain biological processes or chemical reactions are
specified for only one of several possible stereoisomers. Within peptides the focus is on
enantiomers or optical isomers. Generally, stereospecificity in binding processes is an essential
requirement for peptide or protein-target interaction and lacking this characteristic might suggest
a lack of overall specificity105. In AMPs, binding to the target microorganism is required to
achieve an activity; however, the majority of the AMPs are not stereospecific with some
exceptions 106. Several publications have shown that all-D-amino acid peptides demonstrated
similar antimicrobial activities as their all-L-enantiomers 107-110. As a subgroup of AMPs, AFPs
exhibited the same characteristic 107, 111 and multiple examples were published demonstrating the
stereoisomeric AFPs was equal in activity107, 111. For example, all-D variants of the histatin
peptide fragments (including P-113) are equally internalized and they exhibited the same
activity. Therefore, the involvement of a stereospecific receptor was excluded 112, 113 . However,
in some case the stereospecificity may interfere with the AFPs activity but at a lesser extent than
other AMPs. For example , the Bac7 peptide, a cathelicidin derived peptide, has shown a
stereospecific binding to C. neoformans membrane at concentrations near the MIC values;
however, this interaction became non-stereoselective at higher concentrations 114. The thanatin
peptide is another example of a stereospecific peptide, where the activity against Gram-positive
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bacteria was inhibited in all-D enantiomers, but the activity is retained against fungi just like Lthanatin 115.
Conformation. Similar to other AMPs, there is no dominant conformation within the AFPs; they
differ in sequence and secondary structure. The antifungal peptides could be defined according
to their conformation into four categories: α-helix, β-hairpen or sheet, mixed α- helix /β-sheet,
and amino acid rich peptides (Figure 2).
The α-helices are abundant within AFPs; however, they frequently exist as unstructured
conformers. These peptides become helical only upon interaction with an amphipathic membrane
such as a fungal plasma membrane 116. The β-sheet containing AFPs are less abundant than αhelix and this category is highly diverse at the level of primary structure but they share common
features, such as the amphipathic structure 117. While studying the peptides within the
antimicrobial database 118, it has been noted that AFPs with beta structure share a common
feature: they have at least 2 cysteine residues which is not always true within the broader group
of AMPs since beta structure peptides have been identified without a disulfide bridge 119-122 .
Most amino acid-rich AFPs could be further divided into one of the following groups: Gly-rich,
Pro-rich, Arg-rich, His-rich, and Trp-rich. According to the antimicrobial peptide database,
AFPs did not contain any Lys-rich peptides typically found in AMPs, such as the dermaseptin
family 123 and GLK-19 103. AFPs that are enriched in particular amino acids exhibited different
conformations and they can form unusual helices or sheets. For example, Tritrpticin, a
tryptophan-arginine rich peptide, has retained multiple structures upon binding to a micelle,
including a turn-turn and extended α-helix structure 124. Another example is SP-B, a proline-rich
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peptide that exhibited both antibacterial and antifungal activity. The secondary structure of this
peptide is composed of polyproline-II helices, unordered and turn motifs 125.
Charge. The positive charge is an essential requirement for AFP activity whereby an
electrostatic binding to the negatively charged membrane is initiated (Table 1). However,
increasing the positive charge does not always improve the antifungal activity, depending on the
peptide sequence and secondary structure 126. The increase in positive net charge has shown
different effects on the antifungal activity. For example, increasing the number of lysine
residues within dF17-6K (compare with dF21-10K) improved the antifungal activity 127. On the
other hand, increasing the charge within MtDef4 peptide from +6 to +7 had an inhibitory effect
on the activity against F. graminearum 128 . It has been demonstrated that increased peptide
positive net charge beyond a threshold might lead to a strong interaction with the negatively
charged membrane, resulting in an inhibition in peptide translocation into the cell 117. In some
peptides, the amount of the positive charge and the net charge was not as important as the
location of the cationic residue 126. Commonly, AFPs that exhibited positive charge achieve the
activity via pore formation; however, some exceptions have been observed 129. The remaining
AFPs are neutral or anionic and they will be discussed later in this chapter.
Amphipathicity. Most of the AMPs as well as the AFPs form amphipathic structures upon
interaction with target membranes. Amphipathicity is defined as the ability of a molecule to
adopt a shape or structure in which clusters of hydrophobic and hydrophilic amino acids are
spatially organized in discrete sectors 93. Amphipathicity for a peptide is usually determined by
the mean hydrophobicity (H) and the hydrophobic moment (µH) 117. Mean hydrophobicity for a
peptide is calculated by summing the hydropathy values of all the amino acids then dividing it by
the number of residues. The hydropathy value for each amino acid has been determined and
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tallied into different scales. The most common scales are the Kyte-Doolitle130 and the Eisenberg
scales 131. The hydrophobic-moment (µH) is the hydrophobicity of a peptide measured for
different angles of rotation per residue132. Moreover, it is calculated for all angles of rotation
from 0 to 180 degrees 132, 133. Measuring the µH for a peptide assist in recognizing amphipathic
structures via determining when the residues on one side of the structure are more hydrophobic
than on the other 134. In general, increasing the hydrophobic moment leads to increased
antifungal activity via promoting membrane permeabilization. However, it has been reported
that high amphipathicity also leads to increased hemolytic activity. For the development of new
peptides, especially with membrane lytic mechanisms, it has been suggested to keep µH less than
for hemolytic peptides (µH less than 0.3) 92. Several examples demonstrated the importance and
the function of amphipathicity in antifungal activity. For instance, In P19(6/E) peptide research
has shown reduction of the amphipathicity by scrambling the sequence was enough to reduce the
antifungal activity against C. albicans and C. neoformans even though the amino acid
composition, charge, mean hydrophobicity and helix forming propensity in 50% TFE were kept
the same 135. On the contrary, reduction of the YLK peptide amphipathicity by utilizing helix
breaker residues enhanced the antifungal activity 92 .
Most of the α-helical peptides have amphipathic structures, yet it is not a requirement for the
antifungal activity. For example, kaxins are a class of antifungal peptides that do not exhibit an
amphipathic structure 127, 136. This class has displayed antifungal activity with minimum
hemolytic activity and that supported the correlation between peptide amphipathicity and
hemolysis

127

.

The amphipathicity isn’t restricted for α-helix peptides; β-structures could also be amphipathic.
Tachyplesin and polyphemusin are examples of amphipathic β-sheet 137 while Rhesus theta
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defensin-1 (RTD-1) peptide is an example of non-amphipathic β-sheet 138. In amino acid -rich
peptides, the amphipathic structure was also observed such as in histatin 5(His-rich) 139 and Pac525 (Trp-rich)140 . It is also important to mention that all proline-arginine rich peptides (AMP or
AFP) cannot form amphipathic structures, thus the proline abundance results in the formation of
polyproline helical type-II structures 141.
Hydrophobicity. Peptide hydrophobicity is defined as the percentage of hydrophobic residues
within a peptide length. The vast majority of antifungal peptides have hydrophobic values
ranging between 30-60% (Figure 3). Hydrophobicity is an essential requirement for peptide
membrane interactions as well as membrane permeabilization. Furthermore, the peptide
partitioning into the phospholipids layer is also controlled by peptide hydrophobicity. Increasing
peptide hydrophobicity might correlate with an increase in the activity, but it also has been
linked to increased hemolysis activity 117, 142. For example, increasing the hydrophobicity of the
D1 peptide, to generate a peptide termed D4, led to the induction of increased hemolytic activity
by approximately 286-fold. In the same example, the modification of the D1 peptide also
interfered with the fungicidal activity; however, the change was observed for the target
susceptibility rather than the peptide effectiveness. The D1 peptide was more active against
Zygomycota fungi while the D4 peptide was more active against Ascomycota fungi 117, 142.
Lipopeptides is a class of antifungal peptide where lipophilic moieties are attached to cationic
peptides. Although this class is very hydrophobic, they had a low hemolysis activity 143.
It should also be noted that hydrophobicity is not the only factor related to hemolysis, the
presence of tryptophan was also linked to the hemolytic activity. A study has shown that
replacing one asparagine residue with tryptophan in the NDGP peptide was enough to increase
the hemolytic activity approximately 24 fold 92. Further, it has been concluded that tryptophan18

tryptophan interactions and tryptophan-lipid interactions are responsible for the increase in
hemolytic activity of melittin-tryptophan analogs rather than the hydrophobicity 92. It has been
published that tryptophan has a strong ability to insert into membranes as well as to interfere
with lipid polymorphism 144. The hemolytic activity associated with tryptophan-containing
peptides has been inspected in multiple research studies and the results were varied. For
instance, the Pac-525 peptide is a tryptophan-rich peptide that exhibits low hemolysis activity 140.
1.2.1.1.2 -Mechanisms of cationic AFPs action
AFPs achieved fungicidal or fungistatic activity via multistep mechanisms. First, the peptide is
attracted to the negatively charged yeast membrane. The interaction with the membrane results
in secondary structure changes that induce the required conformation for the activity, a required
step for α-helical cationic peptides. The peptide then inserts into the cell membrane and
interferes with the phospholipid bilayer integrity via pore formation or disruption of the whole
membrane barrier. In some cases, the peptide is required to move into the cytoplasm and act on
internal cellular targets.
For simplicity, the mechanism of action of AFPs could be split into two categories: poreforming and non-pore forming mechanisms. In the pore forming mechanism, the peptide
primarily works at the plasma membrane and no internal targets are required to achieve the
activity. Furthermore, permeabilization and pore formation are the major cause of cell death.
This mechanism has been reviewed on several occasions 145-149, and several models have been
proposed to explain peptide action via this mechanism. In the first mechanism, peptides arrange
perpendicular to the membrane to form either a barrel-stave or toroidal channels. The second
model is achieved when peptides orient parallel to the surface of phospholipid bilayer and form
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an extensive layer or carpet 149. In the third mechanism, peptides aggregate in micelle-like
complexes with lipids and span the membrane; however, no particular orientation has been
observed146. In some cases, pore formation and membrane interruption are not enough to cause
cell death unless they are combined with another mechanism as the peptide-generated pore could
be the means by which the peptide reaches the cytoplasm. In some cases, the translocation
across the membrane is energy-dependent, requiring a transporter protein and ATP150 .
Several models have described the other mechanisms where the peptide target is actually inside
the cell. The most common intracellular targets are; the binding to DNA151 , the inhibition of
protein synthesis 152, the inhibition of ATPase activity and protein refolding153, the
depolarization of mitochondria and depletion of ATP 129, the formation of reactive oxygen
species and apoptosis154 and the depolymerization of the actin cytoskeleton 155.
1.2.1.2 Anionic AFPs
The first anionic AMPs were described in 1984 156 and after that several anionic peptides were
identified in both eukaryotes and prokaryotes 157, 158. It has been found that anionic AMPs might
play an important role in innate immunity 159. Out of 116 anionic peptides are described in the
peptide database, only 11 peptides have shown antifungal activity.
The biophysical properties of the anionic AFPs could be summarized as: the net charge ranges
from -1 to -8 at neutral pH, the size ranges from 11 to 90 amino acids, they exhibit an
amphipathic structure and the secondary structure varies between α-helix and β-sheet (Table 2).
This peptide category is more specialized than the cationic group and they displayed a narrow
spectrum of activity, thus the majority of the peptides in this category are active only against
fungi.
20

There is no definite antifungal mechanism for anionic peptides and almost every peptide has its
own mechanism. Nevertheless, all of them share a common step, binding to the target
membrane. In cationic peptides, the positive charge is essential for the initial interaction with the
negatively charged membranes. Moreover, the ionic attraction between the opposite charges also
plays a role in target selectivity. In contrast, the anionic peptides display a negative net charge
that could lead to repulsion with the negatively charged membrane. It was found that the overall
positive charge is not a prerequisite for the binding to the membrane and the key modulators of
lipid bilayers-peptide interaction is the charge distribution and the secondary structure 160.
Consequently, the anionic peptides might be able to interact with the membrane because their
basic amino acids are distributed in such a way as to give them the accessibility and limit the
repulsive effect of negatively charged residues. This model does not fit all anionic peptides since
some of these peptides do not have a single basic amino acid, such as Tn-AFP and EP-20 (Table
2). These peptides retain the capability of binding to the membrane and this binding is critical
for the activity 159,161. The other explanation is that the anionic peptides form cationic salt
bridges with membrane negative charges via metal ion cofactors 158, 159, 161.
Various mechanisms are involved in anionic AFPs activities. The inhibition of cell wall
biosynthesis, protein synthesis 162 as well as the inhibition of spore germination 163 have all been
observed. Another proposed mechanism is the depletion of metal ion (Cu2+ or Fe2+)
supplementation and alteration of yeast respiratory profile 164, 165. Furthermore, membrane
permeabilization and the induction of reactive oxygen species as well as nitric oxide have also
been observed166 . Yet another mechanism reported is the alterations in cell morphogenesis and
membrane disruption 160, 167.
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1.2.1.3 Neutral AFP
As stated previously, the vast majority of AFP families are cationic; however, a few are neutral.
For example, Aurein 1.1 is neutral; whereas, the other 11 Aurin peptides are cationic. The
brevinin family of peptides is another example where brevinin-1- OR3, OR6, OR8, and OR9 are
neutral peptides and the rest are cationic 168. An exceptional case is GP-19 peptide, which is
neutral, and GP-20 peptide is anionic 162.
The general biophysical properties of neutral AFPs are: the net charge is neutral at pH 7, the
peptide size ranges from 13 to 50 amino acids, most of neutral AFPs form an amphipathic
structure, the secondary structures for the know neutral AFPs are helical, except for Drosomycin2 which is a mixture of α-helix and β-sheet (Table 3).
Most of these peptides have both antibacterial activity and antifungal activities with the
exception of GHH20, Galleria defensin and Ha-DEF1, which lack the antibacterial activity.
Surprisingly, Galleria defensin-like peptide, which shares 95% homology with Galleria defensin,
possessed an antibacterial activity for gram-positive bacterium (S. lutea) along with the
antifungal activity.
The mechanisms of action for the neutral AFPs are membrane permeabilization and disruption.
It has been suggested that the positive charges within the neutral peptides are able to initiate
electrostatic interactions with the negatively charged membrane prior the membrane disruption
169 162 170

. However, two neutral AFPs (Gp-19 and Temporin-1PRb) lack charged amino acids

and they exhibit activity via membrane disruption.
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1.2.2 Posttranslational modifications of natural AFPs.
Several post-translation modifications have been observed in naturally occurring AFPs and each
modification had an influence on the AFPs activity. The knowledge of these modifications is
important to reach a full understanding about peptide activity and later, to be used to improve the
activity or solve problems related to antifungal activity. This section will discuss the following
modifications: glycosylation, amidation of C-terminus, isomerization which includes
diasteromers and enantiomers, halogenation, phosphorylation, hydroxylation and cyclization.
The data in this section are general and subjected to change at any time, as new AMPs could be
published or added to the database. Furthermore, some of the AMPs have not yet been tested for
antifungal activity.
Glycosylation. The addition of carbohydrates is one of the most common post-translational
modifications and it is typically observed at asparagine or serine/threonine residues. N-linked
and O-linked are both common types of glycosylation 171, and in rare cases S-linked peptides
have been discovered 172. In AMPs, glycosylation was observed in proline-rich peptides such as
in Drosocin 173 and Pyrrhocoricin 174. Moreover, the O-glycosylation of these peptides was
determined to be essential for full antimicrobial activity; this is not always the case since Slinked glycosylation had no effect on the antimicrobial activity175.
No natural AFPs have been found to be glycosylated in the antimicrobial peptide database 103.
In synthetic AFPs, several cases have been published. For example, the antifungal activities of
caspofungin , a semi-synthetic lipopeptide, was improved after the addition of a monosaccharide
176

.
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Amidation of carboxy terminus. The main role of amidation is to improve peptide stability in the
presence of aminopeptidases 177 and in some cases to increase the anti-fungal activity

178
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Several examples of AFPs with an amidated C-terminal were identified in nature such as
Ctriporin from scorpions 179 and Ranacyclin from Rana esculenta skin 180. Moreover, the
amidation has also been a common approach in synthetic AFPs 100.
Isomerization (Diasteromers). This is the ability of peptide to exist in two conformations, cis
and trans. In general, the isomerization increased the antimicrobial activity and improved the
stability of multiple peptides 181. Diasteromers have been identified in AMPs like Caenopore-5
182

as well as in AFPs like Cyclo(L-Phe- 4-OH-L-Pro)183 .

Isomerization (enantiomers): There are a few examples of naturally occurring AMPs with Dconformation, such as bombinin H4 184, lactocin S 185 and gramicidin A 186. However, none of
them had antifungal activity. Several AFPs have been synthesized using D-amino acids in an
attempt to improve the peptide stability against proteases 112, 113.
Halogenation. In nature, the most common halogenation is bromination and chlorination.
Bromination mainly occurred in AMPs, and more precisely, in the tryptophan indole ring while
chlorination was generally observed in AFPs. Bromination has been described in different
AMPs such as Hedistin and in hagfish cathelicidins 100, 187. The role of indole bromination in
cathelicidins was suggested to reduce the peptide susceptibility to proteolysis via steric
modifications 188. Misgurin from the mudﬁsh Misgurnus anguillicaudatus is an example of an
antifungal peptide that has been modified by chlorination; however, the role of the chlorination
was unclear and it did not alter the antifungal activity 100.
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Phosphorylation. Nature has produced multiple examples of phosphorylated AMPs and AFPs.
Phosphorylation has been found to be essential for AMPs activity. For instance, enkelytin, an
antibacterial peptide derived from proenkephalin A, has two phosphoserines that are required for
the full activity189. Prochromacin and chromacin are also examples in which the modifications
were mandatory for peptide activity (glycosylation and phosphorylation )190. In AFPs, the
situation was different and phosphorylation may be not required for the antifungal activity.
Histatin 1 is an example of a phosphorylated AFP where the modification didn’t have any effect
on the peptide activity; however, it did increase the stability of the peptide in saliva 191.
Hydroxylation. In AMPs, hydroxylation was primarily observed at lysine, arginine, tryptophan
and phenylalanine residues. The effect of hydroxylation on the peptides is unclear and it has
been shown to have different effects. For example, the hydroxylation of the MGD-2 peptide was
essential for antimicrobial activity; however, other studies have suggested that the peptide
activity was not changed by the hydroxylation 192. The Cecropins AMP family is an example of
a hydroxylated lysine peptide and only cecropin B has shown anti-fungal activity 193.
Halocyamines, tetrapeptides from Halocynthia roretzi, are an example of
dihydroxyphenylalanine modified AFP 194. Styelin D and callinectin are examples of antimicrobial peptides with dihydroxyarginine and hydroxyl-tryptophan residues, respectively 192, 194,
but both peptides did not display fungicidal activity.
Methylation: The most common sites of methylation are tyrosine and lysine residues. Clavanins
are natural AMPs with a methylated tyrosine 195; however, none of them has exhibited
antifungal properties. The synthesized AFP cecropin A-melittin had trimethyl-lysines and a
study has shown that the methylation decreased the hemolytic activity and promoted the
selectivity against certain microorganisms196.
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Cyclization. Although not considered a posttranslational modification, cyclization has given
unique properties to peptides, such as increasing antifungal activity, reducing the toxicity and
improving the stability in proteases 197. Tunicyclins B 198, 199 and cyclopsychotride A 200 are
examples of cyclic naturally occurring AFPs. Moreover, there are several examples of synthetic
antifungal peptides such as RTD-1, where the cyclization has improved the antifungal activity 201
1.2.3 Disadvantages of antifungal peptides and proposed solutions.
The general disadvantages of AMPs, and AFPs specifically, could be summarized as: poor oral
and tissue absorption, rapid in vivo degradation, poor stability (shelf-life) and potential
immunogenicity. Moreover, most peptides are rapidly excreted, poorly bioavailable and salt
sensitive. Human toxicity and hemolysis have also been observed with some AMPs. These
issues will be addressed in detail below.
Stability. The stability is not an issue for naturally occurring AMPs within their environment for
multiple reasons. First, most of the AMPs are derived by proteolysis of larger proteins or
peptides; therefore, equilibrium exists between peptide generation and degradation. For
example, buforin II is generated from histone 2A 202, lactoferricin from lactoferrin 203 and histatin
5 from histatin 1. Second, small peptide fragments that are generated via proteolysis of the active
peptide, in some cases, maintain some antifungal activity. For example, 12 fragments of histatin
1 have been identified and most of them retain antifungal activity. Finally, there might be
something within the physiological environment that supports peptide stability and increase the
half-life. For instance, the ability of histatin 1 to bind to hydroxyapatite within the enamel
pellicle decreases the proteolytic degradation 191.
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For synthetic peptides, stability and bioavailability problems may be solved via peptide
formulations or modifications. Several approaches have been used to improve the stability, such
as liposome-encapsulation 204 , use of peptoids 205 , D-conformation-based peptide206 , and βpeptides207. The use of different peptide formulations has been the major approach to improve
peptide bioavalability, delivery, and stability. The melittin-lipid disk is an example of a
formulated peptide in which polyethylene glycol-stabilized lipid was fused to the melittin peptide
208

. Carbon nanotubes and magnetics nanoparticles are useful tools for drug delivery; therefore,

this may represent a promising avenue of research for peptide delivery 209 .
Toxicity. In therapeutics, drug toxicity is directly proportional to the concentration; however, the
toxic concentration varies between the drugs. Natural AFPs, within their tissues, have shown a
high target specificity and low toxicity. Most multicellular organisms express a cocktail of
peptides within their `defensive' tissues, in which the cocktail contains several classes of AMPs
and AFPs 93. Furthermore, these peptides probably have a synergistic effect and work at low
concentrations far from their toxic levels 210. However, the synergistic effect is absent in most in
vitro assays, since each AFP is tested individually. Furthermore, different isoforms of the same
peptide could be present at the same time. For example, different forms of Rhesus θ defensins
(RTD-1, RTD-2, and RTD-3) have been identified in leukocytes of Rhesus macaques, where the
cellular abundance of the three peptides (RTD1, RTD-2 and RTD-3) differs at a ratio of 29:1:2,
respectively. In spite of having multiple forms, all of the RTD isoforms have the same
antifungal activity; however, they do display distinct antibacterial activity as well as differences
in net charges RTD-1 (+5), RTD-2 (+6), and RTD-3 (+4) 201.
Specificity. One major challenge in designing new antifungal peptides is achieving high
specificity toward fungal cells. The perfect AFP would ideally have an affinity for multiple
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targets within the microbe and the targets must be accessible and relatively immutable.
Unfortunately, this is not the case for most AFPs, either natural or synthetic. Host cell toxicity
might be solved after a full understanding of the mechanism by which the peptides recognize
their target 92, 117. The literature has provided several examples in which the cytotoxicity of
synthetic peptides was reduced successfully via modifications in the peptide composition 211-213.
However, each case is unique and the solutions have varied. An example of reduced toxicity was
observed with the melittin peptide, where cytotoxicity was reduced by fusing melittin with
cecropin A or the magainin peptide rather than by amino acids substitution 214, 215.
Salt sensitivity. Salt sensitivity may present the greatest challenge for the majority of AMPs as
well as AFPs, for clinical use since they are typically salt-sensitive at physiological concentration
of ions. Table 4 shows synthetic and natural AFPs that seem to maintain activity in the presence
of salts. Since salt insensitivity is only found in a small number of peptides, the general
biochemical properties of these peptides will be discusses briefly as potential solutions for other
peptides that exhibit salt-sensitivity.
One parameter is the net charge that varies dramatically between anionic and cationic peptides;
however, the majority of salt insensitive peptides are cationic with net charge greater or equal to
+4 at pH 7. There is no preferred secondary structure, as it varies between α-helical and β-sheet.
The amphipathicity has been observed in this group with an exception of RTD-1 which did not
display any amphipathicity, and surface models have suggested a clustering of positive charges
138

. The second parameter of salt-insensitive peptide is the secondary structure. The fungicidal

activity of these structured peptides is accomplished via pore formation or membrane
permeabilization. This group can be subdivided into two groups, helices and sheets, where each
group has something in common other than secondary structure. By looking to the amino acid
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composition, most β-structure peptides have more arginine than lysine and also share the ability
to form disulfide bonds. Studying the peptide structure and amino acid compositions of βpeptides sheds light on the role of disulfide bonds and cyclization in salt tolerance. It has been
found the cyclization and disulfide bonds are essential for the salt insensitivity in RTD-1216 , TP1217, and arenicin-1218 peptides. However, the essential factor in potegrin 1 was structure
rigidity and the presence of disulfide bonds did not have any effect 136. The major general
conclusion is from looking at salt-insensitive β-peptides is that disulfide bonds and/or structure
rigidity may be crucial to salt insensitivity.
On the contrary, α-helical peptides did not have any cysteine nor disulfide bonds. Peptides in αhelical subclass did not show any common essential feature. The only observed similarity is that
the majority of α-helices have lysine more than arginine in their sequence; however, it has been
reported that the substitution of arginine to lysine in Ci-MAM-A24 increased salt sensitivity 219 .
In addition, arginine was not always preferred and in some cases the increase in arginine
percentages led to increase salt sensitivity 202. DCD-1 is a unique example of α-helical peptide,
that has been shown to be only 20% active at low salt conditions and the activity is retained by
increase the salt content; however, this is not the case for the majority of AFPs. Furthermore,
DCD-1 is also affected by pH since basic pH was the optimal 220.
1.3 Histatins
Human histatins are a family of small histidine-rich peptides secreted in saliva by parotid,
submandibular, and sublingual glands221. Histatins have been also identified in some higher
primates species including the great ape, Hylobatidae and Cercopithecidae 222. Histatins are
important members of innate immunity and are essential for dental and oral defense 223.
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Moreover, histatins has been shown to have other functions including wound healing and
formation of the acquired enamel pellicle 224. Research has shown the entire histatin peptide
family is encoded by two genes (HIS1 and HIS2) which are localized on chromosome 4q13.
Both HIS1 and HIS2 are exclusively expressed in the salivary glands where the full length
precursors , histatin 1 and histatin 3, are synthesized, respectively 225. The other members of
histatin family are generated by an irresolute proteolytic pathway226, 227 or via alternative splicing
of the genes 228. The size of human histatins ranges from 7 to 38 amino acids in length103, 228.
The common feature in all histatin members is the fact they are enriched in histidine, lysine, and
arginine residues. The predominant histatins are histatin 1, 3 and 5 consisting of 38, 32 and 24
residues, respectively. These three peptides comprise around 80 % of histatin family. Their
average concentrations in the parotid saliva ranges from 7 to 28 µg/ml for histatin 1, 6 to 43
µg/ml for histatin 3, and 10 to 43 µg /ml for histatin 5. Furthermore, the mean concentrations for
histatin 1, histatin 3, and histatin 5 in submandibular and sublingual saliva are 28 to 122 µg/ml, 5
to 75 µg/ml, and 26 to 90 µg/ml, respectively.
1.3.1 Histatin 5
Histatin 5 is composed of 24 amino acids and it is generated from a proteolytic processing of
histatin 3. Moreover, histatin 5 is the most potent member of the histatin family against fungal
species. Besides its role as an antimicrobial peptide (both fungicidal and bactericidal ) 229-231,
histatin 5 enhances the glycolytic activity of oral micro-organism 226, inhibits lipopolysaccharide
mediated activities232, prevents co-aggregation and hemagglutination in certain bacteria 228,
inhibits bacterial enzymes such as collagenase and trypsin protease233, inhibits Candida albicans
colonization in oral cavity 234, reduces nickel allergy via direct binding with Ni(II) ions235,
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controls oral infection via down regulating the IL-8 responses 236 and promotes the secretion of
histamine from mast cells237.
1.3.1.1Unique features of histatin 5.
Histatin 5 has some unique features not found in other AMPs. First, histatin 5 is enriched in the
amino acid histidine, which has a pKa of 6.0 for the side chain. Thus, this can result in the
alteration of the peptide net charge as well as antimicrobial activities. Histatin 5 net charge is
dramatically changed by altering the pH from 4 to7 to 9 , at pH 4.5 the net charge is +12.9, at pH
7 it is +6.6 and at pH 9 it is +3.6 238. Second, histatin 5 has an ability to form complexes with
several ions metals that may promote histatin 5 killing activity via binding to divalent cations
which are essential to microorganisms life cycle239. Finally, Histatin 5 is adsorbed to
hydroxyapatite on the teeth240. This feature prolongs histatin 5 life via protection from
proteolysis by proteases in the oral cavity. The binding to teeth lowers the overall antimicrobial
activity, but it is sufficient to prevent Candida albicans colonization of the oral cavity234.
1.3.1.2 Histatin 5 spectrum of antimicrobial activity.
Histatin 5 shows a broad spectrum of activity against oral and non-oral pathogens , including
fungi (Candida albicans, Cryptococcus neoformans, Candida stellatoidea, Candida tropicalis,
Candida glabrada, Trichosporon pullulans, Candida guillermondii, Candida lambica, Candida
pseudotropicalis, Candida krusei, and Candida parapsilosis) , bacteria (Streptococcus mutans,
Porphyromonas gingivalis, Actinomyces viscosus, Actinomyces naeslundii, methicillin resistant
Staphylococcus aureus and Actinomyces odontolyticus )228, 231, 241 as well as protozoa
(Leishmania donovani ) 242.
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1.3.1.3 Secondary structure of histatin 5.
Histatin 5 has been studied extensively; therefore, the biophysical properties and NMR structure
have been examined. Regarding the secondary structure, histatin 5 has no defined structure in
water, but it adopts helical conformations in hydrophobic environments such as trifluoroethanol
and synthetic lipids 139, 243, 244. The NMR structure of histatin 5 in aqueous and non-aqueous
solution has been solved244. The NMR studies have been also carried for some of histatin 5
derivatives including the C-16 peptide243 and P-113 peptide245. The NMR studies supported the
other biophysical studies suggesting that histatin 5 and its derivatives have a random coil
structure in aqueous solution, but in a hydrophobic environment or biological membrane , they
adopt a helical conformation and the positively charged residues are clustered together to form a
hydrophilic patch. The electrostatic and hydrogen-bonding interaction of cationic and polar
residues with the head groups of the plasma membranes of target cells are the reasons for
induced helical structure 243. The ability to form α-helical structures is essential for the activity
in most of the cationic peptides246, 247; however, the role of helicity in histatin 5 activity remains
a question. Situ et al. have demonstrated that reducing the ability to form a helical structure in
histatin via replacing three amino acids with proline (a helix breaker) has little effect on the
fungicidal activity 219.
1.3.1.4 Amphipathicity and hydrophobicity of histatin 5.
Amphipathicity is an essential requirement for AMPs activity, especially the pore-forming
peptides 246, 248; however, it has been suggested that histatin 5 exhibits a weak amphipathic
structure as compared to other AMPs. Furthermore, increasing the amphipathic character of
histatin 5 via histidine replacement did not improve the activity 249. Another unique histatin 5
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character is the hydrophobicity. In a comparative study between histatin 5 and other AMPs
(PGLa, dhvar1, dhvar4, KL, CRAMP18, SPLN14-27, SPLN28-41, equinatoxin II and magainin
2) using a hydrophobicity plot that is generated by the mean of hydrophobicity, histatin 5 would
appear as a “globular “ protein region, while the other AMPs were ranked as “surfaceseeking”250 . The hypothetical difference between them is that part of histatin 5 has only little
affinity to biological membranes while another portion contains sequences with high affinity to
biological membrane 131, 139.
1.3.1.5 Charge of histatin 5.
The net charge of the cationic peptides plays an important role in target recognition as it initiates
the interaction with the negatively charged plasma membrane and the AMPs. Therefore,
increasing the peptide cationic charge might lead to increased activity. Unlike other AMPs,
histatin 5 didn’t follow this rule, as its fungicidal activity remained the same at different pH
while the net charge shifted from +12.9 at pH 4 to + 6.6 at pH 9 251.
1.3.1.6 The amino acids composition of histatin 5.
In some AMPs the full length peptide is not essential to achieve optimal antimicrobial activity
and the activity can be restricted to a smaller fragment of the peptide 252-254. Multiple studies
have analyzed the amino acid composition of histatin 5 in attempts to identify the functional
sequence relevant for fungicidal activity. To-date, multiple histatin 5 fragments have shown a
comparable activity to the full peptide and one fragment has an activity exceeding histatin 5.
The fungicidal activity of C-16 peptide, which represents the C-terminal 16 amino acid of
histatin 5, and Dh-5 peptide, which represents the C-terminal 14 amino acid of histatin 5, was
close in activity to the full length 24 amino acid histatin 5. Since that discovery, Dh-5 has been
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referred to as the histatin 5 functional domain 139, 255, 256. A study has claimed the identification
of a six amino acid motif (KRKFHE) in all active histatins. In addition, the same study also
identified H10-1 peptide, a 10 amino acid fragment with significant antifungal activity.
However, the activity of H10-1 was only 30% of the full length histatin 5. Later, P-113, a twelve
amino acid fragment, was identified with fungicidal activities higher than parent histatin 5
peptide. In a comparative analysis between histatin 5 and P-113, the fungicidal activity was
improved in P-113 with the LD50 reduced nearly two-fold from 7.3 µg/ml to 3.9 µg/ml under the
assay conditions used.
1.3.1.7 Structure-function relationship for histatin 5.
In spite of the fact that histidine is the predominant amino acid in histatin 5, replacing all of the
histidines in the histatin 5 derivative termed P-113 with phenylalanine did not affect the
fungicidal activity in vitro. Moreover, the histidine side chain will be uncharged at physiological
pH. Nevertheless this finding did not exclude the role of histidine in vivo since the presence of
the histidines could be essential for peptide stability and tissue binding 257.
Despite the above finding, the role of the positive charges that arise from lysine and arginine has
not been eliminated. Any change in Lys-11 or Arg-12 or Lys-13 or Arg-22 in histatin 5 via
replacing them with an uncharged amino acid leads to a reduction in the fungicidal activity or
complete inhibition of activity228 . Another study also confirmed this result by showing the
replacement of Lys-11 and Arg-22 with glutamic acid and glycine, respectively, inhibits histatin
5 activity and eliminates peptide localization to the cytoplasm 238. This phenomenon has been
observed not only with the full length histatin 5, but also with the active derivatives (P-113 and
Dh5). A single replacement of Lys-13 with threonine or glutamic acid in Dh5 was sufficient to
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diminish the fungicidal activity 241. Furthermore, replacement of Lys-2 and Lys-10 in another
histatin 5 derivative (P-113) peptide with glutamine abolished activity. Additionally, replacing
any of the arginines in P-113 with glutamic acid leads to reduced activity 257. A single lysine
substitution for a histidine in Dh5 peptide increases the candidacidal activity of the peptide by
almost two-fold 249. Taken together, these studies suggest that the lysine and arginine residues of
histatin 5 are of greater relevance for fungicidal activity than the presence of the abundant
amount of histidine residues.
1.3.1.8 Structural modifications of histatin 5.
Histatin 5, along with its derivatives, has undergone several structural modifications in an
attempt to improve the antimicrobial activity and to increase the stability of the peptide. The
modifications include: cyclization, acetylation of N-terminus and lysine residues, amidation of
the C-terminus, the addition of a hydrophobic lipid tail, and the use of D-conformation amino
acids as well as other amino acid derivatives.
Peptide cyclization has been used to improve the activity and serum stability of antimicrobial
peptides124 . For example, the cyclic form of histatin1 has a superior activity to the linear peptide
258

. The cyclization did not only increase the biological activity, the receptor affinity also

improved through the stabilization of the peptide conformation253. This has not been the case
with histatin 5 as head-to-tail cyclization did not affect its antimicrobial activity 259.
Nonetheless, DB2-121, a cyclic analog of histatin 5 has shown potent activity and less toxicity
than the linear version 260.
One of the major problems with AMPs in general and histatin 5 specifically is the susceptibility
to protease degradation. Modification of N-terminus and lysines via acetylation or methylation
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is a method that has been used to improve the peptides stability 261. The acetylation of histatin 5
N-terminus and methylation of lysine did not show any effect on histatin 5 activity, while the
acetylation of the lysines abolished the fungicidal activity262. In general, it has been observed
that amidated peptides exhibit higher antimicrobial activity over a peptide with a free C-terminus
263

. This improvement could be explained by the fact that the amidated peptides have a higher

positive charge than those with a free C-terminus 263. Furthermore, the amidation may enhance
the antimicrobial activity by stabilizing the α-helical structure at the membrane interface and/or
by improving the peptide stability159, 264. The amidation of histatin 5 analogs , Dh5 and P-113,
increased the candidacidal activity almost twofold 249.
The conjugation of a fatty acid to antimicrobial peptides has been used as a method to enhance
the activity and selectivity of the peptide265. This effect result from increasing the hydrophobic
interaction between the plasma membrane and the peptide266. Research has shown that the
addition of an eight carbon hydrophobic tail to histatin 5 derivative H10-2 increased the
antifungal activity approximately by 50% in comparison with the native peptide 267.
Using peptide enantiomers has always been an ideal method to bypass peptide susceptibility to
proteases and a way to improve peptide half-life. D-amino acids have been used in histatin 5 and
its derivative P-113 and the results were the same for both of them; the enantiomers had
improved stability in proteases and exhibited the same fungicidal activities 206, 257 .
As mentioned previously, all cationic antimicrobial peptides exhibit a similar problem,
sensitivity to salts270. This problem leads to inactivation of the antimicrobial activity of peptides,
even at physiological salt concentrations 271. Histatin 5 and its fragments are also salt sensitive
and their activity was totally abolished in a presence of 150 mM NaCl 257. However, a strategy
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to increase salt resistance of the histatin 5 derivative peptide P-113 has been published. The
strategy is based on using uncommon amino acids via replacement of tryptophan or histidine
residues with the bulky amino acids β-naphthylalanine and β-(4, 4′-biphenyl)-alanine 272, 273,
respectively.
1.3.1.9 Histatin 5 mechanism of action.
The exact mode of action of histatin 5 remains unclear. The proposed antifungal activity of
histatin 5 occurs through a multi-step mechanism that involves binding, translocation and
toxicity to fungal cells. Unlike other AMPs, the binding of histatin 5 to the cell wall was
proposed to be the first step 150, 238, 274, 275 with laminarin (β-1,3-glucan ) reported to modulate
histatin 5 binding to Candida albicans 275. Besides carbohydrate, histatin 5 has been shown to
bind to the cell wall protein (Ssa2), which may facilitate the intracellular translocation150.
The Ssa proteins are conserved members of the heat shock protein 70 family in yeast.
Candida albicans only has two members: Ssa1p and Ssa2p. It has been found that Ssa2, but not
Ssa1, was required for histatin 5 translocation into the cell276. The role of Ssa2 in the fungicidal
activity of histatin 5 has been the subject of debate since an ssa2Δ homozygous mutant was
susceptible to histatin 5, demonstrating an activity that was only 25 % less than with an SSA2
wild type strain. Moreover, the role of a specific protein receptor would seem unlikely given that
a histatin 5 derivative containing only D-amino acids were as active as the L-conformation.
In addition other cell surface proteins, including polyamine transporters, have been suggested to
have a role in histatin 5 translocation into cells. Six different polyamine transporters have been
identified in Candida albicans and named the Dur gene family. However, the deletion of the
Dur genes reduced the fungicidal activity of histatin 5, but did not completely abolish it.
Nevertheless, the involvement of an energy-dependent process in histatin 5 killing mechanism
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seems to be unanimously agreed upon, but at what stage in the process this occurs remains
unresolved.
Several models have been proposed to explain histatin 5 activity and intracellular targets. The
first model hypothesized that histatin 5 attaches and depolarizes energized mitochondria238. The
cause of death in this model was assigned to the generation of reactive oxygen species277 rather
than loss of respiration, because Candida spp. are fully functional under anaerobic conditions 275.
However, the role of ROS is disputed, as other studies showed ROS has no role in histatin 5
induced yeast death 278, 279. In another model, histatin 5 binds to cell membranes and increases
the permeability, resulting in the efflux of cellular content, such as ATP129, ions (magnesium and
potassium)280, and nucleotides129. Moreover, it has been shown that loss of intracellular contents
was facilitated by Trk1, a membrane potassium transporter after exposure to histatin 5281. In this
model, the fungicidal activity is achieved via disruption of cellular ionic balance instead of
membrane integrity273. In another proposed mechanism, histatin 5 causes a disordered volume
regulation and cell cycle arrest 273, which might be correlated to the loss of ATP129. In summary,
the mechanism of histatin 5 antifungal activity remains unresolved. Any of the proposed models
or a combination of the models may prove to be true.
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Table 1: Examples of cationic anti-fungal peptides sorted in ascending order by the net
charge.
Name

Origin

Sequence

Activity

Heliomicin

Heliothis
virescens
(worm)

Metchnikow
in
Maximin 1

Drosophila
melanogaster
Bombina
maxima (frog)
Rana
catesbeiana
(frog)
Apis mellifera
(bee)
Achypleus
tridentatus
(crab)

DKLIGSCVWGAVNY
TSDCNGECKRRGYK
GGHCGSFANVNCW
CET
HRHQGPIFDTRPSPF
NPNQPRPGPIY
GIGTKILGGVKTALK
GALKELASTYAN
SMLSVLKNLGKVGL
GFVACKINKQC

Ranatuerin 1

Melittin
Tachystatin
A2

MBP-1

Maize, Zea
mays L (plant)

Lactoferricin
B

Bos Taurus
(cow)

1AFP

Aspergillus
giganteus

BMAP-27

Bos taurus
(cow)
Ovis arues
(shep)

sBD-1

Buforin I

CXCL14

CodCath

bufo
gargarizans
(frog)
Homo sapiens

Gadus morhua
(fish)

GIGAVLKVLTTGLP
ALISWIKRKRQQ
YSRCQLQGFNCVVR
SYGLPTIPCCRGLTC
RSYFPGSTYGRCQR
Y
RSGRGECRRQCLRR
HEGQPWETQECMR
RCRRRG
FKCRRWQWRMKKL
GAPSITCVRRAF

ATYNGKCYKKDNIC
KYKAQSGKTAICKC
YVKKCPRDGAKCEF
DSYKGKCYC
GRFKRFRKKFKKLF
KKLSPVIPLLHLG
NRLSCHRNKGVCVP
SRCPRHMRQIGTCR
GPPVKCCRKK
AGRGKQGGKVRAK
AKTRSSRAGLQFPV
GRVHRLLRKGNY
SKCKCSRKGPKIRYS
DVKKLEMKPKYPHC
EEKMVIITTKSVSRY
RGQEHCLHPKLQST
KRFIKWYNAWNEK
RRVYEE
SRSGRGSGKGGRGG
SRGSSGSRGSKGPSG
SRGSSGSRGSKGSRG
GRSGRGSTIAGNGN
RNNGGTRTA
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Charge

C. albicans
C. neoformans

Secondary
structure
Helix and
Beta-1I2U

+1

282

F. graminearum

unknown

+2

283

C. albicans

unknown

+3

284

C. albicans

unknown

+4

285

C. albicans

Helix1MLT
Beta-1CIX

+5

286

+6

287

F. graminearum
F. moniliforme

Helix-CD

+7

288

C. albicans
T.
mentagrophytes
T. rubrum
(not all fungi)
F. sambucinum
N. crassa
A. niger
(not all fungi)
C. albicans
C. neoformans
C. albicans

Beta-1LFC

+8

289

Beta-1AFP

+9

290

Helix2KET
unknown

+10

291

+11

292

C. albicans
S. cerevisiae
C. neoformance
C. albicans

unknown

+12

293

unknown

+13

294

C. albicans

unknown

+15

295

C. albicans

Ref.

Table 2: Anionic anti-fungal peptides sorted in ascending order by the net charge.
Name

Origin

Sequence

Activity

Charge

Ref.

-1

296

Unknown

-1

297

Helix and
Beta- 1PT4

-1

298,
299

Trapa atans
(Plant fruit)
Aspergillus
niger
(Fungi)

LMCTHPLDCSN

Viola
betonicifolia
(plant)
Phaseolus
vulgaris
(plant seed)

GLPVCGETCFGGTCNT
PGCTCTWPICTRD
KTCENLADTYKGPCFT
TGSCD

C. albicans,
C. parapsilosis,
C. tropicalis
C.
guilliermondii,
K. marxiannus
S. cerevisiae

Expected
Helix and
Beta

-1

166,
300

human
Dermcidin

Homo sapiens
(sweat)

C. albicans

Helix-2KSG

-2

161

EP-20

Xenorhabdus
budapestensis
(Bacteria)
Homo sapiens

SSLLEKGLDGAKKAV
GGLGKLGKDAVEDLE
SVGKGAVHDVKDVLD
SV
EGPVGLADPDGPASAP
LGAP

P. capsici
V. dahliae

Unknown

-3

162

DAEFRHDSGYEVHHQ
KLVFFAEDVGSNKGAI
IGLMVGGVV

C. albicans

Helix
-1IYT

-3

160

SSFSPPRGPPGWGPPC
VQQPCPKCPYDDYKC
PTCDKFPECEECPHISI
GCECGYFSCECPKPVC
EPCESPIAELIKKGGYK
G
EADEPLWLYKGDNIER
APTTADHPILPSIIDDV
KLDPNRRYA

F. oxysporum

Unknown

-3

163

P. pastoris
P. stipites
C. albicans
C. fructus
Z. marxianus
S. cerevisiae
C. neoformans

Unknown

-4

302

Helix- 2KNJ

-8

164

Tn-AFP
An-AFP

Kalata B1

PvD1

Betaamyloid
peptide
including
beta -42
Ls-Stylicin1

Litopenaeus
stylirostris

Gm anionic
peptide-2

Galleria
mellonella
(Moth)

Microplusin

Rhipicephalus
(Boophilus)
Microplus
(cattle tick)

C.tropicalis

Secondary
structure
Unknown

SKYGGECSVEHNTCT
YLKGGKDHIVSCPSAA
NLRCKTERHHCEYDE
HHKTVDCQTPV

HHQELCTKGDDALVT
ELECIRLRISPETNAAF
DNAVQQLNCLNRACA
YRKMCATNNLEQAMS
VYFTNEQIKEIHDAAT
ACDPEAHHEHDH
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C. albicans
S. cerevisiae
T. beigelii
F. solani
F. oxysporum
A. fumigatus
A. flavus
C. kefyr

Table 3: Example of neutral anti-fungal peptides.
Name
Aurein 1.1

Maculatin 1.1

Skin peptide
tyrosinetyrosine
-Galleria
defensin

Origin

Histatin 2

Activity

Litoria
raniformis
(frog)

GLFDIIKKIAESI

Litoria
genimaculate
(frog)
Phyllomedusa
bicolor (frog)

GLFVGVLAKVAAH
VVPAIAEHF

Galleria
mellonella
(moth)

-Galleria
defensin like

Gm cecropin
D-like peptide

Sequence

Galleria
mellonella
(moth)
Homo sapiens

GLFDIIKKIAESF

YPPKPESPGEDASPE
EMNKYLTALRHYIN
LVTRQRY
DTLIGSCVWGATNY
TSDCNAECKRRGYK
GGHCGSFLNVNCW
CE
DKLIGSCVWGATNY
TSDCNAECKRRGYK
GGHCGSFWNVNCW
CEE
ENFFKEIERAGQRIR
DAIISAAPAVETLAQ
AQKIIKGGD
RKFHEKHHSHREFPF
YGDYGSNYLYDN
ILPILGNLLNSLL

C. albicans
C. Tropicalis
C. Krusi
C. Parapsilosis
C. glabrata
C. albicans

Secondary
structure
Helix-2F3A
1VM5

Ref.
303

Helix

304

C. albicans
A. fumigatus
C. neoformans
C. albicans
G. candidum
C. neoformans
F. oxysporum

unknown

305

unknown

306

A. niger

unknown

302

C. albicans

unknown

307

C. albicans
>100 µM
C. neoformans
C. albicans
C. krusei
C. utilis
C. parapsilosis
C. albicans

unknown

308

Helix-1RON

169
309

Helix

310

302

Temporin1PRb
Neuropeptide
Y

Rana pirica
(frog)
Homo sapiens

GHH20
Histidine rich
glycoprotein

Homo sapiens

GHHPHGHHPHGHHP
HGHHHPH

Helianthus
annuus
(sunflower)

ELCEKASQTWSGTC
GKTKHCDDQCKSW
EGAAHGACHVRDG
KHMCFCYFNC

S. cerevisiae

unknown

311

Drosomycin-2

Drosophila
melanogaster

N. crassa
G. candidum
S. cerevisiae

Helix and Beta1MYN

312

Sm-AMP-D1

Stellaria media
L
(plant)

Phytopathogenic
fungi

unknown

313

Brevinin-1OR3

Odorrana
rotodora (frog)

DCLSGKYKGPCAV
WDNEMCRRICKEEG
HISGHCSPSLKCWCE
GC
KICERASGTWKGICI
HSNDCNNQCVKWE
NAGSGSCHYQFPNY
MCFCYFDC
IDPFVAGVAAEMMQ
HVYCAASKKC

C. albicans

unknown

168

Ha-DEF1

YPSKPDNPGEDAPA
EDMARYYSALRHYI
NLITRQRY

45

OR6

IIPFVAGVAAEMME
HVYCAASKKC

OR8
OR9

ILPFVAGVAAEMME
HVYCAASKKC

AndersoninX1

ILPFVAGVAAMEME
HVYCAASKKC
GLFSKFAGKGIVNFL
IEGVE

GP-19

Odorrana
andersonii
(frog)
Xenorhabdus
budapestensis
NMC-10
(bacteria)

GPVGLLSSPGSLPPV
GGAP

46

C. albicans

unknown

168

F. omysporum
P. capsici
V. dahlia
F.graminearum

unknown

162

Table 4: Salt-resistant anti-fungal peptides.
Name

Sequence

Source

Thanatin

GSKKPVPIIY
CNRRTGKC
QRM

Podisus
maculiventris
(insect)
recombinant

Thanatin-1

Seconda
ry
structur
e
beta

Disulfide
bond

1(C11C18)

Activity
(MIC)

-N. crassa
0.6-1.2 µM

Net
char
ge

Ref.

+6

314

+5
+6
+4

216
201

+6

137
217

-B. cinerea
1.2-2.5 µM

S-Thanatin
GSKKPVPIIY
CNRRGKCQ
RM

-N. haematococca
1.2-2.5 µM
-T. viride
1.2-2.5 µM

GSKKPVPIIY
CNRRSGKCQ
RM

-A. brassicola
2.5-5 µM
-F. culmorumn
2.5-5 µM
-A. pisi
5-10 µM
-F. oxysporumn
10-20 µM
-C.albicans
25-50 µM

RTD-1
(thetadefensin)

GFCRCLCRR
GVCRCICTR

Rhesus
Macaque
(monkey)

beta

RTD-2
RTD-3

3 (C3C16)
(C5-C14)
(C7-C12)

-C.albicans
1μg/ml
-C. neoformans
4μg/ml

GVCRCLCRR
GVCRCLCRR

GFCRCICRR
GFCRCICTR
Tachyplesin
I
Tachyplesin
II

KWCFRVCY
RGICYRRCR

Tachypleus
tridentatus
(crab)

beta

RWCFRVCY
RGICYRKCR

2(C3C16)
(C7-C12)

-C. albicans
3.1 μg/ml
-C. neoformans
1.56 μg/ml
-C. kefyr
0.9 µM
C. tropicalis
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0.5 uM
Arenicin-1

Protegrin 1

Ci-MAMA24

RWCVYAYV
RVRGVLVR
YRRCW

RGGRLCYCR
RRFCVCVGR

WRSLGRTLL
RLSHALKPL
ARRSGW

Arenicola
marina
Sand worm

Pig

Ciona
intestinalis

beta

beta

helix

1(C3(20)

2 (C6C15)
(C8-C13)

no

+6

218

+6

315

+6

219

+4

270

+7

297

-2

220

-C. albicans
4.5 μg/ml

-C. neoformans
2 μM
-C. albicans
4 μM,
-C. albicans
6 μM
-C. albicans (SC
5314) 3.1 μM

N-[RLLR]2C

RLLRRLLR

synthetic

helix

no

-C. albicans
0.5 μg/ml
-S. cerevisia
0.5 μg/ml

P-18
human
Dermcidin
(DCD-1)
rDCD-1L

Melittin

Pelteobagrin

KWKLFKKIP
KFLHLAKKF
SSLLEKGLD
GAKKAVGG
LGKLGKDA
VEDLESVGK
GAVHDVKD
VLDSV
SSLLEKGLD
GAKKAVGG
LGKLGKDA
VEDLESVGK
GAVHDVKD
VLDSVL
GIGAVLKVL
TTGLPALIS
WIKRKRQQ
GKLNLFLSR
LEILKLFVG
AL

synthetic
Homo
sapiens

helix

no

helix

no

-C. neoformans
0.5 μg/ml
C. albicans
2-4 μM
-C. albicans
10 μg /ml

recombinant

316

-C. albicans
12 μg /ml

Apis mellifera
(insect)

helix

no

NA

+5

286

Yellow catfish

unknown

no

-C. albicans
5.4 μM

+2

317
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Chapter 2
Analysis of wild-type, enantio, retro and retroenantio derivatives of the Histatin 5 16mer
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2.1 Introduction
Candida species are the fourth most common cause of nosocomial blood infections in the United
States, resulting in a mortality rate of up to 40 % 1. The estimated health care costs for the
treatment of Candida infections is approximately 1.8 billion dollars annually 2. Given the
morbidity and mortality associated with Candida infections, and the increased incidence of drugresistant Candida species, there is a strong emphasis on the development of new anti-fungal
drugs with novel mechanisms-of-action 3. To this end, antimicrobial peptides (AMPs) are
considered a promising alternative to the traditional chemical antifungal drugs that are currently
available. Antimicrobial peptides (AMPs) are known to play an important role in the human
innate immune response against pathogenic and opportunistic microorganisms 2. In addition,
some of these naturally occurring peptides have displayed anti-fungal activities with distinct
modes of action 4, 5. AMPs also offer the advantage of higher selectivity against target organisms
with reduced host toxicity as compared to the currently available anti-fungal drugs. Thus, a
logical starting point in the development of novel anti-fungal peptides would be to identify a
naturally occurring peptide with fungicidal activity and seek to enhance that activity.
Histatins are a family of naturally occurring peptides found on the mucosal surfaces of the oral
cavity, a common location of Candida infections 7. In fact, the oral cavity is one of the
predominant sites of Candida infection in the human body, with Candida albicans being the
most commonly isolated 8. In oral cavity, there are actually five distinct AMPs; however, only
three exhibit significant anti-fungal activity: HNP1-4 , histatins, and β-Defensins 9. The histatins
are a family of histidine-rich cationic peptides produced by the human parotid, submandibular,
and sublingual salivary glands 10, 11 . Histatin 5 is one member of the histatin peptide family that
has been shown to possess the most potent fungicidal activity and it has been extensively

78

characterized4, 13. Moreover, histatin 5 is among the smallest of the AMPs, making it
economically suitable for development as an antifungal compound.
Histatin 5 is a twenty-four amino acid peptide whose mechanism of action has been examined in
detail; however, the mechanism by which it kills fungi remains controversial. Two distinct
mechanisms-of-action have been proposed, a membrane lysis mechanism and a nonlytic
mechanism. In the membrane lysis mechanism, histatin 5 binds directly to the lipids of the
Candida plasma membrane, increases membrane permeability, and consequently causing cell
death due to loss of membrane integrity 14, 15. In contrast, the non-lytic mechanism suggests that
histatin 5 targets the metabolic activity of C. albicans, where the killing would result from the
inhibition of cellular respiration via depolarization of the energized mitochondrion and the
inhibition of ATP production16,17.
To target the mitochondria for inhibition, histatin 5 must be transported across the plasma
membrane. The translocation of histatin 5 across the plasma membrane has been proposed to
occur by multiple mechanisms. Artificial liposome experiments have suggested that the
translocation of histatin 5 is independent of any active endocytic pathways 14; whereas, several in
vivo studies have suggested that a plasma membrane protein Ssa2 is essential for the histatin 5
translocation process18, 19. However, the involvement of a specific protein receptor in histatin 5
translocation and subsequent antifungal activity seems unlikely since it was found that a histatin
5 derivative containing only D-amino acids was as active at the native peptide containing Lamino acids in fungicidal activity20, 21.
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Several studies have shown that the full-length twenty-four amino acid peptide is not required for
histatin 5 fungicidal activities since a truncated peptide, termed C-16 (a 16 amino acid fragment
of histatin 5), retains the full fungicidal activity 20. Since histidine is a major substituent in
histatin, the net charge for histatin 5 should be affected by pH. Moreover, changing the pH from
acidic to basic is sufficient to shift the net charge of the peptide from +14 to +5 based on
computational analyses. Surprisingly, histatin 5 and C-16 retain the same activity against
Candida albicans over a broad range of pH (from pH 5 to 9); indicating the optimal number of
positive charges and their role in fungicidal activity of histatin 5 remains unknown.
For the studies described in this chapter, histatin 5 has been selected as a model peptide.
Moreover, the 16 amino acid derivative of histatin 5 (C-16) was used since it is smaller, yet
retains antifungal activity indistinguishable from the 24 amino acid peptide found naturally [20].
The work presented in this chapter focuses on understanding the structural requirements for the
fungicidal activity of histatin 5 using C-16 as a model. A simple approach was used to initially
examine the structural requirements of the peptide, namely to evaluate whether the linear order
of amino acids from N- to C-terminus or the enantiomeric form of the peptide affects the antifungal activity. To address these questions, four C-16 histatin 5 derivatives were synthesized:
the wild-type C-16 peptide; C-16 peptide in which the amino acid sequence is reversed (retro-C16); the wild-type C-16 with D-amino acids (enantio); and the retro-C-16 peptide with D-amino
acids (retroenantio). The availability of these four histatin 5 derivatives allowed us to address
the relevance of the specific amino acid sequence as well as the stereochemistry of the peptide as
it relates to anti-fungal activity.
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2.2 Materials and Methods
Peptide synthesis. N-Fmoc protected amino acids and Wang resin was purchased from
NovaBiochem (San Diego, CA) and Advanced Chemtech (Louisville, KY), respectively. All
peptides were synthesized on a Model 433A solid-phase peptide synthesizer (Applied
Biosystems; Foster City, CA) using the Wang resin and Fmoc-protected amino acids. To
improve the synthesis yields, modified FastMoc chemistry was used with extended deprotection
and coupling times. After synthesis, the peptides were deprotected and cleaved from the Wang
resin using a high concentration TFA (trifluroacetic acid) cleavage cocktail consisting of 85%
TFA, 5% dH2O, 5% triisopropylsilan, and 5% phenol. The resin was allowed to mix in the
cocktail solution at room temperature for 3 h then precipitated in 50 ml 1:1 v/v methyl-t-butyl
ether/hexane per ml of cleavage cocktail. The peptides were subsequently dissolved in 1:1 v/v
acetonitrile/ddH2O and recovered by lypholization under high vacuum. Crude peptides were
purified on a PRP-3 reverse phase column (7 by 305 mm; Bio-Rad, Hercules, USA) on a Hitachi
L7100 HPLC instrument using a linear gradient of 0 – 30% acetonitrile and water. Peptides
were lyophilized multiple times from acetonitrile:water (1:1) to ensure complete removal of
TFA. The peptide was then further purified by HPLC and peptide purity was verified by mass
spectroscopy. Concentrations of the four peptides were determined by dried weight.
Fungicidal activity assays. The fungicidal activities of the peptides were determined by the
microdilution plate assay using Candida albicans SC5314 as described previously 13. C.
albicans SC5314 was grown overnight on Sabouraud Dextrose agar plates at 30oC. Following
overnight growth, a single C. albicans colony was diluted in 1 ml of 10 mM sodium phosphate
buffer at pH 7.4. A hemocytometer was used to quantify the number of cells/ml and the cell
concentration was adjusted to 1.8 × 105 cells/ml. Cell suspensions (20 µl) were mixed with 20 µl
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of peptide dissolved in 10 mM sodium phosphate buffer at pH 7.4 and incubated for 2 h at 37C
with shaking at speeds of 550 rpm. The reactions were stopped by the addition of 360 µl yeast
nitrogen base (3.4 g yeast nitrogen base without ammonium sulfate or amino acids and 10 g
ammonium sulfate per liter) and 40 µl of cell suspension was spread on Sabouraud dextrose agar
plates and incubated for 24 h at 37C. The number of colony-forming units (CFUs) was
qualified and each assay was repeated in triplicate. Loss of viability was calculated as [1-(CFUs
in the presence of the peptide/CFUs with no peptide)] × 100.
Minimum Inhibitory Concentration (MIC) assay. MIC assays were carried following the
CLSI M27-A2 standard with the modification as described below. Briefly, two-fold serial
dilutions of the peptides were prepared with RPMI-1640 (Sigma R-7755) in 100 μl per well of a
96-well flat-bottom microtiter plates (Costar, Cambridge, MA). To demonstrate the effect of salt
on peptide activity, different RPMI-1640 dilutions (1X, 0.5X, 0.25X, and 0.125X) were used.
To each well of the microtiter plates containing the peptide, a 100 μl C. albicans cell suspension
containing 1 × 104 cells /mL in a resazurin/water solution (0.01% w/v) was added. The final
concentration of the peptides in the assay ranged from 0.2 to 100 μM (0.4 to 206.7μg/ml,
respectively). The microtiter plates were subsequently incubated at 35°C and examined at both
24 h and 48 h after exposure to peptide. Each assay plate contained a positive control of
Candida albicans without added peptide and the negative control of RPMI-1640 medium
containing only the resazurin/water solution. For each peptide three independent assays were
performed. The MIC assay results were interpreted visually using the criteria of the lowest
peptide concentration that remained blue (indicating no growth) or the first dilution that changed
from blue to slightly purple (equivalent to prominent growth inhibition). The peptide
concentrations were determined based on the extinction coefficient of the four peptides.
82

Effect of pH, sodium chloride, EGTA, sodium azide and temperature on peptide killing
activity. The effect of pH on the killing activity of the four peptides was tested by performing
the fungicidal activity assays as described above using 10 mM sodium phosphate buffer at pH
values ranging from 5 to 9. The pH of the buffer was adjusted using 2 M HCl or NaOH. The
peptide net charge was calculated at the same pH range using Protein Calculator v3.3 server
(http://www.scripps.edu/~cdputnam/protcalc.html) 24. To study the effect of temperature on the
killing activity, the fungicidal activity assay was performed in 10 mM phosphate buffer pH 7 at
two different temperatures, 4oC and 37oC. The effect of sodium chloride (5 mM, 10mM and 25
mM), EGTA (10 µM, 50 µM, 100 µM, 250 µM, and 1000 µM) and sodium azide (5 mM) was
evaluated using the fungicidal assays in 10 mM phosphate buffer pH= 7 at 37°C.
Circular dichroism spectroscopy. Circular dichroism spectroscopy measurements for the four
peptides were performed using a Jasco-710 spectropolarimeter as described previously with
some modifications 25. The reading was made using a quartz cell with a 0.1cm path length at 25o
C. The measurements were performed on the peptides at a final concentration of 240 µM (100
µg) in the presence of 50% trifluoroethanol (v/v) (TFE). The spectra were recorded every 0.2
nm between the absorbance range of 190 to 250 nm with a 1.0 nm bandwidth and a scan speed of
20 nm/min. Six scans were performed and averaged. The background was subtracted from all
spectra, and curve smoothing applied. The CD spectra are reported as the mean residue
ellipticity ([Ө]) in degrees. cm2. dmol-1. The CD data were further analyzed using the web-based
K2D2 program (http://www.ogic.ca/projects/k2d2/). The helical wheel projections were made
with a tool created by Don Armstrong and Raphael Zidovetzki 26, 27.
Peptide Stability in Artificial Gastric Juice. The stability of each peptide was tested using
artificial gastric juice prepared as described previously with slight modifications 28. The artificial
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gastric juice was prepared by dissolving 2 g NaCl and 3.2 g pepsin in 7.0 ml 0.085 M HCl and
the volume was increased to 1000 ml with distilled water (pH 1.2). The peptide (5 µg in volume
of 10 µl) was added to 90 µL of artificial gastric juice and incubated at 37oC for 60 min. The
reaction was terminated by boiling for 10 min and the sample was centrifuged at 13,000 rpm for
10 min. in a microcentrifuge. The supernatant was collected, neutralized with NaOH, and
analyzed by reverse phase HPLC. The HPLC run time was 15 min with an injection volume of
50 µl. Chromatograms were recorded by UV detection at 220 nm. The individual peptides in 10
mM phosphate buffer (pH=7.4), were used as positive controls. Concentrations of the peptides
were determined based on the extinction coefficient.
Peptide Stability in Human Saliva. Whole saliva samples (5 ml) were collected from three
healthy donors ranging in age from 25 to 35 years in accordance with a protocol approved by the
University of Arkansas Institutional Review Board. The stability of the peptides in human
saliva was determined as described previously with slight modifications 28. After the saliva was
collected, it was immediately centrifuged at 13,000 rpm for 10 min at 4oC in a microcentrifuge
and the supernatant was aliquoted 1 ml portions and stored at -80o C. One milliter of saliva from
each volunteer was pooled, mixed and filtered through a 0.45 µm membrane filter. The stability
assays was performed using a constant ratio of peptide to saliva (1:9). Twenty µl of peptide in 10
mM sodium phosphate buffer (pH=7.4) was mixed with 180 µl of saliva to give a final peptide
concentration of 0.5 mg/ml. The mixture was incubated for 60 min at 37oC, and the reaction
terminated boiling the samples for 10 min. The samples were subsequently filtered and analyzed
by reversed phase HPLC. The HPLC total run time was 15 min and the injection volume was
100 µl. Chromatograms were recorded by UV detection at 220 nm. The peptide dissolved in
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artificial saliva was used as a control. The peptide concentration was determined based on the
extinction coefficient of the peptides.
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2.3 Results
Synthesis of the histatin 5 peptide derivatives. To understand the structural features and
stereochemistry of histatin 5 that is important for the antifungal activity we synthesized the wildtype histatin 5 C-16 peptide (termed W) 20 along with three derivatives shown in Table 1. The
first derivative was identical to the C-16 peptide except it contained only D-amino acids (termed
WD). The second derivative is a “retro” isomer in which the order of amino acids is reversed
from N- to C-terminus (termed R). The third derivative was identical to the retro isomer except
D-amino acids were used for the synthesis. The W and R peptides had the identical amino acid
composition with the difference being the N- to C- terminal linear order. The N- to C- terminal
sequence of R is represented by 1, 2, 3...n amino acid, while R peptide is represented by the
sequence n, n-1,..3, 2, 1. The WD and RD peptides are stereoisomers of W and R, respectively.
All peptides were synthesized and the molecular mass of each peptide was evaluated by mass
spectrometry and was shown to match the predicted mass based on the amino acid composition
(Figure 1). The quality of each peptide was verified by HPLC to be >97% pure (Figure 2).
Fungicidal activity of the histatin 5 derivatives. To compare the relative antifungal activity of
the four peptides, two different assays were performed with C. albicans SC5314. First, the dosedependent killing activity of the four peptides was examined. In this assay, different
concentrations (0.1, 1, 5, 10, 25, 50 and 100 µM) of the four peptides were evaluated and the
dose-dependent killing activity after 2 h incubation was found to be indistinguishable (Figure 3).
. Furthermore, all four peptide exhibited a similar fungicidal activity with an LD50 of less than
3µM (Table 2 and Figure 4).
Since the dose-dependent killing assay is not time dependent, it is possible that all of the peptides
demonstrated similar killing activity, yet the rate at which they killed the fungal cells varied over
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the 2 h incubation time. To address this possibility, a time-dependent fungicidal activity assay
was performed in which C. albicans was incubated with 10 µM of each peptide and the
fungicidal activity was determined at time intervals of 15, 30, 60 and 120 min (Figure 5). The
kinetics of the anti-fungal activity of all four peptides was found to be similar at all data points (p
< 0.05). Since the standard fungicidal assay is incubated for 2 h, it was relevant to determine
whether the four peptides continued to demonstrate activity beyond the 2 h incubation;
alternatively, the activity of the peptides may plateau at some point prior to 2 h. To address this
question, another fungicidal activity assay was performed over a period to 8 h (Figure 6). These
data demonstrate that the activity of all four peptides plateau at approximately 2 h with 20% of
the cells remaining viable when exposed to 10 µM of each peptide.
On the basis of the fungicidal activity data, the R, RD, W, and WD peptides demonstrated
similar killing activity, suggesting the linear order of amino acids from the N- to the C-terminus
is not relevant for the fungicidal activity. Moreover, these data also demonstrate that the
enantiomeric form of the peptide is also not significant for fungal killing activity. These
observations strongly argue against a cell surface protein receptor playing a role in the killing
activity as will be discussed later.
The effect histatin 5 inhibitors on fungicidal activity. To further explore the similarities or
differences between the four histatin 5 peptide derivatives, a series of experiments were
performed using conditions known to inhibit the fungicidal activity of histatin 5, namely
reduced temperature 29, increased concentrations of sodium chloride and the respiratory inhibitor
sodium azide 30. The goal was to determine whether the four peptides display any differences in
killing activity as compared to the native histatin 5.
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Previous studies have demonstrated that the killing of C. albicans cells by histatin 5 is halted at
4oC by presumably preventing translocation of the peptide into the cytoplasm29, 31 or by altering
the fluidity of the plasma membrane. To evaluate the effect of temperature on the activity of the
W, R, WD and RD peptides, each peptide was incubated with Candida albicans at two different
temperatures, 4oC and 37oC. The activity of all four peptides was found to be dramatically
inhibited at 4oC as compared to 37oC (Figure 7).
As common with many peptide-based antimicrobials, it has been shown previously that
increasing concentrations of sodium chloride (NaCl) can inhibit the killing activity of histatin 5.
To examine the inhibitory effect of NaCl on the W, R, WD, and RD peptides, two different
assays were performed. First, the peptides were tested at different concentrations of NaCl up to
25 mM, which mimics the physiological concentration of NaCl in human saliva 32. Second, a
minimum inhibitory concentration assay (MIC) was performed for each peptide to evaluate the
fungicidal activity at physiological concentration of various salts 33. As shown in Figure 8, NaCl
has the same inhibitory effect on fungicidal activity for the four peptides using 5 µM of each
peptide. The decrease in the activity was clearly observed at 10 mM NaCl or higher. For the
MIC assay, the standard RPMI-1640 medium used at 1X, 0.5X, 0.25X and 0.125X normal
concentrations. The logic was to set up a visual assay typically found in a clinical setting that
would reflect the effect of physiologic salts on the activity of candidate fungicidal peptides. As
expected, the activity of the four 16mer peptides was completely inhibited in 1X, 0.5X, and 0.25
X RPMI-1640 medium. The only observed activity was at the lowest RPMI-1640 concentration
(0.125X) (Table 3). Interestingly, the D-conformation peptides (WD and RD) displayed slightly
better activity in 0.125X RPMI. The MIC value for WD and RD peptides was 103-207 µg/ml,
while the W and R peptide activity was outside the range of the assay (>207 µg/ml).
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Sodium azide, an inhibitor of cytochrome oxidase activity, has been shown previously to inhibit
histatin 5 fungicidal activity 30 which is likely reflective of its killing mechanism. Hence, the
sensitivity of the four histatin 5 peptide derivatives W, R, WD, and RD to the treatment of cells
with sodium azide would provide preliminary evidence suggesting that all four peptides are
killing by similar mechanisms. Thus, the fungicidal activity of the four peptides was evaluated
in the presence of 5 mM sodium azide. To compensate for ionic strength effects caused by the
presence of sodium and azide ions, the control reactions without sodium azide were performed in
buffer supplemented with 5 mM of sodium chloride. These data demonstrated that the inhibitory
activity of sodium azide was similar for all four peptides, providing support for the model that all
four peptides function via similar killing mechanisms (Figure 9).
pH sensitivity of the histatin 5 derivatives. As mentioned in the Introduction, histatin 5 is a
cationic peptide containing a large number of histidine residues (29% histidine). If the histidines
are structurally important for the killing activity, and the fact that pKa of imidazole sidechain is
approximately 6.0, it would not be surprising that the fungicidal activity of histatin 5 is pHsensitive. Consistent with this hypothesis, the predicted peptide net charge was calculated across
a range of pH values (Figure 10A). It is predicted that the net charge changes significantly as the
pH shifts from acidic to basic, from +8 net charge at pH 5 to +3 net charge at pH 9. To evaluate
the relevance of pH in the activity of the histatin 5 derivatives, the fungicidal activity of the
peptides were determined at various pH values ranging from 5 to 9 (Figure 10B). It was found
that no significant difference in the fungicidal activity occurred across the range of pH values,
suggesting the histidine residues within histatin 5 may not be a primary factor in the killing
activity of histatin 5.
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The role of zinc in the fungicidal activity of the histatin 5 derivatives. It has been previously
demonstrated that Histatin 5 contains a zinc-binding domain of a general sequence HEXXH 34, 35
that is part of the C-16 peptide used in the studies reported in this chapter. However, it is unclear
whether the retro peptides retain the ability to bind zinc. Moreover, the overall contribution of
zinc-binding to the fungicidal activity of histatin 5 remains controversial. To evaluate whether
zinc-binding contributes to the killing activity of the W, WD, R, and RD peptides, EGTA was
added as a metal chelator to remove any metal ions, including Zn+2 in the fungicidal activity
assay. EGTA was chosen in preference to EDTA because EGTA shows no fungicidal activity
alone in concentrations up to 10 mM. As shown in Figure 8, the addition of EGTA to the
fungicidal activity assay had only a slight inhibitory effect on the killing activity of the four
peptides, suggesting that zinc is not a major contributing cofactor to the killing mechanism of the
histatin 5 peptide derivatives.
Structural analysis of the histatin 5 derivatives. To evaluate whether there were any major
differences in secondary structure of the four histatin peptide derivatives, circular dichroism
(CD) spectroscopy was performed (Figure 12). The data were acquired for each peptide in the
presence of 50% trifluoroethanol. As illustrated in Figure 12, all four peptides folded into alpha
helical structures and the deconvolution of the spectrum using the K2D2 software program 38
yielded a similar percentage of helical structure in all peptides (41.1 % in W and WD, while the
value was 40.8% in R and RD). As expected, the CD spectra of WD and RD were mirror images
of W and R, respectively, with the same ellipticity value but with the opposite sign. The
distribution of charges on a hypothesized alpha helical structure was evaluated using helical
wheel projections (Figure 13) 39. The charge distribution remained the same in the R peptide
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versus the W peptide keeping the basic amino acids biased to one side of the helix, and
uncharged and nonpolar on the other side.
The stability of the histatin 5 derivatives in human saliva. Histatin 5 is secreted from the
salivary glands into the oral cavity where it is active in controlling microbial cell growth. Thus,
the stability in human saliva of the wild-type C-16 versus the retro-C16 peptide was compared to
determine whether they displayed any differences. The stability assay was performed by
incubating the W and R peptides with human saliva for 60 min and concentration of the peptide
after the incubation period was monitored using HPLC (Figure 14) as described in the Materials
and Methods. These data demonstrated that both peptides were completely degraded after 60
min incubation in human saliva.
The stability of histatin 5 derivatives in simulated gastric juice. Since histatin 5 is present in
saliva, it is likely to pass through to the stomach, and to the small bowel. Since Candida spp. are
a common commensal of the gastrointestinal tract, the stability of the histatin 5 peptide may be a
relevant issue for the control of Candida spp. growth in the gastrointestinal tract. To examine
the stability of the histatin 5 related peptides, artificial gastric juice was prepared as described in
the Materials and Methods. The simulated gastric juice was subsequently used to evaluate the
stability of the peptides after 60 min at 37oC. Surprisingly, these data demonstrated that the
wild-type 16mer peptide (W) was extremely stable in gastric juice, while the retro (R) peptide
was degraded completely during the 60 min incubation (Figure 15). The results were confirmed
by mass spectrometry. The W peptide with a mass of 2067 g/mole was the only molecule
detected, which represents the full-length 16 amino acid peptide (Figure 17). In contrast, two
fragments were detected in R peptide samples with the full-length peptide barely detectable
(Figure18). The analysis of mass spectrometry data revealed that the R peptide was cleaved only
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in one location, immediately after the single phenylalanine in the peptide (Table 4). The Disomers of both the W and R peptides were stable in artificial gastric juice as expected
(Figure16). The results of peptide stability in artificial gastric juice are summarized in Figure 19.
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2.4 Discussion
Currently available antifungal agents have been effective against fungal infection for an extended
number of years; however, the increased use of these agents has been associated with a
development of new resistant strains, including Candida species. The increase in resistant fungal
pathogens has emphasized the need for new antifungal agents. AMPs have been used widely as
a base for the development of new clinically approved antibacterial and antifungal drugs 40,41, 42.
Studying the structure and mode of action of AMPs could lead to a development of new drugs
via chemically mimicking AMPs in structural features such as the net charge, amphipathicity,
and selectivity for the pathogen. For example, Ceragenix, a squalamine peptide based antibiotic,
is effective against a broad spectrum of bacterial infections 43and mPE (PMX70004), a
phenylethynylene derivative of the maganin peptide, exhibits a broad-spectrum of activity
against oral cavity pathogens44.
Despite the lack of understanding the mechanism of action of histatin 5, all of the proposed lytic
or nonlytic mechanisms for histatins would imply that they have a target that is distinct from the
current antifungal agents. After a careful analysis of the histatin 5 amino acid sequence and
studying the published data, we developed the hypothesis that the distribution of positively
charged amino acid residues and secondary structure are the critical factors in histatin 5
fungicidal activity rather than the total net charge or the specific N- to C-terminal amino acid
sequence. The question was how to effectively begin to address the proposed hypothesis.
Several prior studies with different peptides have shown that using the retro peptide model has
been a successfully strategy in dissecting the structural requirements of antimicrobial peptides.
In most cases retro and diastereo analogs retained the same activity as the original peptides 49-53.
Thus, the generation of retro peptides and stereoisomers was adopted as a strategy to understand
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the structure features of histatin 5 important for fungicidal activity. We chose to use the C-16
histatin 5 peptide derivative since several publications have shown that the C-16 peptide of
histatin 5, an N-terminal truncated derivative containing 16 amino acid residues, retains the same
fungicidal activity as the full-length 24 amino acid peptide. Thus, the C-16 peptide, referred to
as the W peptide in this study, was used as a model due to the shorter sequence that eliminates
amino acid residues that did not influence antifungal activity. The optimal way to test our
hypothesis that the linear N- to C-terminal order of amino acids was not relevant was by
generating a retro peptide, where the amino acid composition and the total net charge remained
the same as the W peptide. The retro peptide, referred to as the R peptide, was synthesized using
same amino acid sequence as the W peptide but the amino acid sequence was reversed (Table 1).
To evaluate stereospecificity, two additional peptides with D-amino acids were synthesized, and
termed the WD and RD peptides (Table 1).
The first step was to examine the fungicidal activity of the four histatin 5 derivatives. The
fungicidal activity assays showed that the W, WD, R and RD peptides were equally active over a
range of concentrations against Candida albicans. The differences in activity were found to be
insignificant (P<0.05) (Figure 1). The LD50 value for histatin 5 and C-16 peptide has been
published previously, and the values range from 2 to 7.3 µM against most Candia albicans
strains 10, 45-48. The LD50 values for W, WD, R, and RD peptides were calculated and shown to
be similar to each other and to the previously published data (Table 2). Since there was the
possibility that the four peptides may kill C. albicans at different rates, the kinetics of killing was
examined in a time course assay. These studies indicated that all four peptides reached a
maximum killing activity after 2 h of incubation (Figure 5, 6). The kinetic studies indicated no
significant difference between the four histatin 5 peptide derivatives.
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While the four histatin 5 peptides derivative demonstrated similar fungicidal activities, it was
plausible that they were functioning via distinct mechanisms. Thus, we examined the activity of
the four histatin 5 peptide derivatives under conditions known to effect histatin 5 killing activity.
Low temperature has been shown to inhibit histatin 5 fungicidal activity via one of two
suggested mechanisms: affecting cell metabolism by reducing cell respiration and ATP
production 31, and increasing membrane rigidity. This in turn leads to a decrease in the binding
of histatin 5 to the yeast cell membrane and reduces or eliminates the translocation to cytoplasm
30

. Our data showed that low temperature displayed the same effect on all four peptides,

inhibiting 70% of their fungicidal activity against Candida albicans. This result demonstrates
that regardless of the exact effect of temperature on histatins 5 activity, the retro peptides likely
work through the same pathways as W peptide. The inhibitory effect of low temperature was not
unique to histatin 5, as it has been observed in several antibacterial and antifungal peptides54-56.
Histatin 5 activity can also be blocked by the inhibition of cellular respiration using sodium
azide17. Sodium azide is a potent inhibitor of mitochondrial respiration as it inactive cytochrome
c oxidase via intercalating between the home a3 iron and Cu3 at the oxygen reduction site 57.
Also, sodium azide binds to the F1 catalytic domain within mitochondrial F-ATPase’s and
inhibits the hydrolyase activity 58,59. Multiple previous studies have shown that 5 mM sodium
azide inhibits both the conventional and the alternative respiratory pathways in Candida
albicans17, 60.
This observation led to the hypothesis that histatin 5 may target energized mitochondria. Thus,
the influence of azide on Candida albicans susceptibility to the four histatin 5 peptide derivatives
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was examined. As illustrated in Figure 9, the activity of the peptides was equally inhibited by
azide. Taken together, the inhibition by low temperature and azide suggests that the fungicidal
activity of the four peptides is occurs via a similar or identical mechanism.
In general, the killing activities of cationic AMPs are sensitive to ionic strength, with some
limited exceptions 32, 61, 62, 63. Because of the nature of the ionic interaction between cationic
AMPs and the negatively charged membrane of the target organism, it can be weakened by
monovalent and divalent cations to reduce their activity 64. Histatin 5 activity has been
evaluated under different physiological conditions and it was found to be affected by the
presence of salts including sodium chloride 32. In this study, the four peptides were evaluated in
a presence of NaCl simulating two different physiological environments: oral cavity with salt
concentration ranges from 5 to 25 mM sodium chloride 65 and RPMI1640 tissue culture medium.
The RPMI-1640 medium contains multiple salts along with 150 mM sodium chloride, which
simulates the human cellular environment29. At 25 mM NaCl, the four histatin 5 peptide
derivatives were all inhibited by 35%, while it was totally impaired in RPMI-1640 medium.
Published data showed that the activity of histatin 5 against Candida albicans (SC5314) was
abolished totally in 150 mM NaCl 66 and was undetectable in RPMI medium 67. It’s important to
mention that besides salt content, RPMI 1640 medium also induces the hyphal growth of C.
albicans 68, 69. The role of hyphae will be discussed later. Our results show the effect of NaCl on
R and RD peptides matches W and WD peptide. This finding further supports the hypothesis
that these peptides work via similar mechanisms that require an ionic interaction for activity.
In addition to salt sensitivity, cationic AMPs activity is also pH dependent in many cases61. The
pH has an effect on AMPs activities by interfering with the target cell or the peptide. C. albicans
has the ability to grow either as unicellular budding spherical yeast or as filamentous
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pseudohyphal and hyphal forms 70. The ability to switch between these two forms plays an
important role in Candida pathogenicity 71. This switching process can be stimulated by changes
in pH 72, namely moving toward pH 7 or greater. Previously published data suggests that the
activity of antifungal agents against different Candida forms varies with the hyphae being more
resistant 71. This factor must be taken into consideration when developing an effective
therapeutic agent against Candida spp. In the case of histatin 5, prior studies have suggested the
peptide has the same activity against all of the morphological forms of Candida46.
The net charge of cationic peptides plays an important role in their activity and an increase in net
charge usually leads to an increase in the antimicrobial activity 15, 73 . The net charge on
peptides is dictated by the presence and abundance of basic amino acids (arginine, lysine and
histidine) and acidic amino acids (aspartic acid and glutamic acid). The pH interferes directly
with the peptide net charge as each amino acid has a unique pKa and isoelectric value. Thus, the
vast majority of cationic AMPs are more active at acidic medium than basic medium 32. Unlike
other AMPs, pH has little effect on histatin 5 fungicidal activity 74. As the data shown in Figure
10A the net charge decreased dramatically as the pH shifted from acidic to basic and that change
can be related to the abundance of histidine residues. The pKa of histidine side chain (imidazole
ring) is 6 75 which means it will lose the positive charge and become neutral at physiological pH
(7.4) and above. Changing the pH from 5 to 9 is sufficient to shift the net charge of histatin 5
from +14 to +5; however, the published data suggest that this change in histatin 5 charge did not
correlate with any significant effect on the fungicidal activity. The same observation was made
with bot the W and R peptides in our study; they retained fungicidal activity over the same range
of pH from 5 to 9 (Figure10B). After excluding the positive charges contributed by histidine
residues, only few positive charges remained in histatin 5 or the derivatives examined in this
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study. Thus, if there is a role for positive charge in histatin 5 activity, it would be represented by
lysine and arginine residues. Several published results have supported this conclusion. For
example, the replacement of lysine-13 with glutamic acid and arginine-22 with glycine was
enough to reduce histatin 5 killing activity 76. A single substitution of histidine for a lysine
increases the fungicidal activity of histatin 5 by 50 % 5. Because pH did have an effect on our
four peptides, not all positive charges may be required for R and W peptide. These results are
not unique to histatin 5, as similar observations have been reported with other peptides 32.
Histatin 5 peptide sequence contains two different metal binding motifs, ATCUN and a zinc
binding domain 77. Binding to Cu2+ and Ni2+ ions, the ATCUN motif is located at the N-terminal
and it is represented by a sequence of DSH. On the other hand, the HEXXH sequence represents
the zinc binding motif. The C-16 peptide sequence used in our study still contains the zinc
binding motif, but not the ATCUN motif. The zinc-binding motif could improve histatin 5
activity by binding with metal ions78. Since reversing the C-16 sequence in the retro peptide
may influence zinc-binding, it was important to evaluate the relevance of metal ion binding to
the activity of the four peptides. Thus, the influence of zinc-binding on the activity of the four
histatin 5 peptide derivatives was examined by the inclusion of EGTA in the fungicidal activity
assay in an effort to chelate any divalent ions in the medium. EGTA was chosen over EDTA
because the latter displays some antifungal activity of its own, while EGTA lacked any
antifungal activity up to 10mM 37. The data demonstrated that the fungicidal activity of all four
peptides was not affected significantly over a wide range of EGTA concentrations (10 µM to
1mM) (Figure 11). This finding strongly suggests that metal binding is not a major factor in the
fungicidal activity of histatin 5.
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Histatins in general and the C-16 (W) peptide specifically have been shown to form an alpha
helical structure in a presence of trifluoroethanol (TFE) and synthetic lipids 5, 79. The formation
of a helical structure leads to the amphipathic structure by which the hydrophobic residues are
biased to one side of helix and the hydrophilic residues to the opposite side. Furthermore, the
ability to form an amphipathic alpha helix was found to be essential for the fungicidal activity of
histatins5. To evaluate the effect of reversing the sequence on peptide structure and to determine
whether the R peptides retained the ability to form an amphipathic alpha helix, CD spectra were
performed in 50% TFE to mimic a hydrophobic environment 80. The percentage of alpha helix
in each peptide was calculated using K2D2 software. CD spectra have been used in several
publications to determine the secondary structure of retro peptides and the results have varied. In
some cases the percentage of α-helix was similar in the retro peptide 81 while it was different in
others 51, 52, 82. The CD data obtained with the four histatin 5 derivatives demonstrated that
reversing the sequence of the W peptide, generating R peptide, did not interfere with the ability
of the peptide to form an alpha helical structure as the percentage of helix was very similar
(Figure 12). The amphipathicity of R peptide was evaluated using a helical wheel model and the
results for the R peptide suggested that this peptide could form an amphipathic structure (Figure
13). It should be noted that the exact region of the peptides that form the helix at 50% TFE is
undefined. The CD data confirm the similarity between the tested peptides and proof that
reversing the sequence of W peptide didn’t interfere with the potential amphipathicity or the
propensity to form an alpha helix.
Human saliva contains a pool of protease enzymes, more than thirteen, with various activities
such as trypsin-like, chymotrypsin-like and histidine peptidase 83, 84. These enzymes are mostly
secreted from white blood cells and microflora, but some are produced by the salivary glands 85,
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. The main cleavage sites of salivary proteases are lysine and arginine residues for trypsin-like

enzymes, aromatic amino acids for chymotrypsin-like, and histidine is the primary target for
histidine protease 83, 84. The stability of histatin 5 in saliva has been evaluated in multiple
publication and the kinetics of histatin proteolysis in saliva have also been measured 78, 83. The
rate of histatin 5 degradation in saliva was approximately17.8 µg/ml/h and the T1/2 was
approximately 8 h 33. However these studies didn’t use whole saliva, instead they used a diluted
version (1:10) 33. Histatin 5 is not highly stable in saliva due to the abundance of histidine,
lysine and arginine residues. In this study, the stability of the four histatin 5 derivatives was
evaluated using undiluted saliva. Not surprisingly, D-amino acid peptides (WD and RD) showed
extreme stability, while the L-peptides (W and R) were totally degraded after a sixty minute
period of time. The stability of D conformation AMPs in saliva and protease enzymes has been
confirmed in multiple occasions 28, 86-90. The stability of other AMPs has been evaluated in
saliva and in several cases they were degraded completely in less than 60 min 86, 87. For
example, the T1/2 for the KSL peptide, in saliva was less than 5 minutes and the peptide was
totally degraded within 10 minutes 28. In summary, no superior stability was observed for the
retro peptide in human saliva; however, the D-amino acid peptides are highly stable.
Since the histatin 5 that is secreted from the oral cavity will travel to the stomach, the stability in
simulated gastric juice was measured. Pepsin, a major digestive enzyme found in gastric juice,
cleaves peptides and proteins before and after any hydrophobic residue, such as phenylalanine,
tryptophan, and tyrosine. Therefore, there were three possible cleavage sites within the W and R
peptides (two tyrosine and one phenylalanine), which could generate six possible proteolytic
fragments (Table 4). Unexpectedly, HPLC data showed that the W peptide is stable in the
simulated gastric juice for over 60 minutes, while the R peptide was totally degraded within the
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same period of time (Figure15). The mass spectrometry data revealed that pepsin selectively
cleaved the R peptide at phenylalanine and it did not cleave at tyrosine residues as anticipated.
This is not the first reported case in which pepsin selectively cleaved one predicted residue over
another 28, 91. In addition, the stability of the W peptide is not the first AMP to be stable in the
stomach as several peptides that target H. pylori 92, 93 have proved to be stable in the stomach.
Because we are the first to report a stability of histatin 5 analogs in gastric juice, we cannot
generalize these data or compare it to the full-length histatin 5. As predicted, the Dconformation peptides were stable in simulated gastric juice 28.
In an attempt to understand the stability of the W peptide, we used the software program Expasy
Peptide Cutter to predict the stability of the W peptide over the R peptide in pepsin. The
possible explanation could be the accumulation of positively charged amino acid residues before
the susceptible residue because in W peptide there are three basic amino acid residues before the
phenylalanine (K+R+K+F) while in R peptide the basic residues occur after the phenylalanine
(FK+R+K+). Thus, the stretch of positively charged amino acids may interfere with pepsin
activity with the W peptide. It is important to mention that this observation was considered in
the design of other antifungal peptides under development in our laboratory.
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2.5 Conclusions
In summary, reversing the sequence of the W peptide to generate the R peptide did not interfere
with the fungicidal activity or the peptide secondary structure. The results of the killing assays
in a presence of common histatin 5 inhibitors (NaCl, sodium azide, EGTA and low temperature)
endorse the similarity between the W and R peptides, and support the hypothesis that both work
through the same pathway. An ionic interaction step is required for all peptides to achieve their
activity. Chirality and stereospecificity have no role in the peptide activity as the Dconformation peptides retained the full activity. The secondary structure and distribution of
certain positive charges are essential factors for the fungicidal activity rather than the specific Nto C-terminal amino acid sequence.
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Table 1: Histatin 5 peptide derivatives synthesized.
Peptide
Sequence1
Histatin 5 (24 amino acid natural peptide
DSHAKRHHGYKRKFHEKHHSHRGY
Normal (C-16) Histatin 5 (W)
GYKRKFHEKHHSHRGY
Normal (C-16) Histatin 5 with D-amino acids
GykrkfhekhhshrGy
(WD)
Retro (C-16) Histatin 5 (R)
YGRHSHHKEHFKRKYG
Retro (C-16) Histatin 5 with D-amino acids (RD)
yGrhshhkehfkrkyG
1
Lower case sequence is used to designated D-amino acids
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Table 2: The LD50 for the W, WD, R, and RD peptides against Candida albicans (SC5314).
Peptide
LD50 (µM)1
Normal (C-16) Histatin 5 (W)
2.705 ± 0.445
Normal (C-16) Histatin 5 with D-amino acids (WD)
2.400 ± 0.289
Retro (C-16) Histatin 5 (R)
2.928 ± 0.472
Retro (C-16) Histatin 5 with D-amino acids (RD)
2.477 ± 0.177
1
Data represents three independent experiments and the error represents the standard
deviations. LD50 is defined as the peptide concentration at which 50% of the viable cells were
killed under the assay conditions and was determined using linear regression equations as
shown in Figure 4.
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Table 3: Minimum Inhibitory Concentration assay for the W, WD, R and RD peptides
RPMI-1640 medium1.

1

Peptide

1X

0.5X

0.25X

0.125X

W

>206.7

>206.7

>206.7

206.7

R

>206.7

>206.7

>206.7

>206.7

WD

>206.7

>206.7

>206.7

103-206.7

RD

>206.7

>206.7

>206.7

103-206.7

Data are expressed in µg/ml.
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Table 4: Mass Spectrometric identification of the degraded R and W peptides in simulated
gastric juice as determined by MALDI-TOF.
Peptide

Sequence1

Mass (m/z)

R

Y-G-R-H-S-H-H-K-E-H-F-K-R-K-Y-G

2067

Degraded R-1

Y-G-R-H-S-H-H-K-E-H-F

1434

Degraded R-2

K-R-K-Y-G

651

W

G-Y-K-R-K-F-H-E-K-H-H-S-H-R-G-Y

2067

1

Slash (/) represents the detected cleavage site .The bold underlined amino acids represent the
possible cleavage sites for pepsin.
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RD
1000

1500

2000

2500

Figure 1: Mass spectrometry of the four peptides (W, WD, R, RD) using matrix-assisted
MALDI-TOF mass spectrometry. The expected mass of the four peptides is 2067 g/mol. W is
normal (C-16) histatin 5 peptide while R is the retro peptide. WD and RD are enantiomers of W
and R peptide, respectively.
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12:45
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12:50
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Figure 2: HPLC elution profiles of the four peptides. Elution time (minute: seconds) of the
main peak is shown for each peptide. The peptides are W is normal (C-16) histatin 5 peptide
while R is the retro peptide. WD and RD are enantiomers of W and R peptide, respectively.
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Figure 3: Relative fungicidal activity of W, WD, R and RD peptides against C. albicans
SC5314. Different concentrations of each peptide were incubated with C. albicans (1.8×105
cells/ml) in 10 mM Sodium phosphate buffer for 2 h at 37oC. The percent fungal cell viability
was determined by counting the viable colonies on Sabouraud dextrose agar (SDA) as compared
to the number of colonies on peptide-free control plate. Data represents the mean of three
independent experiments and the error bar represents the standard deviation.
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Figure 4: Determination of the LD50 for W, WD, R and RD. The data generated in Figure 3
was used to calculate the LD50 of each peptide using linear regression equations and the results
are summarized in Table 2.
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Figure 5: Kinetics of fungicidal activity against C. albicans for the W, WD, R, and RD
peptides. For each assay, 10 µM peptide was incubated with Candida albicans (1.8×105
cells/ml) in 10 mM sodium phosphate buffer for different time periods (15 ,30 ,60 and 120 min).
The percentage of viable cells at each time point was calculated relative to a control without
peptide incubated for an identical time. Data represents the mean of three independent
experiments and the error bar represents the standard deviation.
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Figure 6: Extended kinetics of fungicidal activity against C. albicans for the W, WD, R, and
RD peptides. For each assay, 10 µM peptide was incubated with Candida albicans (1.8×105
cells/ml) in 10 mM sodium phosphate buffer for different time periods (0.25, 0.5, 1, 2, 4, 6, and 8
h). The percentage of viable cells at each time point was calculated relative to a control without
peptide incubated for an identical time. Data represents the mean of three independent
experiments and the error bar represents the standard deviation.
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Figure 7: The effect of temperature on fungicidal activity. For each assay, 10 µM of W, R,
WD, and RD peptides were incubated with C. albicans (1.8×105 cells/ml) in 10 mM sodium
phosphate buffer for 2 h at either 4oC or 37oC as indicated. The percentage of viable cells was
calculated as (viable colonies in the presence of peptide / viable colonies without peptide) × 100.
Data represents the mean of three independent experiments and the error bar represents the
standard deviation.
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Figure 8: The effect of sodium chloride on fungicidal activity. For each assay, 5 µM of W, R,
WD, and RD peptides were incubated with C. albicans (1.8×105 cells/ml) in 10 mM sodium
phosphate buffer for 2 h in the presence of increasing concentrations of sodium chloride ( 0, 5
,10, and 25 mM). The percentage of viable cells was calculated as (viable colonies in the
presence of peptide / viable colonies without peptide) × 100. Data represents the mean of three
independent experiments and the error bar represents the standard deviations.
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Figure 9: The effect of sodium azide on fungicidal activity of W, WD, R and RD peptide against
C. albicans. 5µM of each peptide was incubated with Candida albicans (1.8×105 cells/ml) in 10
mM Sodium phosphate buffer for 2 hours in the presence of 5mM sodium azide. A control
contains 5mM sodium chloride was used. The percentage of viable cells was calculated as
(viable colonies in the presence of peptide / viable colonies without peptide) × 100. Data
represents the mean of three independent experiments and the error bar represents the standard
deviations.
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Figure 10: The pH dependence of fungicidal activity of the four histatin 5 peptide
derivatives. (A) The calculated net charge of the peptides at different pH values. The net
charges were calculated using Protein Calculator v3.3 - Scripps Research Institute. (B) For each
assay, 20 µM of the indicated peptide was incubated with Candida albicans (1.8×105 cells/ml)
for 2 h at 37oC in 10 mM sodium phosphate buffer at different pH values (5, 6, 7, 8 and 9). The
percentage of viable cells was calculated as (viable colonies in the presence of peptide / viable
colonies without peptide) × 100. The data represents the mean of three independent experiments
and the error bar represents the standard deviation.
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Figure 11: Role of zinc binding in fungicidal activity of the histatin 5 peptide derivatives.
For each assay, 10 µM of peptide was incubated with Candida albicans (1.8×105 cells/ml) in 10
mM sodium phosphate buffer in a presence of increasing concentrations of EGTA as indicated.
The percentage of viable cells was calculated as (viable colonies in the presence of peptide /
viable colonies without peptide) × 100. The data represents the mean of three independent
experiments each and the error bars represents the standard deviation.
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Figure 12: CD spectra in 10 mM phosphate (pH 7.4) at 25oC in the presence of 50% TFE (A) R
and RD peptides (B) W and WD peptides. The samples were prepared as described in Materials
and Methods. CD spectra are displayed in mean residue ellipticity [θ].
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Figure 13: Predicted helical wheel projections of the R peptides (left) and the W peptides
(right). The helical wheel projections were prepared with the tool created by Don Armstrong and
Raphael Zidovetzki. Amino acids illustrated in the light background are charged while those
amino acids depicted in the dark background represent non- polar and polar uncharged amino
acids.
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Figure 14: Stability of the wild-type (W) versus retro (R) peptide in human saliva. The R
(panel A) and the W (panel B) peptides were incubated in human saliva for 60 min at 37oC and
the level of peptide degradation was determined by HPLC. The samples were prepared and
processed as described in Materials and Methods.
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Figure 15: Stability of the wild-type (W) versus retro (R) peptide in artificial gastric juice.
The R (panel A) and the W (panel B) peptides were incubated in artificial gastric juice for 60
min at 37oC and the level of peptide degradation was determined by HPLC. The samples were
prepared and processed as described in Materials and Methods.
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Figure 16: Stability of D-isomers of the wild-type (WD) versus retro (RD) peptide in
artificial gastric juice. The RD (panel A) and the WD (panel B) peptides were incubated in
artificial gastric juice for 60 min at 37oC and the level of peptide degradation was determined by
HPLC. The samples were prepared and processed as described in Materials and Methods.
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Figure 17: Mass spectrum analysis of the wild-type (W) 16mer peptide. The W peptide was
incubated in artificial gastric juice for 60 min at 37oC. The peak shown in Figure 15B was
analyzed by mass spectrometry.
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Figure 18: Mass spectrum analysis of the retro (R) 16mer peptide. The R peptide was
incubated in artificial gastric juice for 60 min at 37oC. The peak shown in Figure 15A was
analyzed by mass spectrometry. The relevant peaks are indicated by the arrows with the
appropriate amino acid sequence.
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Figure 19: The relative stability of the four histatin 5 peptide derivatives. Following
exposure of the peptides to human saliva or artificial gastric juice for 60 min at 37oC, the relative
stability of the peptides were evaluated by HPLC and the percent of peptide present a 0 min
versus 60 min at exposure to saliva or gastric juice is shown. The error bars represent the
standard deviation from three independent experiments.
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CHAPTER 3
Identification of a small domain within histatin 5 essential for fungicidal activity
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3.1 Introduction
Candida species are one of the most common opportunistic pathogens in humans, and the fourth
leading cause of nosocomial blood infection that lead to a high level of mortality. Candida
albicans is the major cause of invasive mucosal fungal infections observed in humans. The
increased incidence of drug-resistant Candida and the high frequency of fungal infections in
immune compromised patients emphasize the need for a new class of antifungal drugs with novel
mechanisms of action.
Naturally occurring antimicrobial peptides (AMPs) play an important role in the human innate
immune response against pathogenic and opportunistic microorganisms. Moreover, some of
these peptides exhibit antifungal activities with distinct modes of action 1, 2. AMPs could
represent promising candidates for the treatment of fungal infections, and they may serve as an
alternative to chemical therapeutics. These peptides are also advantageous because they exhibit a
selective toxicity against the target microorganism and target organisms are less likely to acquire
resistance to the peptides due to their common mechanism of action at the plasma membrane.
Nevertheless, AMPs cannot enter the therapeutic drug market unless some general application
problems are solved, including the susceptibility to enzymatic degradation, pharmacokinetic
problems, salt sensitivity, and manufacturing costs.
Human histatins are a family of histidine-rich peptides that are secreted into the saliva by the
parotid, submandibular and sublingual glands. They are important members of the innate
immune response that is essential for dental and oral microbial defense. Thus, the histatins
possess significant antimicrobial activities, and they are considered to be the first line of defense
against Candida infections of the oral cavity. Histatin 5 has the most potent fungicidal activity
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among the histatin family as well as compared to other oral antimicrobial peptides. Histatin 5
structure has been well-characterized, so it is a useful model for designing new antifungal drugs.
Unfortunately, prior studies have failed to identify a region of histatin 5 less than 12 amino acids
that maintains antifungal activity. It has been shown previously that the fungicidal activity of
histatin 5 does not require the full length peptide as several fragments exhibit similar activity. C16 (16 amino acid) is an example of an active histatin 5 fragment that retains full activity
(Chapter 2). The previous chapter demonstrated that the fungicidal activity of C-16 peptide
depends on the distribution of positive charges over an alpha helical structure, as the retro C-16
retained a similar activity. In addition, the essential positive charges seem to be those derived
from lysine and arginine residues, but not the histidine residues, as suggested by the lack of
sensitivity to pH (Chapter 2).
The studies described in this chapter seek to further delineate the structural requirement for the
fungicidal activity of histatin 5. After our previous finding that retro C-16 is as active as the
normal peptide (C-16), we identified a small symmetrical sequence within the C-16 peptide that
would not appear to be affected by the orientation of the amino acid sequence (retro versus
normal), and the sequence of this fragment is -YKRKF- , later referred to as the KM motif. The
role of the KM motif in histatin5 antifungal activity was further investigated by comparing with
the sequence of known histatin 5 derivatives published over the past decade (see Table 1 and 3
with references therein). The result revealed that the KM motif was found in nearly every
peptide fragment that displayed antifungal activity, and any change in the five amino acid KM
sequence led to the abolishment or decrease in antifungal activity.
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The studies described in this chapter seek to evaluate the importance of the KM motif in
antifungal activity. This was accomplished by initially synthesizing and evaluated two peptides,
KM-5 and KM-6. Both peptides were pentameric and contained the same amino acid
composition as KM; however, KM-5 had a retro sequence (FKRKY) while KM-6 a normal
sequence (YKRKF). We then evaluated and compared the activity of these pentamers against
the C-16 peptide. To date, the KM motif appears to be the shortest active histatin 5 fragment
identified and it will serve as a model for designing a therapeutic peptide.
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3.2 Materials and methods
Strains : Candida albicans (SC5314)3, and Saccharomyces cerevisiae BY4741(MATa his3Δ0
leu2Δ0 met15Δ0 ura3Δ0 pat1::natMX4 ) were used. S. cerevisiae strain was a generous gift
from Dr. Ines Pinto (University of Arkansas-Fayetteville).
Peptide synthesis. N-Fmoc protected amino acids and Rink resin was purchased from
NovaBiochem (San Diego, CA) and Advanced Chemtech (Louisville, KY). All KM peptides
were synthesized with an acetylated N-terminus and amidated C-terminus. The peptides were
synthesized on a model 433A solid-phase peptide synthesizer (Applied Biosystems; Foster City,
CA) using Rink resin and Fmoc-protected amino acids (NovaBiochem). After synthesis, the
peptides were deprotected and cleaved from the resin using a high TFA (trifluroacetic acid)
cleavage cocktail consisting of 85% TFA, 5% dH2O, 5% triisopropylsilan, and 5% phenol. The
resin was mixed in the cocktail solution at room temperature for 3 hours, after which the peptide
was precipitated into 50 ml 1:1 v/v methyl-t-butyl ether/hexane per ml of cleavage cocktail. The
peptides were subsequently dissolved in 1:1 v/v acetonitrile/ddH2O and recovered by
lypholization under high vacuum. Crude peptides were purified on PRP-3 reverse phase column
(7 by 305 mm; Bio-Rad, Hercules, USA) on a Hitachi L7100 HPLC instrument using a linear
gradient of 0 – 30 % acetonitrile and water (both were contained 0.1% TFA). The purity of each
peptide was evaluated by mass spectroscopy .The peptides concentrations were determined by
the extinction coefficient.
Fungicidal activity assays. The fungicidal activities to C. albicans and S. cerevisiae were
examined by micro dilution plate assay as described previously4. C. albicans and S. cerevisiae
was grown overnight on agar plates at 30oC. Sabouraud dextrose agar plates were used for C.
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albicans, and YPD (2% yeast extract, 1% Bacto-peptone and 2% glucose)5 and YPL (2% yeast
extract, 1% Bacto-peptone and 2% lactate)6 plates for S. cerevisiae. Following overnight
growth, a single C. albicans colony was diluted in 1 ml of 10 mM sodium phosphate buffer at pH
7.4. A hemocytometer was used to quantify the number of cells/ml and the cell concentration
was adjusted to 1.8 × 105 cells/ml. Cell suspensions (20 µl) were mixed with 20 µl of peptide
dissolved in 10 mM sodium phosphate buffer at pH 7.4 and incubated for 2 h at 37C with
shaking at speeds of 550 rpm. The reactions were stopped by the addition of 360 µl yeast
nitrogen base (3.4 g yeast nitrogen base without ammonium sulfate or amino acids and 10 g
ammonium sulfate per liter) and 40 µl of cell suspension was spread on the appropriate growth
medium plates and incubated for 24 h at 37C. The number of colony-forming units (CFUs)
was counted and each assay was repeated in triplicate. Loss of viability was calculated as [1(colonies from suspension with peptide/colonies from suspension with no peptide)] × 100.
Effect of pH, low temperature, and sodium chloride on KM-5 activity. The effect of pH on
the fungicidal activity of KM-5 peptide was tested at three distinct pH values: 5 (acidic), 7
(neutral) and 9 (basic). Briefly, the fungicidal activity assays were performed using 25µM of
each peptide. The pH was adjusted using 2 M HCl or 2 M NaOH. The influence of pH on the
peptide net charge was evaluated using Protein Calculator v3.3 serve
(http://www.scripps.edu/~cdputnam/protcalc.html)7. To study the effect of temperature on the
fungicidal activity, fungicidal activity assays were performed at neutral pH at two different
temperatures, 4oC and 37oC. The effect of sodium chloride on peptide activity was evaluated
using the fungicidal activity assays in phosphate buffer (10 mM, pH 7) at 37°C. Different
concentrations of sodium chloride were added to the phosphate buffer: 5mM and 10mM. In all
assays, C-16 (W) was used as a control for a direct comparison.
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Circular dichroism spectroscopy. Circular dichroism spectroscopy measurements were
performed on a Jasco-710 spectropolarimeter as described previously with some modifications8.
The reading was made using a quartz cell of 0.1cm path length and at 25o C. KM-5 was
measured in water and in the presence of 50% TFE (v/v), and all samples had a 120 µM final
concentration. The spectra were recorded every 0.2 nm between the absorbance range of 190 to
250 nm with a 1.0 nm bandwidth and a scan speed of 20 nm/min. Six scans were performed and
averaged. The background was subtracted from all spectra, and curve smoothing applied. The
CD spectra are reported as the mean residue ellipticity ([Ө]) in degrees.cm2.dmol-1. CD data
were further analyzed using the web-based K2D3 program (http://www.ogic.ca/projects/k2d2/).
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3.3 Results
Analysis of histatin 5 and derivative peptides. After the studies described in Chapter 2,
namely that the retro C-16 showed activity similar to the normal peptide (C-16), we examined
the sequence of both versions of the peptide and we identified a small symmetrical sequence
within the peptides that would not appear to be dramatically affected by the orientation of the
amino acid sequence (retro versus normal), and the sequence of this region was -YKRKF- , later
referred to as the KM motif. Our hypothesis was that this small five amino acid peptide could be
responsible for a significant portion of the antifungal activity. This was supported by the
observation that the antifungal activity of histatin 5 was not dramatically influenced by pH,
suggesting the abundance of histidine residues within histatin 5 were not relevant for fungal
killing activity.
To further support the proposed hypothesis, the published sequence of various histatin 5
derivatives that were generated over the past several years were examined. The comparison was
divided into two categories: peptides derived directly from histatin 5 (Table 1) and histatin 5
substituted analogs (Table 2). Since the published data for each peptide was reported from
different laboratories in which the threshold of peptide concentration and LD50 was unique to
each laboratory, the activity of each peptide was correlated to the maximum concentration used
in that particular study. Any peptide exhibiting an activity at a concentration lower than the
threshold concentration was considered active, while all other peptides that did not show any
activity at the maximum concentration were classified inactive.
In the first step of the comparative analysis, histatin 5 peptide derivatives were compared to each
other and to the retro C-16 peptide, R described in Chapter 2 (Table 1). The result of the first
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comparison suggested that the sequence YKRKF (later named as KM) is found in all active
fragments, and an incomplete KM sequence caused significant reduction in the peptide activity.
The next step in the comparison was to examine histatin 5 derived peptides that contained amino
acid substitutions, and the activity correlated to the presence of KM motif. This comparison
demonstrated that a single amino acid substitution within the KM motif was sufficient to reduce
or totally abolish the antifungal activity of the peptide, further emphasizing the significance of
KM motif in antifungal activity (Table 2). Nevertheless, there were some exceptions identified
in which peptides were either not active, despite the presence of KM motif, or the existence of
KM motif didn’t promote 50% killing activity (Table 3).
Fungicidal activity of the KM motif. Given the comparative sequence data described above,
we hypothesized that the fragment YKRKF or the KM motif may be solely responsible for the
antifungal activity, and the major functional domain within histatin 5. To evaluate this
hypothesis, two peptides were synthesized KM-5 (FKRKY) and KM-6 (YKRKF), and the
antifungal activity of the peptides was evaluated. Both peptides were pentamers containing the
KM motif, but KM-5 had the retro sequence. In addition, both peptides were modified by Nterminal acetylation and C-terminal amidation to improve the stability. The fungicidal activity of
both peptides was evaluated with C. albicans using 25µM peptide and correlated to the activity
of the C-16 histatin 5 peptide derivative. As Figure 1 illustrates, both KM-5 and KM-6
possessed equivalent antifungal activity as 25 µM of peptide killed approximately 80% of the
cells; however, both peptides were less potent than the C-16 that killed 95% of the fungal cells at
the same concentration.
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Since KM-5 and KM-6 had identical results in the fungicidal activity assays, we proceeded in
studying the activity of only one of them: KM-5. Dose-dependent and killing kinetic
experiments were performed to determine the LD50 and the kinetics of antifungal activity by
KM-5. The LD50 was found to be 5.2 µM as determined from a dose response curve (Figure 2).
The results of the kinetic studies are shown in Figure 3. The fungicidal activity against
C.albicans was time-dependent, reaching the maximum killing activity in two hours, similar to
the C-16 histatin peptide (see Chapter 2).
Fungicidal Activity of KM-5 substitution analogs. Since the relevant sequence of histatin 5
was delimited to five amino acids, it was important to next determine the contribution of the
various amino acids to the antifungal activity of the peptide. Thus, several amino acid
substitutions within KM-5 were evaluated for fungicidal activity to optimize the sequence for the
maximum antifungal activity (Table 4). The fungicidal activity of these analogs was tested with
C.albicans using a standard 25 μM concentration of each peptide. In general, increasing the
positive charge in cationic antimicrobial peptides (AMPs) enhances the activity, especially if the
positive charges are derived from arginine or lysine residues. Besides the net charge, the
secondary structure of AMPs plays an important role by inducing the amphipathic character
essential for antifungal activity.
Role of positively charged amino acids as well as secondary structure on the antifungal activity
was assessed using two different KM-5 analogs, KM-7 and KM-8, where the central arginine
was replaced by either serine or proline, respectively. In KM-7, this alteration should only
change the charge and preserve the symmetry, size and amphipathic character of the peptide. On
the other hand, the proline-substituted peptide (KM-8) was synthesized by introducing a
nonpolar alpha-helix breaker. In KM-8, proline will interfere with any peptide secondary
144

structure as well as the amphipathic character. For both peptides, KM-7 and KM-8, the
fungicidal activity was abolished (Figure 4).
To evaluate the role of the tyrosine in the antifungal activity as well as to increase the symmetry
within KM-5, KM-9 was generated, in which tyrosine was substituted with phenylalanine. As
illustrated in Figure 4, KM-9 exhibited a slight decrease in the activity. The same results were
observed using KM-10, an analog in which the amino acids were randomly shuffled within the
peptide (Figure 4). To further compare the antifungal activity of KM-5, KM-9, and KM-10 a
dose-dependent assay was performed to distinguish slight differences between these three
peptides. As shown in Figure 5, the activity of the three peptides similar at multiple
concentrations; however, the antifungal activity of KM-5 was consistently stronger.
Finally, the role of stereospecificity was evaluated by generating KM-5-D, in which the peptide
was synthesized using D-enantiomers of the amino acids. The fungicidal activity assays
demonstrated that using D-enantiomers did not affect the antifungal activity as both KM-5 and
KM-5-D possessed the same activity (Figure 4).
Effect of pH on KM-5 fungicidal activity. Many AMPs display pH-dependent antimicrobial
activity via interfering with the target cell or with the peptides itself. To evaluate the pHdependency of KM-5, the fungicidal activity was examined at pH values of 5, 7, and 9. For
comparison, the C-16 histatin peptide was analyzed in parallel. The results showed that the
antifungal activity of C-16 did not change across the range of pH levels as shown in Chapter 2;
however, KM-5 demonstrated slightly greater activity under neutral or basic pH (Figure 6). At
acidic pH, the activity of KM-5 was inhibited by approximately 30% compared to neutral and
basic conditions than at acidic pH. As shown in Figure 6B, changes in the pH from acidic to
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basic had a large effect on C-16 net charge, from +12 to +4 when the pH changed from 5 to 9,
respectively. However, under the same circumstances the net charge of KM-5 was slightly
reduced from +3 to +2.
Effect of temperature and salt on KM-5 fungicidal activity. It has been reported that the
activity of antimicrobial peptides in general and histatin 5 specifically are often weaker in a
presence of NaCl as well as at low temperature. In the studies shown in Chapter 2, it was
demonstrated that the activity of C-16 is affected by NaCl and low temperature. Since KM-5 is a
derivative of histatin 5, its antifungal activity was evaluated under the same conditions. To study
the role of temperature, the antifungal activity was measured for KM-5 and C-16 at 4oC and
37oC. As Figure 7A shows, the activity of both peptides was inhibited dramatically at 4oC.
The salt effect was measured by incubating KM-5 and C-16 at 5 mM and 10 mM NaCl (Figure
7B). As was expected, the antifungal activity of KM-5 and C-16 were attenuated by the addition
of NaCl in a dose dependent manner. While 5 mM NaCl was sufficient to inhibit the activity of
KM-5 by 50%, the activity of C-16 was not affected. However, the inhibitory effect of NaCl on
both peptides was obvious at a concentration of 10 mM NaCl.
Role of respiration in the fungicidal activity of KM-5. It is known that the activity of histatin
5 is affected by the metabolic activity of Candida and the activity was completely inhibited in a
presence of inhibitors of respiratory metabolism such as sodium azide, as shown in Chapter 2.
Furthermore, several studies have shown that the yeast Saccharomyces cerevisiae, which
produces ATP primarily by fermentation, is resistant to the antifungal activity of histatin 510.
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To evaluate the role of respiratory metabolism in the fungicidal activity of KM-5, S. cerevisiae
and C. albicans were grown in rich medium containing glucose; whereby, S. cerevisiae would
produce ATP primarily by fermentation while C. albicans would use respiration. Thus, the
prediction would be that S. cerevisiae would be more resistant to KM-5 antifungal activity than
C. albicans. As shown in Figure 8A, S. cerevisiae was resistant to killing by KM-5 at 25 µM
concentration; whereas, C. albicans was sensitive at the same concentration.
To further explore the role of respiratory metabolism in the KM-5 killing mechanism, S.
cerevisiae was grown on rich medium containing either glucose to induce fermentation or lactate
to induce respiratory metabolism. As shown in Figure 8B, when S. cerevisiae cells are grown
under conditions that induce respiratory metabolism (lactate as a carbon source), they become
more sensitive to the fungicidal activity of KM-5, suggesting respiratory metabolism is important
for the killing activity.
Analysis of the secondary structure of KM-5 by circular dichroism spectroscopy. To study
the possible secondary structure of KM-5, CD spectroscopy experiments were conducted. The
data were acquired for KM-5 in aqueous solution as well as in the presence of 50% TFE. As
illustrated in Figure 9, KM-5 did not obtain a defined secondary structure, but maintain a random
coil structure in both water and 50% TFE. However, the possibility of beta-turn structure was
observed. The deconvolution of the spectrum using K2D3 program 13 yielded a similar
percentage of helical and beta structure in both environments (in water: 1 % helix and 26% beta
while in TFE: 1% helix and 24% beta).
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3.4 Discussion
The current therapeutic agents have been effective in treating fungal infection for a long period
of time; however, the increased use of these agents has been associated with the development of
new resistant strains. The increase of resistant fungal pathogens underscores the search for new
antifungal agents with different mechanism of action. AMPs have been used widely as a base for
the development of new clinically approved antibacterial and antifungal drugs 14,15, 16. Histatin
5, a salivary antimicrobial peptide , may serve as a good model for new therapeutic peptides 2, 1720

. While the histatin 5 mechanism of action has not been fully explained, all suggested modes

of actions would imply histatin 5 has a distinct target from the currently available antifungal
agents 2 on the commercial market.
One of the general problems limiting the use of therapeutic peptides as drugs is the cost
effectiveness. In order to utilize a peptide as a commercial drug it must be cost effective to
produce. Several attempts were carried out to optimize the histatin 5 peptide and attain the
smallest active fragment. To date, P-113 is the most effective and smallest fragment of histatin
5, and it is composed of 12 amino acids. However, using histatin 5 peptide derivatives coupled
with our prior studies (Chapter 2), we have identified a shorter antifungal peptide, referred to as
KM-5; it is less than half the size of P-113.
Previously, we reported that the retro C-16 peptide, retained fungicidal activity equivalent to the
as non-retro peptide. Following this finding, a direct comparison between the retro and non-retro
peptide showed the existence of a short symmetrical sequence. This fragment contains five
amino acids with a sequence of YKRKF, later named as the KM motif, where arginine is the
dyad of symmetry between two lysine residues and two aromatic amino acids. We hypothesized
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that this sequence might be the active motif of C-16 as well as histatin 5, yet this sequence would
remain the same in both the retro and non-retro peptide.
Before we proceed with testing this hypothesis, a sequence comparison of several histatin 5
peptide derivatives and analogs was carried out, focusing on the presence of the KM motif and
how its presence correlated fungicidal activity. It was found that the KM motif was present in
the majority of peptides that maintained antifungal activity. Given these observations, the
putative fungicidal activity of this small peptide was tested using KM-5 and KM-6, and the
activity of both peptides was compared to C-16. The fungicidal activity assays performed with
Candida albicans demonstrated that both KM-5 and KM-6 have an antifungal activity and they
are equivalent, and this finding endorses the hypothesis of symmetry. On a molar basis, both
KM-5 and KM-6 was found to be less active than the C-16 peptide. However, the fungicidal
activity of KM-5 against Candida albicans in mg/mL is equal to if not better than C-16.
In order to optimize KM-5 activity, several KM-5 analogs were synthesized and their fungicidal
activity against C. albicans was measured. The results showed that KM-5 is the optimal
sequence and any interference with the positive charge, secondary structure or the amino acid
sequence reduces the antifungal activity. The single arginine residue in KM-5 is equivalent to
Arg-22 in histatin 5. There are other studies that have shown the importance of this residue, as a
substitution leads to a decrease in the activity. It is not surprising that the removal of a single
positive charge from a five amino acid peptide would have a dramatic effect on activity due to
the change in the net charge of the peptide. In general, positive charges in AMPs have an
essential role in membrane binding because of the ionic interaction between the cationic peptide
and the negatively charged membrane. Introducing a helix breaker in KM-5 abolished the
activity completely; however, this change might also be contributed to the change in the peptide
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net charge. In addition, generating an analog of KM-5 that was symmetrical, via replacing
tyrosine with phenylalanine, had a slightly inhibitory effect on fungicidal activity. This could
result from the lack of hydrogen-bonding with phenylalanine. Using D-enantiomer of KM-5 did
not affect the antifungal activity, eliminating the role of stereospecficity in KM-5 activity.
Similar results were reported in several antimicrobial peptides including full length histatin 5 and
C-16 peptide (see Chapter 2).
The secondary structure of KM-5 was evaluated by circular dichroism spectroscopy. It was
found that KM-5 in aqueous solution was largely a random coil structure with a possibility to
form a beta-turn. Unexpectedly, the presence of 50% TFE did not induce a change in the
structure as it remained a random coil. Similar cases of small AMPs (even tetramer) adopting a
beta-turn have been reported 26, 28-32. Besides, TFE has been reported to induce less effect on
short peptides that adapted a beta-turn structure. For example, increasing the percentage of TFE
up to 90% showed a small effect on Prp peptides. On the contrary, increasing TFE percentage
resulted in an increase in the percentage of beta-turn 33.
The study of secondary structure suggests that KM-5 has significantly less α-helical character
than histatin 5 and C-16 histatin. This reduction in helical content of KM-5 could be due to the
fact that KM-5 is too small to adapt a thermodynamically stable helical structure as the potential
number of hydrogen bonds along the backbone for KM-5 is reduced to five. The same pattern of
secondary structure was also observed in P-113 peptide, a dodecameric derivative of histatin 5.
As previously shown, NaCl and low temperature have an inhibitory effect on C-16 histatin as
well as on full length histatin 534. The antifungal activity of KM-5 was also found to be salt and
temperature dependent. With some exceptions, the killing activities of cationic AMPs are
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sensitive to the ionic strength of the surrounding medium 34, 35, 36, 37. As the nature of interaction
between cationic AMPs and the negatively charged plasma membrane is ionic, it can be
weakened by monovalent and divalent cations, consequently the fungicidal activity will be
reduced 38. As Figure 7 illustrates, the activity of KM-5 follows the same trend at C-16 as both
were inhibited by NaCl; however, the NaCl inhibitory effect was more pronounced in KM-5.
This might be related to the fact that C-16 has more basic amino acids than in KM-5, hence the
interaction between C-16 and the membrane is stronger, and a higher concentration of the salt is
required to interrupt this interaction.
Besides salt and temperature dependence, the antimicrobial activity of most cationic AMPs is pH
dependent 35. Changing the pH typically has an effect on AMPs activity through two different
mechanisms, either interfering with the target microorganism or directly with the peptide.
Candida albicans has the ability to grow either as unicellular budding yeast or filamentous, as in
pseudohyphal and hyphal forms41. This ability, which plays an important role in Candida
pathogenicity 42 can be stimulated by pH 43. Moreover, the effect of AMPs on each Candida
morphological form is not equivalent42. The pH can also directly influence the antimicrobial
peptide as several studies have shown the secondary structure and the net charge of AMP are to
change at different pH 44-46.
Unlike other AMPs, the antifungal activity of histatin 5 and the C-16 peptide against C. albicans
was similar over a wide range of pH (from 5 to 9) (see Chapter 2). On the contrary, the activity
of KM-5 was observed to change slightly by a pH shifting from acidic to basic as the activity
decreased in acidic medium. The net charge of KM-5, within the tested range, would not change
since all positive charges in KM-5 come from lysine and arginine residues. It is unlikely that the
pH made a significant change on the secondary structure because KM-5 adopted a partial
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secondary structure and has largely remained a random coil. We tested the possibility that KM-5
might be losing the C-terminal amide under the influence of acidic or basic medium, but the
mass spectrometry results did not detect any changes (data not shown). Similar observations
have been reported for several other AMPs34, 47, 48.
The mode of action of histatin 5 is unclear as numerous studies have suggested the involvement
of multiple pathways. However, it has been demonstrated that cellular respiration and
mitochondrial ATP synthesis are necessary for the antifungal activity of histatin 5. The role of
respiration was clearly observed in Saccharomyces as it is resistant to killing by histatin 5. There
is an important metabolic difference between Saccharomyces and Candida. S. cerevisiae is
classified as a Crabtree-positive yeast; when it is grown on a fermentable medium (glucose)
under aerobic conditions, the sugar is largely fermented to ethanol. On the other hand, C.
albicans is a Crabtree-negative yeast; when grown under the same conditions the cells respire,
even when the carbon source is fermentable. This difference could explain the observed
susceptibility of Candida albicans to KM-5 and C-16. Fungicidal activity of both peptides
requires the presence of active mitochondria49. To evaluate the effect of respiration on KM-5
activity, the activity was measured on S. cerevisiae in non-fermentable medium (YPL) and
compared to the fermentable medium YPD. The results showed that KM-5 has more effective
antifungal activity in YPL over YPD. These data strongly suggest that oxidative
phosphorylation is required for KM-5-induced cell death.
Although small peptides (5 or 6 amino acids) are traditionally not considered long enough to
form a distinctive secondary structure or pass through the membrane of microorganisms, several
small antifungal22-24, antibacterial25, 26and antiviral 27peptides have been reported including a
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currently available antifungal drug class, the echinocandins. The KM5 peptide represents an
excellent lead peptide for the future development of an effective antifungal therapeutic peptide.
3.5 Conclusion
KM-5 is the shortest active fragment in histatin 5 and our results show that it might work through
the same mechanism as histatin 5. The activity of KM-5 was inhibited in the presence of histatin
5 inhibitors: low temperature and sodium chloride. Moreover, KM-5 activity requires respiratory
metabolism to be active in killing fungi. Although KM-5 is less active than the C-16 peptide, it
offers a model target peptide to be further developed as an antifungal therapeutic. The smaller
size makes it attractive for development because of the lower cost of production.
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Table 1: The sequence and activity of histatin 5 peptide derivatives
Name

Sequence

Activity1

Reference

Histatin 5

DSHAKRHHGYKRKFHEKHHSHRGY

Yes

50

Fragment 1

DSHAKRHHGYKRK

No

51

N-16

DSHAKRHHGYKRKFHE

Yes

19, 50

P-118

AKRHHGYKRKF

Yes

2

P-119

AKRHHGYKRK

No

2

P-113

AKRHHGYKRKFH

Yes

2

P-103

KRHHGYKRKFHEKHHSHR

Yes

2

P-117

KRHHGYKRKFH

Yes

2

No

51

Fragment 2

HGYKRK

C-16

GYKRKFHEKHHSHRGY

Yes

50

Dh5

KRKFHEKHHSHRGY

Yes

50, 52

H10-1

KRKFHEKHHS

Yes

21

Histatin 9

RKFHEKHHSHRGYR

No

2

C-12

KFHEKHHSHRGY

No

2, 50

Fragment 3

FHEKHHSHR

No

51

No

50

Yes

Our study

HEKHHSHRGY

C-10
Retro C-16 (R)

YGRHSHHKEHFKRKYG
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Table 2: The histatin 5 substitution derivatives.
Name

Sequence

Activity

Reference

m68

DSHAKRHHGYKREFHEKHHSHGGY

No

53

reHsn-5

GSHAKRHHGYKRKFHEKHHSHRGY

Yes

19

reHsn-5- K13T

GSHAKRHHGYKRTFHEKHHSHRGY

Yes

19

reHsn-5- K13T/R22G

GSHAKRHHGYKREFHEKHHSHGGY

Yes

19

reHsn-5- K13E

GSHAKRHHGYKREFHEKHHSHRGY

Yes

19

reHsn-5-F14A/H15A

DSHAKRHHGYKRKAAEKHHSHRGY

No

19

3P

DSHAKRHHGYKRKFHPKHPSPRGY

Yes

54

P-113-Q2.10

AQRHHGYKRQFH

No

2

P-113-Q2.3.9.10

AQQHHGYKQQFH

No

2

P-113-Q3.9

AKQHHGYKQKFH

Yes

2
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Table 3: Inactive histatin 5 substitution derivatives containing the KM motif.
Name
P-114

Sequence
HHGYKRKFHEKH

Activity

Reference

No

2

P-115

YKRKFHEKHHSH

No

2

P-123

DSHAKRHHGYKRKF

No

55

No

19, 21

HGYKRKFHEK

No

51

1P

DSHAKRHHGYKRKFHEKHHSPRGY

Yes

54

2P

DSHAKRHHGYKRKFHEKHPSPRGY

Yes

54

M10
Fragment 4

HHGYKRKFHE
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Table 4: KM peptides containing amino acid substitutions.
Name

Sequence

Activity1

KM-5

Ac-FKRKY-NH2

Yes

KM-5-D

Ac-fkrky-NH2

Yes

KM-6

Ac-YKRKF-NH2

Yes

KM-7

Ac-FKSKY-NH2

No

KM-8

Ac-FKPKY-NH2

No

KM-9

Ac-FKRKF-NH2

Yes

KM-10

Ac-KFRYK-NH2

Yes

1 Fungicidal activity summarized based on data in Figure 5.
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Figure 1: Comparison of the fungicidal activity of KM-5, KM-6 and histatin C-16.
Fungicidal activity assays were performed using 25 µM of each peptide incubated with C.
albicans (1.8×105 cells/ml) in 10 mM sodium phosphate buffer for 2 hours at 37oC. The
percentage of viable cells was calculated as (viable colonies in the presence of peptide / viable
colonies without peptide) × 100. The data represents the mean of three independent experiments
with the error bars representing the standard deviation.
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Figure 2: Determination of the LD50 for KM-5. A) A dose-dependent assay was performed in
which C. albicans cells were exposed to varying concentrations of KM5 (2.5, 3.5, 5, 10, 15, 20,
25, 35 and 50 µM) for 2 hours at 37oC. B) The LD50 of the peptide was calculated using a linear
regression equation. The data represents the mean of three independent experiments with the
error bars representing the standard deviation.
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Figure 3: The kinetics of KM-5 fungicidal activity. The kinetics of KM-5 fungicidal activity
was determined using 10 µM KM-5. KM-5 was incubated with C. albicans (1.8×105 cells/ml)
in 10 mM sodium phosphate buffer for different time periods (30, 60 ,120 and 240 min). The
percentage of viable cells was calculated as (viable colonies in the presence of peptide / viable
colonies without peptide) × 100. The data represents the mean of three independent experiments
with the error bar representing the standard deviation.
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Figure 4: Fungicidal activity of KM-5 substitution analogs. The fungicidal activity of the
KM-5 peptide analogs described in Table 4. For each peptide (25µM) was incubated with C.
albicans (1.8×105 cells/ml) in 10 mM sodium phosphate buffer for 2 hours at 37oC. The
percentage of viable cells was calculated as (viable colonies in the presence of peptide / viable
colonies without peptide) × 100. The data represents the mean of three independent experiments
with the error bar indicating the standard deviation.
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Figure 5: Dose-dependent comparison of the fungicidal activity of KM-5, KM-9 and KM10. The indicated concentrations of each peptide were incubated with C. albicans (1.8×105
cells/ml) in 10 mM sodium phosphate buffer for 2 hours at 37oC. The percentage of viable cells
was calculated as (viable colonies in the presence of peptide / viable colonies without peptide) ×
100. The data represents the mean of three independent experiments with the error bars
representing the standard deviation.
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Figure 6: Effect of pH on fungicidal activity of KM-5. (Panel A) 25 µM of the indicated
peptides were incubated with Candida albicans (1.8×105 cells/ml) for 2 hours in 10 mM sodium
phosphate buffer adjusted to the indicated pH (5 , 7 and 9). The percentage of viable cells was
calculated as (viable colonies in the presence of peptide / viable colonies without peptide) × 100.
The data represents three independent experiments and the error bar representing the standard
deviation. (Panel B) The calculated net charge of each peptide at different pH values as
determined by the Protein Calculator v3.3 software.
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Figure 7: The effect of sodium chloride and low temperature on the fungicidal activity of
KM-5. For each assay, 25 µM of peptide was incubated with C. albicans (1.8×105 cells/ml) in
10 mM sodium phosphate buffer for 2 hours at 37oC. (Panel A) Fungicidal assay performed in
the presence of the indicated concentrations of sodium chloride. (B) Fungicidal assay performed
at either 4oC or 37oC. The percentage of viable cells was calculated as (viable colonies in the
presence of peptide /viable colonies without peptide) × 100. The data represents the mean of
three independent experiments and the error bars indicate the standard deviation.
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Figure 8: The role of respiratory metabolism in the fungicidal activity of KM-5. A) Comparison
of the fungicidal activity of 25 µM KM-5 on S. cerevisiae versus C. albicans. B) Comparison of
the fungicidal activity of KM-5 on S. cerevisiae grown in the presence of glucose (YPD) or
lactate (YPL) as the carbon source. The activity was measured in 10 mM sodium phosphate
buffer for 2 hours at 37oC. The percentage of viable cells was calculated as (viable colonies in
the presence of peptide / viable colonies without peptide) × 100. The data represents the mean of
three independent experiments with the error bars indicating the standard deviation.
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Figure 9: CD spectra of KM-5. The CD spectra were determined in aqueous solution using
120 µM KM-5, and in the presence of 50% TFE at 25oC as indicated. The samples were
prepared as described in Materials and Methods. The CD spectra are displayed in mean residue
ellipticity [θ]. The percentage of secondary structure is indicated in the graph legend in the inset.
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CHAPTER 4
The development and characterization of KM-12 as a potent fungicidal peptide.
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4.1 Introduction
Although Candida species are primarily commensal microorganisms in the gastrointestinal,
urinary, and vaginal tracts of healthy individuals 1,2, they are also opportunistic pathogens that
can be associated with high mortality especially in immune compromised patients 3. In fact,
Candida species are the most common fungal pathogens that cause disease in humans 1.
Recently, infections by Candida spp. have increased as drug resistant strains have emerged. The
drug resistance mainly developed from the overuse of antifungal drugs, as well as crossresistance between Candida spp.4. Moreover, some Candida spp. exhibit inherent resistance to
the available fungal drugs. For example, Candida glabrata is resistant to fluconazole at
therapeutic concentrations and Candida lusitaniae shows resistance to amphotericin B5. Due to
the toxicity issues associated some antifungal agents, such as amphotericin B: the triazoles are
considered the drug of choice for treating Candida infections6. Unfortunately, the widespread
use of the azoles has resulted in an increase in azole-resistance7. These circumstances have led
to a renewed interest in the development novel antifungal drugs with different mechanisms of
action.
Histatin 5 is a cationic antimicrobial peptide (AMP) produced in human saliva and it is the first
line of defense against oral fungal infection. Histatin 5 possesses the most potent antifungal
activity among the oral antimicrobial peptides and it has been a potential candidate for drug
therapy or as a template for antifungal drug design8. Previously, we identified the KM motif
(Chapter 3), as a possible functional motif in histatin 5 and its antifungal activity has been
examined on C. albicans. In this chapter, we describe the further development of a potent
antifungal peptide utilizing the KM motif. The peptide, termed KM-12 is a dimeric peptide
composed of two KM motifs, with a cysteine residue introduced to facilitate dimerization of the
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monomeric KM motif. It was hypothesized that the antifungal activity displayed by the KM
motif may be improved additively by using two copies of the motif. To our surprise, the
dimerization of two KM motifs caused a synergistic effect, with fungicidal activity that was
much greater than the additive prediction. Our results show that KM-12 exhibited a potent
activity against multiple Candida species and that the dimerization of the KM motif improved
the fungicidal activity by almost 15-fold. The pharmacological and fungicidal activity of KM-12
was examined. These studies include: an evaluation of the dose dependency, the kinetics of
activity, the effect of general histatin 5 inhibitors, the secondary structure of the peptide, and the
stability of KM-12 in saliva, serum and artificial gastric juice.
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4.2 Material and method
Strains : Candida albicans SC5314 9 and Saccharomyces cerevisiae BY4741(MATa his3Δ0
leu2Δ0 met15Δ0 ura3Δ0 pat1::natMX4) are strains available in the McNabb laboratory.
Candida glabrata ATCC90030, Candida parapsilosis ATCC22019, Candida tropicalis
ATCC750, Candida krusei ATCC6258, Candida lusitaniae (ATCC200951), Candida kefyr
(ATCC4135) and Candida dubliniensis MYA-646 were purchased from the American Type
Culture Collection (ATCC).
Peptide synthesis. N-Fmoc protected amino acids and Rink resin was purchased from
NovaBiochem (San Diego, CA) and Advanced Chemtech (Louisville, KY). All peptides were
synthesized with an acetylated N-terminus and amidated C-terminus. The peptides were
synthesized on a model 433A solid-phase peptide synthesizer (Applied Biosystems; Foster City,
CA) using Rink resin and Fmoc-protected amino acids (NovaBiochem).
Cleavage of the peptide from the Rink resin. After synthesis, the peptides were deprotected
and cleaved from the resin using two high TFA (trifluoroacetic acid) cleavage cocktails.
Method A. The cleavage cocktail consisted of 85% TFA, 5% dH2O, 5% triisopropylsilan, and
5% phenol. The resin was mixed in the cocktail solution at room temperature for 3 h at 480 rpm,
after which the peptide was precipitated into 50 ml 1:1 v/v methyl-t-butyl ether/hexane (MTBE)
per ml of cleavage cocktail. The peptides were dissolved in 1:1 v/v acetonitrile/ddH2O and
recovered by lypholization under high vacuum. Crude peptides were then purified on a PRP-3
reverse phase column (7 by 305 mm; Bio-Rad, Hercules, USA) on a Hitachi L7100 HPLC
instrument with a linear gradient of 0 – 30 % acetonitrile and water (both were contained 0.1%
TFA). The purity of each peptide was evaluated by mass spectroscopy (MALDI and ESI). The
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peptides concentrations were determined by the extinction coefficient. Method B. KM peptides
were cleaved from the resin using 90% TFA, 5% Thioanisol, 3% Ethandithiol, and 2% anisole.
The cleavage mixture was shaken for 4 h at 480 rpm at room temperature, and then precipitated
in ether. Two different solutions were evaluated; 1:1 v/v methyl-t-butyl ether/hexane and diethyl
ether, where 50 ml of ice-cold solution was used per ml of cleavage cocktail. After which the
crude peptides were purified, processed and identified as described above.
Dimerization of the peptides. The 10 mg/ml concentration of peptides in reduced form, except
for KM-18, was oxidized in an aqueous solution (10 mM sodium phosphate buffer) containing
10% DMSO at pH 8.5. For KM-18, the intramolecular disulfide bond was initiated at a peptide
concentration of 1 mg/10ml. The mixture was incubated in a shaking incubator at 550 rpm
overnight at 37oC. The dimerization was monitored by Ellman reagent (Sigma-Aldrich), reverse
phase-HPLC, and verified by ESI mass spectroscopy. The sample was subsequently lyophilized
three times and precipitated in isopropanol (10% v/v) to ensure the removal of any trace amounts
of TFA and DMSO. The reduction of KM-12 dimer to the monomeric form was achieved by the
addition of 5 mM DTT and incubated at room temperature overnight 10, 11. The oxidation state of
the peptide was verified by reverse phase-HPLC.
Fungicidal activity assays. The fungicidal activity of the peptides against C. albicans and S.
cerevisiae was examined by micro dilution plate assay as described previously12. C. albicans
and S. cerevisiae was grown overnight on agar plates at 30oC. Sabouraud dextrose agar was used
for C. albicans growth, and YPD (2% yeast extract, 1% bacto-peptone and 2% glucose)5 and
YPL (2% yeast extract, 1% bacto-peptone and 2% lactate)6 plates for S. cerevisiae. Following
overnight growth, a single colony was diluted in 1 ml of 10 mM sodium phosphate buffer at pH
7.4. A hemocytometer was used to quantify the number of cells/ml and the cell concentration
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was adjusted to 1.8 × 105 cells/ml. Cell suspensions (20 µl) were mixed with 20 µl of peptide
dissolved in 10 mM sodium phosphate buffer at pH 7.4 and incubated for 2 h at 37C with
shaking at speeds of 550 rpm. The reactions were stopped by the addition of 360 µl yeast
nitrogen base (3.4 g yeast nitrogen base without ammonium sulfate or amino acids and 10 g
ammonium sulfate per liter) and 40 µl of cell suspension was spread on the appropriate growth
medium plates and incubated for 24 h at 37C. The number of colony-forming units (CFUs) was
counted and each assay was repeated in triplicate. Loss of viability was calculated as [1(colonies from suspension with peptide/colonies from suspension with no peptide)] × 100. KM12 lethal dose 50 (LD50) was estimated by performing linear regression analysis (the percent of
viability versus the log10 concentration) and determining the x axis intercepts 14. The LD50 was
the concentration that killed 50% of Candida albicans. For examining the kinetics of fungicidal
activity, the peptide was incubated with Candida albicans for different periods of time and the
viability determined as described above.
Minimum inhibitory concentration (MIC) assay. MIC assays were carried following the CLSI
M27-A2 standard with the modification as described below. Briefly, two-fold serial dilutions of
the peptides were prepared with RPMI-1640 (Sigma R-7755) in 100 μl per well of a 96-well flatbottom microtiter plates (Costar, Cambridge, MA). To demonstrate the effect of salt on peptide
activity, different RPMI-1640 dilutions (1X, 0.5X, 0.25X, and 0.125X) were used. To each well
of the microtiter plates containing the peptide, a 100 μl C. albicans cell suspension containing 1
× 104 cells /mL in a resazurin/water solution (0.01% w/v) was added. The final concentration of
the peptides in the assay ranged from 0.2 to 100 μM (0.4 to 206.7 μg/ml, respectively). The
microtiter plates were subsequently incubated at 35°C and examined at both 24 h and 48 h after
exposure to peptide. Each assay plate contained a positive control of Candida albicans without
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added peptide and the negative control of RPMI-1640 medium containing only the
resazurin/water solution. For each peptide three independent assays were performed. The MIC
assay results were interpreted visually using the criteria of the lowest peptide concentration that
remained blue (indicating no growth) or the first dilution that changed from blue to slightly
purple (equivalent to prominent growth inhibition). The peptide concentrations were determined
based on the extinction coefficient of the four peptides.
The MIC values for fluconazole-sensitivity on Candida spp. were also determined using the
same procedure.
Circular dichroism spectroscopy. CD spectra were obtained for KM-12 in 10 mM sodium
phosphate buffer pH 7 as well as following incorporation into liposomes of 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC) and micelles of sodium dodecyl sulfate (SDS) at 1:50
(mol/mol) peptide :lipid ratio. Preparation of samples for CD spectroscopy. Tubes containing
4.5 µL (0.1µmol) of KM-12 were vacuumed dry overnight, and the buffer and/or appropriate
lipids were added separately. To study the structure in an aqueous solution, KM-12 was
hydrated with 500 µl of 10mM of sodium phosphate buffer pH=7 to achieve a final concentration
of 200 µM peptide. For DMPC liposomes, 678 µl of DMPC/chloroform stock (5 mg/ml)
(Avanti, AL, USA) were added to KM-12, mixed and dried under nitrogen, and vacuumed dry
for 48 hours. Following drying, 500 µl of 10mM of sodium phosphate buffer pH=7 was added
and the sample treated with ultra-sonication for 1 h. For SDS micelles, 1.44 mg of SDS was
dissolved in 500 µl of 10 mM of sodium phosphate buffer pH 7 to yield 10 mM SDS. Then SDS
solubility was ensured by sonication in a water bath for 10 min. The SDS solution was then used
to rehydrate KM-12, and the sample was mixed and subsequently sonicated for 30 min. All
samples were centrifuged at 10,000 rpm for 5 min to remove any particulate material, and the
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absorbance was measured on diode array (200 -300 nm) to confirm that the absorbance across
the spectrum was below 1 absorbance unit. Circular dichroism measurements. CD spectra for
KM-12 were generated using a Jasco-710 spectropolarimeter as described previously with some
modifications15. The reading was made using a quartz cell with a 0.1cm path length at 25o C.
The spectra were recorded every 0.2 nm in the absorbance range of 190 to 250 nm with a 1.0 nm
bandwidth and a scan speed of 20 nm/min. Six scans were performed and averaged. The
background was subtracted from all spectra, and curve smoothing applied. The CD spectra are
reported as the mean residue ellipticity ([Ө]) in degrees. cm2. dmol-1. The mean residue
ellipticity ([θ]mrw) was calculated by the following equation 15:
[θ]mrw = θ/ (10 x c x l x N) where c is molar protein concentration, l is the cell path length in cm,
and N is the number of amino acids in the peptide. CD data were further analyzed using the
web-based K2D3 program (http://www.ogic.ca/projects/k2d2/)16 and CDPro software17.
Effect of sodium chloride, sodium azide and temperature on fungicidal activity. To study
the effect of temperature on the killing activity, the fungicidal activity assay was performed
using 2.5 µM KM-12 in 10 mM phosphate buffer pH 7 at two different temperatures, 4oC and
37oC. The effects of sodium chloride and sodium azide were studied using the fungicidal
activity assays in 10 mM sodium phosphate buffer pH 7 at 37°C with the variable being the
different concentrations of sodium chloride (5 mM,10 mM and 25 mM) , or 5 mM sodium azide.
Peptide Stability in Artificial Gastric Juice. The stability of KM-12 was tested using artificial
gastric juice prepared as described previously with slight modifications 18. The artificial gastric
juice was prepared by dissolving 2 g NaCl and 3.2 g pepsin in 7.0 ml 0.085 M HCl and the
volume was increased to 1000 ml with distilled water (pH 1.2). The peptide (5 µg in volume of
10 µl) was added to 90 µL of artificial gastric juice and incubated for different periods of time (0,
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5, 10 and 20, 40 minutes) at 37oC. The reaction was terminated by boiling for 10 min and the
sample was centrifuged at 13,000 rpm for 10 min. in a microcentrifuge. The supernatant was
collected, neutralized with NaOH, and analyzed by reverse phase HPLC. The peptides were
analyzed by reverse phase HPLC using a PRP-360 column (Bio-Rad). A gradient elution was
performed with mobile phase A (0.1% TFA in water) and mobile phase B (0.1% TFA in
acetonitrile). The peptide was eluted with a gradient from 95:5 to 65:35 (mobile phase A: B) for
15 min at flow rate 1 ml/min. The HPLC total run time was 20 min and the injection volume was
50 µl. Chromatograms were recorded by UV detection at 220 nm and the data analyzed using
CHROMULAN v0.79 software. Data were recorded from three independent assays to determine
the half-life of the peptide. For the detection of cleavage sites, two samples (0 min and 60 min
post exposure to gastric juice) of KM-12 were subjected to ESI mass spectrometry analysis, and
then the spectra were overlapped and further analyzed.
Peptide Stability in Human Saliva. Whole saliva samples (5 ml) were collected from three
healthy donors ranging in age from 25 to 35 years in accordance with a protocol approved by the
University of Arkansas Institutional Review Board. The stability of the peptides in human
saliva was determined as described previously with slight modifications 28. After the saliva was
collected, it was immediately centrifuged at 13,000 rpm for 10 min at 4oC in a microcentrifuge
and the supernatant was aliquoted 1 ml portions and stored at -80o C. One ml of saliva from each
volunteer was pooled, mixed and filtered through a 0.45 µm membrane filter. The stability
assays was performed using a constant ratio of peptide to saliva (1:9). Twenty µl of peptide in
10 mM sodium phosphate buffer (pH 7.4) was mixed with 180 µl of saliva to give a final peptide
concentration of 0.5mg/ml. The peptide in saliva was incubated for different periods of time (0,
20, 40, and 60 min) at 37oC, and the reaction terminated boiling the samples for 10 min. The
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samples were subsequently filtered and analyzed by reversed phase HPLC as described above.
The HPLC total run time was 20 min and the injection volume was 100 µl. The peptide dissolved
in artificial saliva was used as a control. The sample was analyzed by mass spectrometry to
identify the peptide fragments.
Calculation of peptide half-life. Following HPLC, the peak area of the KM-12 peak was
examined (after subtraction of saliva and simulated gastric juice baseline) and correlated to the
concentration. The area under the curve for KM-12 at time 0 (500 µg/ml) was considered as
100% and the change in the peak area was correlated to the concentration of KM-12. Natural
logarithm of the peptide concentration (ln) was plotted versus incubation time, and fit into firstorder decay equation 20.
ln[A] kt ln[A]o

Where [A] the concentration of peptide at time t, k is the reaction rate coefficient, t is the time and
[A]0 is initial peptide concentration . The first order decay equation is a linear equation under

natural logarithm:

The t1/2 was then calculated using this formula:
t1/2
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The stability and protein binding capacity of KM-12 in serum. Peptide stability and protein
binding capacity was assayed in diluted serum as previously described with some modification
19

. Forty microliters of fetal bovine serum (Equitech-Bio) were added to 20 μl of KM-12

dissolved in distilled water at a concentration of 0.5 mg/ml. The volume was adjusted to 200 μl
with 10 mM phosphate buffer (pH 7) and the samples incubated a 37oC for 5 min. After
incubation, 20 μl of trichloroacetic acid (TCA) was added and the mixture incubated at 4°C for
10 min and subsequently centrifuged at 13000 rpm for 10 min. The supernatant was
subsequently neutralized with NaOH. The amount of KM-12 present in the supernatant was
determined by reverse phase-HPLC as described in previous section with the controls of peptide
alone and peptide in serum after 0 min incubation.
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4.3 Results
Peptide synthesis and cleavage from the resin: The peptides used in this study are shown in
Table 1. Due to the presence of cysteine in the peptide, the synthesis and preparation of the
peptides required an optimization of the protocols for cleaving the peptide from the resin after
synthesis. Three different cleavage protocols were evaluated to achieve the optimal yield. All
three protocols contained the same percentage of TFA and the differences between them were
the thiol scavengers and the precipitation procedure. Method A utilized non-thiol scavengers
(5% triisopropylsilan, and 5% phenol), MTBE and 3 h incubation time that resulted in a complex
HPLC profile where several byproduct peaks appearing along with KM-11 (Figure 1A).
Moreover, the yield of KM-11 was low as the height of KM-11 peak was less than the
byproducts. In the second approach, the thiol scavengers were changed to thioanisol,
ethandithiol, and anisole (Figure 1B) to improve the yield of KM-11 and simplify the complexity
of the HPLC profile, but some byproducts remained. The sizes of the two major byproducts
were determined by mass spectrometry to be larger than KM-11 with 58 m/z and 288 m/z.
Finally, using the same thiol scavengers as in the second approach, the precipitation step was
performed using diethyl ether and this yielded an HPLC profile containing the single KM-11
peak (Figure 1C) that was confirmed by mass spectrometry.
To determine whether these conditions for cleavage and precipitation were unique to KM-11, the
first and third approaches outlined above were reevaluated for the cleavage of the KM-13 peptide
that also contains an N-terminal cysteine. As illustrated in Figure 2, the HPLC profile for the
cleavage products using the non thiols scavengers and methyl-t-butyl ether/hexane precipitation
was very complex as seen with KM-11, while the thiols scavengers and diethyl ether
precipitation yielded a single KM-13 peak. These data demonstrate that the cleavage of
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cysteine-containing peptides from the Rink resin requires nontraditional cleavage procedures,
and the inclusion of thiol scavengers and diethyl ether precipitation was subsequently used for
the preparation of all cysteine-containing peptides.
Peptide dimerization: All of the peptides used in this study (Table 1), except KM-17, were
synthesized as a monomer and subsequently dimerized via disulfide bond formation. For KM17, which contains both an N- and C- terminal cysteine a disulfide bond was formed to produce a
circular peptide. The dimerization was accomplished by incubation of the peptides in the
presence of 10% DMSO and dimerization monitored by Ellman reagent and HPLC. As
illustrated in Figure 3, the oxidation is a time dependent process and 24 h of incubation at room
temperature was the optimal time for 95% of the monomer to be converted to a dimer.
The efficiency of dimerization and the identity of the peptides purified by HPLC were confirmed
by mass spectrometry. Unfortunately, MALDI-TOF was unable to confirm the effectiveness of
the dimerization process. For example, the MALDI spectrum for KM-12 (the dimer of KM-11)
contained two peaks at 885 m/z (KM-11) and 1767 m/z (KM-12) with equal intensity (Figure
4A); however, when the same sample was analyzed by ESI, the major peak was the dimer
(Figure 4B). Since the HPLC elution profile and the Ellman reagent reaction also suggested the
samples were dimers with no free cysteine residues, it was concluded that the MALDI-TOF
analysis was inherently causing the reduction of the disulfide bonds. Thus, peptide samples
containing a cysteine residue were confirmed using ESI spectrometry.
The circularized monomer of KM-17, referred to as KM-18, was dimerized at a concentration of
1mg/10 ml to promote intramolecular disulfide bond formation. The HPLC profile showed two
additional peaks, besides KM-17, representing possible dimers (Figure 5). The peptide mixture

184

produced from KM-17 oxidation was also reduced by dithiothreitol to confirm the peaks in the
HPLC profile were derived by the disulfide bond formation of KM-17 (Figure 5). Mass
spectrometry was used to verify the identity of the KM-17-derived peptides (Figure 6).
Fungicidal activity of the KM-12: To evaluate whether the KM-11 dimer, termed KM-12,
resulted in the enhancement of the fungal killing activity against Candida albicans fungicidal
activity assays were performed (Figure 7). The antifungal activity increased significantly by the
dimerization of KM-11, as a 2.5 µM concentration of KM-12 killed close to 100 % of the cells
while the KM-11 monomer killed only 55%. The monomeric form of KM-11 was maintained by
performing the fungicidal activity assay in the presence of 5 mM DTT. In data not shown, it was
determined that 5 mM DTT does not affect the viability of C. albicans.
To specifically define the LD50 of KM-12 with C. albicans, a dose dependent fungicidal assay
was performed (Figure 8). It was found that the peptide reached 100% killing at a concentration
of 2.5 µM and the LD50 was determined to be 0.308±0.035 µM. To determine the rate of
fungicidal activity against C. albicans, the kinetics of killing was determined using 2.5 µM of
KM-12 (Figure 9), and it was found that less than 20% of the cells were viable after 1h and KM12 achieved nearly 100% killing in 2 h.
Characterization of fungicidal activity of KM-12. Since KM-12 was developed using the
histatin 5 model, it is plausible that the mechanism of action may be the same. To determine
whether the antifungal activity of KM-12 was similar to that of histatin 5, some of the known
characteristics of histatin 5 were examined for KM-12; namely sensitivity to salt, sodium azide,
low temperature, and the activity against Saccharomyces cerevisiae.
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The salt sensitivity was evaluated by examining the effect of NaCl on the activity of KM-12 at
different concentrations of NaCl (5mM, 25mM and 150mM). It was found that NaCl possessed
an inhibitory effect that was dose dependent with a 50% reduction in the maximum antifungal
activity achieved at 150 mM NaCl (Figure 10A). Although the KM-12 antifungal activity is
sensitivity to NaCl concentration, it was less sensitive than the C-16 histatin 5 or KM5 peptide
examined in Chapter 2 and 3. It was also observed that incubation at 4oC exhibited an inhibitory
effect on killing as shown in Figure 10B.
The role of cellular respiration in the activity of KM-12 was evaluated using two different
approaches: killing activity in the presence of the respiratory inhibitor sodium azide and the
killing activity of S. cerevisiae during fermentative growth. It was found that 5 mM sodium
azide inhibited the fungicidal activity of KM-12 by 80% (Figure 10C). On the other hand, as
illustrated in Figure 10D, KM-12 exhibited a similar potency of killing against S. cerevisiae
versus C. albicans, where 2.5 µM of KM-12 killed 93% of S. cerevisiae cells while the same
concentration killed 99% of the C. albicans. The explanation for the latter observation is
unclear. Nevertheless, the results with sodium azide inhibition suggests that active respiration is
important for the killing activity of KM-12, similar to the other histatin 5 peptide derivatives that
have been examined (Chapter 2 and 3).
Activity of KM-12 in the minimum inhibitory concentration assay. The fungicidal activity of
KM-12 was evaluated using a more clinically relevant assay, the minimum inhibitory
concentration assay (MIC). This assay is performed in RPMI-1640 tissue culture medium,
composed of several salts and cations, to more closely simulate the physiological condition. To
evaluate the effect of ionic strength, an assay was performed at different concentration of RPMI1640: 1X, 0.5 X, 0.25 X and 0.125 X, where X is the full ionic strength. Not surprisingly, it was
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found that RPMI-1640 demonstrated an inhibitory effect and the activity of KM-12 was totally
abolished in 1X RPMI-1640 (Table 2). Furthermore, the antifungal activity was improved by
diluting the RPMI-1640, demonstrating the salt sensitivity of the peptide. For example, the MIC
value decreased from >176 µg/ml in 1X RPMI to 5.5 µg/ml in 0.125X RPMI. Nevertheless, it is
important to note that the MIC value for KM-12 was dramatically improved over that of the C-16
histatin 5 peptide which had virtually no killing activity even in 0.125X RPMI-1640 (Table 3 of
Chapter 2).
Optimizing the KM12 fungicidal activity. KM-12 is a prototype peptide where the sequence
could potentially be optimized to achieve increased fungicidal activity. Moreover, the
optimization could assist in solving problems associated with KM-12, such as salt-sensitivity. To
achieve that, several analogs were synthesized with slight modifications to the sequence. Two
types of modifications were tried: mutating specific amino acid residues and changing the
position of the cysteine residue to alter the structure of the peptide dimer. Following synthesis,
preparation of the dimer and purification, the fungicidal activity of each peptide was evaluated
by MIC assay against Candida albicans in 0.125X RPMI. The MIC activity of KM-12 and each
of the analogs is shown in Table 3.
The effect of the hydrophobicity on fungicidal activity was examined by changing both the
phenylalanine and tyrosine residues to tryptophan to produce the KM-14 peptide. This change
did not improve the antifungal activity as the MIC value was 11.8 µg/ml. To improve the salt
sensitivity, the lysine residues were replaced with histidine and arginine residues, generating
KM-26 and KM-28, respectively. This change also did not improve either the activity or the salt
sensitivity as the MIC values for KM-26 and KM-28 were 44.7 and 11.2 µg/ml, respectively. To
evaluate whether the position of cysteine within the peptide influenced activity, the cysteine
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residue was moved to the center of the peptide (KM-16), and this had an inhibitory effect on
fungal cell killing as the MIC value for KM-16 was 44 µg/ml. The addition of an extra cysteine
to the C-terminus to permit circularization of the monomer, generating KM-18 and two circular
dimeric byproducts (KM-19 and KM-20) was evaluated. The activity of KM-18 was less potent
than KM-12 with a MIC value ranging from of 8 to16 µg/ml, while the activity of the circular
dimers (KM-19 and KM-20) was essentially abolished. It is important to note that the activity of
KM-18 was near to that of KM-12, and if the circularization improves with the pharmacokinetic
and stability properties of the peptide the slight reduction in activity may be a reasonable
exchange for improved physiological properties. Therefore, the circular monomer remains a
viable lead peptide worthy of further in vivo investigation in the future.
Spectrum of KM-12 fungicidal activity. To evaluate whether KM-12 exhibited a broad
activity spectrum, the killing activity of the peptide was examined on the most common
pathogenic Candida species (C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae,
C. kefyr and C. dubliniensis) and MIC values were determined. First for each strain, the activity
of a common therapeutic azole compound, fluconazole, was evaluated in parallel to determine
whether KM-12 displayed a broader activity spectrum than current azole therapeutics. As shown
in Table 4, three strains displayed resistance to fluconazole: C. glabrata, C. krusei and C.
tropicalis. KM-12 exhibited a broader spectrum of activity against the fluconazole-resistant
Candida species (C. krusei and C. tropicalis). C. glabrata was resistant to both fluconazole and
KM-12. C. glabrata resistance to KM-12 may prove to be a useful observation in the future as
we explore the mechanism-of-action of KM-12.
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Structural analysis of KM-12. The secondary structure of KM-12 was evaluated using circular
dichroism (CD) spectroscopy in aqueous solution as well as in the presence of charged lipids
(neutral and negatively charged). An experiment was conducted to study the effect of charged
lipids on the secondary structure of KM-12. In this study DMPC liposomes (1:50) were used to
mimic neutral lipids, while SDS micelles (1:50) were used to simulate negatively charged lipids.
As illustrated in Figure 11, KM-12 remained largely in a random coil structure in aqueous
solution with some tendency to form a partial secondary structure, 5% α-helix and 11% β-turn. In
the presence of DMPC liposomes the overall structure did not change as the majority of KM-12
remained in a random coil conformation, but the propensity to form a β-turn increased to 20%. In
contrast, the peptide tendency to form β-turn reduced (12%) in SDS micelle and the peptide
adopted a partial α-helix (23%), suggesting that negatively charged lipids on the membrane may
be important for the formation of the secondary structure of KM-12.
Stability of KM-12 in human saliva. To evaluate the potential of using KM-12 in
pharmaceutical applications for Candida infections of the oral cavity, the stability of KM-12 in
human saliva was evaluated. The peptide was incubated in human saliva for various periods of
time and the level of remaining peptide was determined using HPLC. In addition, the T1/2 and k
constant was calculated, and the proteolytic cleavage sites were identified using mass
spectrometry. The chromatogram (Figure 12A) shows that KM-12 is susceptible to the enzyme
degradation in saliva as the peak representing KM-12 decreased dramatically by extending the
incubation time in saliva. The initial concentration of KM-12 was 500 µg/ml and after 60 min in
human saliva, the peptide concentration was reduced to approximately100 µg/ml. The kinetics of
degradation suggested that KM-12 proteolysis in human saliva is following a first order reaction
in which the estimated T1/2 was 26.35 ±2.45 minute and k constant was 0.0263 min-1 as shown in
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Figure 12B. Mass spectrometry suggested one major fragment at 1321.8 m/z. This size is
correlated with only one possible fragment that would occur if KM-12 has been cleaved after the
first lysine from the N-terminus of one monomer as shown in Figure 13.
Stability of KM-12 in artificial gastric juice. In order to use KM-12 for systemic
pharmaceutical applications via oral administration, the stability of KM-12 in simulated gastric
juice was evaluated. Stability was examined at various times over a 60 min incubation period
and the presence of the full length peptide was quantified using HPLC. The kinetics of KM-12
degradation in pepsin, including T1/2 and k constant, were also determined. Mass spectrometry
was also used to identify the cleavage sites. The HPLC data shows that the KM-12 peak
decreased rapidly in the presence of simulated gastric juice and the peptide was completely
degraded after a 40 min incubation period (Figure 14). The degradation of KM-12 by pepsin
follows a first order reaction (Figure 14B) where the estimated T1/2 was 7.83 ± 1.44 min and the k
constant was 0.0946 min-1. The comparison between the mass data of KM-12 exposed to
artificial gastric juice for 0 min versus 60 min revealed that KM-12 is primarily cleaved after the
phenylalanine leaving 1174.6 and 593 m/z peptides (Figure15).
Stability in Serum. Since oral medications will be absorbed into the blood stream or potentially
delivered as an intravenous drug, the stability of KM-12 in serum as well as KM-12 binding to
serum components was evaluated. KM-12 was incubated in 20% FBS for 0 and 5 minutes, and
the serum proteins were precipitated with TCA before the supernatant was quantified by HPLC.
Two important observations were seen during the HPLC analysis (Figure 16): a reduction in
KM-12 peak and an increase in KM-11 monomer peak. Although the 0 min sample was mixed
with serum and instantly precipitated with TCA, that was a sufficient time period to decrease the
concentration of KM-12 by 40% and increase the concentration of KM-11 (monomer ) by 50% .
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After 5 min, approximately 80 % of KM-12 was either bound to serum proteins and precipitated
or reduced to monomer.
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4.4 Discussion:
In the last decade, the number of drug-resistant Candida strains has increased, emphasizing the
need to develop novel drug models with unique mechanisms of action. Several researchers have
shown histatin 5 is a good model for an antifungal drug and several attempts have been
conducted to optimize and utilize histatin 521, 22. Previously, we identified a short sequence
(Chapter 3) within histatin 5 that contributes the majority of the antifungal activity, referred to as
the KM motif. The KM motif is composed of five amino acids and retains strong antifungal
activity against C. albicans.
In this study we took a step forward and tried to develop a more potent antifungal peptide
utilizing the KM motif. The optimal goal of this study was to design peptides with the following
properties: work via a mechanism similar to histatin 5, maintain a relatively small size, to have
stronger fungicidal activity than histatin 5, to have broad spectrum activity against multiple
Candida species, and finally to be stable in human fluids. Furthermore, this study defines the
optimal conditions to synthesize these peptides efficiently.
Since KM-5 exhibited antifungal activity similar to histatin 5, a logic way to increase the
activity without interfering with the mode of action was to dimerize KM-5 with the goal of
additively increasing activity. To accomplish this objective, a cysteine residue was added to the
N-terminus of KM-5, and the dimer generated by a disulfide bridge. To achieve the optimal
production of these peptides several protocols were evaluated for the cleavage of the peptide
from the Rink resin. The differences between the protocols were the type of scavengers and the
precipitation strategy. The change in cleavage protocol was required because the use of nonthiol
scavengers yielded various byproducts and poor cleavage, likely related to the presence of a
cysteine residue. Our results showed that using thiol (Thioanisol, Ethandithiol, Anisole)
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scavengers, and performing the precipitation in diethyl ether were the optimal conditions for
obtaining the highest yield of pure peptide (Figure 1 and 2). The unexpected complexity of the
cleavage product using standard conditions of peptide synthesis occurred because of the presence
of cysteine, arginine, and tryptophan. The main function of scavengers is to reduce the amount of
byproduct formed23. It has been published that thiol scavengers are essential for peptides
containing cysteine-tert-butyl 24. Although the tert group is easily removed during the cleavage,
it tends to reattach to the free sulfhydryl if a thiol scavenger is not present 25. Also tert-butyl can
form carbocation counterparts (tert-butyl cations) which might interact with tryptophan, tyrosine
and methionine 25.
Even though several protocols showed the use of thiol scavengers to be enough to reduce the
byproducts, a large contaminating peak was still observed in the KM-11 cleavage product
(Figure 1). The mass spectrometry showed this byproduct is 56 m/z larger than KM-11, which is
equal to a tert-butyl group. So it is likely that the tert-butyl alkylation occurred in spite of the
presence of thiols. It has been published that the use of MTBE in some peptides, especially
aromatic-rich peptides, produces a significant level of tert-butyl-peptide byproduct 26. The tertbutyl was not generated from the peptide protecting group; rather it came from tert-butyl-O
cleavage of MTBE under the strongly acidic condition. This problem was alleviated by using
diethyl ether for peptide precipitation.
After the peptide had been synthesized, the dimerization process was initiated. All peptides were
dimerized successfully in the presence of 10 % DMSO at pH 8 (Figure 3 and 5). The
dimerization was monitored using HPLC, Ellman reagent and mass spectrometry (MALDI-TOF
and ESI). Interestingly, although HPLC and Ellman reagent confirmed the oxidation, MALDITOF failed to support the result as the spectrum showed the dimer and monomer at the same
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intensity (Figure 4). In contrast, ESI confirmed that the dimer is the predominant species in the
reaction consistent with the HPLC and Ellman data. This observation is not new as the
ionization used in MALDI is capable of breaking the disulfide bonds and causing rearrangements
unless a special matrix is used (2-(4-hydroxyphenylazo) benzoic acid: α-cyano-4hydroxycinnamic acid (1:10)) 27 .
KM-12 was the first dimer generated and it contained two copies of the KM motif. The
dimerization boosted the antifungal activity of the KM motif by almost 15 fold over the
monomer as the LD50 decreased from 5 µM to 0.3 µM (Figure 8). Previously we measured the
LD50 of the C-16 histatin 5 and KM-5 peptides with C. albicans using the fungicidal activity
assay, and these peptides displayed an LD50 of 2.7 µM and 5µM, respectively. It has also been
previously published that the LD50 of histatin 5 and P-113 (an active fragment of histatin 5) on C.
albicans are 2.3 µM and 4.47 µM, respectively 28. In the light of the reported data, KM-12
exhibited a significantly more potent fungicidal activity than KM-5, C-16, histatin-5, or P-113.
This comparison may not be completely valid since all of these peptides were not directly
compared in the same experiment. However, the C-16 peptide has been shown to retain the full
activity of histatin-5 and the LD50 value obtained from our study is in agreement to histatin 5
from other studies, 2.7 µM and 2.3 µM respectively. It is important to emphasize that the in vitro
fungicidal assay does not reflect the actual activity in vivo. For example, histatin 5 in the oral
cavity is more active than in the fungicidal activity assay for multiple reasons. First, it is
constantly produced in the oral cavity. The mean concentration of histatin 5 in submandibular
and sublingual saliva at any giving time is 26 to 90 µg /ml29. Secondly, histatin 5 has an ability
to bind with Zn+2 and this may enhance the antifungal activity 30. Finally, histatin 5 is adsorbed
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to the hydroxyapatite of the teeth31, and this prolongs half-life of histatin 5 by protecting it from
proteolysis enzymes 32.
Several examples of antimicrobial peptides (AMPs), both naturally occurring and synthetic,
have been published utilizing disulfide dimerization to improve the activity 33. For example,
PAMP-36 , a cathelicidin-derived peptide produced naturally by pig leukocytes, is a homodimer
composed of 36 amino acid in which the dimerization improved the activity as well as the ability
to permeabilize the target membrane 34. An example of a synthetic antimicrobial peptide is
(CKPV)2 , a homodimer peptide developed from melanocortin hormone 35.
With some exceptions, most cationic antimicrobial peptides, including histatin 5, are inhibited by
sodium chloride. As the nature of interaction between cationic AMPs and the negatively charged
membrane is ionic, it can be weakened by monovalent and divalent cations, thus the fungicidal
activity will be reduced36, 37, 38-40. KM-12 is also inhibited by sodium chloride but to a lesser
extent than histatin 5 (Figure 10). The presence of 150 mM NaCl was enough to inhibit the
activity of histatin 5 completely37, while KM-12 was only 50% inhibited. This phenomenon
might be related to the fact that KM-12 has more basic amino acids than in histatin 5, hence the
interaction between KM-12 and the membrane is stronger; thereby a higher concentration of the
salt is required. The effect of salts on the activity of KM-12 was also evaluated using RPMI1640 tissue culture medium to more closely simulate a physiological environment in which
multiple salts are present. Moreover, the MIC assay in RPMI-1640 is the standardized clinical
assay used to evaluate fungal sensitivity to drugs; hence, it provides a platform for the analysis of
the KM peptides consistent with that used in a clinical environment. The influence of RPMI
ionic strength on KM-12 activity was obvious as the activity was decreased by increasing the
concentration of RPMI (Table 2). In spite of the sensitivity to salt, the activity of KM-12 is
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superior to histatin-5 and KM-5. The MIC value for KM-12 at 0.125X RPMI-1640 was 5.5-11
µg/ml, while histatin 5 C-16 peptide displayed a MIC value of 206.7µg/ml (Chapter 2).
Moreover, histatin 5 did not demonstrate fungicidal activity at 0.25 X and 0.5 X RPMI while
KM-12 did with MIC values of 44-88 and 176.8µg/ml, respectively. It’s important to mention
that MIC is also an in vitro assay and it does not necessarily correlate with the potential in vivo
activity; however, it is an excellent assay for comparing the KM peptides to known antifungal
compounds.
Although the exact mode of action of histatin 5 remains unclear, research has shown histatin 5
targets active mitochondria and subsequently depolarizes the mitochondrial membrane43. In this
study, two assays were conducted to evaluate the role of respiration in KM-12 activity: sodium
azide sensitivity and the fungicidal activity against S. cerevisiae grown by fermentation. Sodium
azide, as a potent inhibitor of mitochondrial respiration, inactivates cytochrome c oxidase via
intercalating between the heme a3 iron and Cu3 at the oxygen reduction site 44. In addition, azide
binds to the F1 catalytic domain within mitochondrial F-ATPases and inhibits the hydrolyase
activity 45,46. Multiple publications have shown that 5 mM sodium azide inhibits both the
conventional and the alternative respiratory pathway in Candida albicans43, 47. The activity of
KM-12 was inhibited severely by the presence of 5mM sodium azide. These data suggests that,
similar to histatin 5, the fungicidal activity of KM-12 may be related to the cellular respiration
(Figure 10).
Although Saccharomyces and Candida produce energy via respiration and fermentation, histatin
5 48, 49, C-16 and KM-5 possess potent activities only against Candida species. This difference
may be related to the fact that S. cerevisiae grows as a Crabtree-positive yeast that ferments
glucose even in the presence of oxygen; whereas, C. albicans is a Crabtree negative yeast that
196

relies on respiration in the presence of oxygen. Consequently, S. cerevisiae mitochondria will be
less active and histatin-5 will lose the ability to kill these cells. The ability of S. cerevisiae to
hinder the translocation of histatin 5 to the cytoplasm is another possible explanation that has
been suggested 49. Surprisingly, KM-12 killed 92% of S. cerevisiae at a concentration of 2.5µM
on a fermentable medium, while C-16 and KM-5 failed to achieve killing at 25 µM (Figure 10).
This result suggests that KM-12 may work through a modified mechanism. This activity is not
unique for KM-12 as several antimicrobial peptides have been published that exhibit potent
activity on S. cerevisiae, such as MUC7 50, Cecropin B, and Arasin 151 .
Another difference between the histatin 5 C-16 peptide and KM-12 is the kinetics of fungicidal
activity. KM-12 attains the maximum activity within 1 hour while C-16 and the KM-5 peptides
required two hours (Figure 9). This suggests that KM-12 is not only more potent that C-16 and
KM-5, it also has a more rapid onset of action. Unfortunately, the kinetic results cannot be
compared directly with other AMPs due to the use of different peptide concentrations and
different incubation times.
After the killing activity of KM-12 had been characterized, several KM-12 analogs were
generated in an effort to improve the fungicidal activity and to increase the tolerance to salt. The
first KM-12 derivative involved replacing the tyrosine and phenylalanine with tryptophan to
increase the hydrophobicity (KM-14). It has been published previously that tryptophan has a
greater propensity to insert into membranes as well as to interfere with lipid polymorphism 52
which may lead to increase the activity . Although such an amino acid change has boosted the
activity of other AMPs53, 54, it did not improve the activity of KM-12 (Table 3). Therefore KM14 was excluded from further studies. Other reasons that lead to the exclusion of KM-14 from
further study are: tryptophan tends to increase red blood cell hemolysis activity55 and it is less
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stable in gastric juice56. The second replacement involved substituting lysine residues with
histidine (KM-26) to improve the salt tolerance. The histidine positive charge is pH dependent,
and at physiological pH it exhibits less positive charge than lysine. Accordingly, the
hydrophobicity will be increased by this substitution as well retaining some of the positive
charge. This amino acid replacement was shown to improve the activity of the histatin 5 related
P-113 peptide28; however, it did not improve the activity or salt tolerance of KM-12 (Table 3).
Another analog was KM-28, in which lysine residues were substituted with arginine. It has been
published that the arginine side chain interacts more strongly with lipid phosphates than the
lysine side chain at physiological temperature 57; therefore, this change was expected to improve
the activity and salt tolerance . Unfortunately, this change did not improve fungicidal activity or
salt tolerance. On the contrary, the MIC value (µg/ml) was higher than KM-12 (Table 3).
The final peptide modifications involved changing the cysteine location (KM-16) and the
addition of an extra cysteine (KM-18 and KM-19). The influence of cysteine location within
KM-12 was studied by shifting the cysteine to the center (FKCRKY) rather than being at the Nterminus (CFKRKY). The relocation of the cysteine was not a random selection; it was picked
because a related sequence was found in another naturally occurring AMP which has potent
antibacterial and antifungal activities, Lactoferricin B (FKCRRW) 58, 59. The dimerization of
KM-16 didn’t improve the activity; in contrast it increased the MIC value. This result indicates
the continuity of positive charges is essential for maintaining maximal antifungal activity (Table
3).
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Several naturally occurring antimicrobial peptides contain multiple cysteine residues, where the
disulfide bond is responsible for improving the rigidity of the peptide structure. Consequently,
this enhances the activity and more importantly, the salt resistance 60, 61,62 . Theta-defensin is an
example of an AMP in which multiple disulfide bonds play an essential role in salt sensitivity 63,
64

, and the rigid structure may also enhance the activity through reducing the sensitivity to

proteolytic cleavage 51, 65 . The addition of an extra cysteine to the C-terminus of KM-11,
producing a cyclic monomer (KM-18) and cyclic dimers (KM-19 and KM20), did not increase
the activity or the salt tolerance (Table 3. However it should be noted that KM-18, the cyclic
monomer, had an MIC value similar to KM-12. Thus, KM-18 remains a viable candidate for
further investigation, particularly since cyclization of peptides has been shown to increase the
activity of antifungal peptides64,66, 67, 68, 69.
Non-albicans species of Candida are responsible for 35-65% of systemic Candida infections in
the general patient population70. They are more frequent in immune compromised patients
including HIV/AIDS, cancer, and neonatal pediatric patients70-72. Some of these species also
exhibit resistance to the most common fungal medications : C.parapsilosis73, 74 75, C. dubliniensis
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, C. kefyr 72 and C. lusitaniae 70, 71 isolates have been found that are resistance to amphotericin

B, while C.glabrata77, C.tropicalis78, C.krusei79 are inherently resistant to fluconazole . The
ultimate goal of our work is to design an antifungal peptide that is not only active against C.
albicans but also on non-albicans strains. Excluding C. glabrata, KM-12 possesses a potent
activity on all non-albicans species when assayed in 0.125X RPMI-1640 medium, while
fluconazole failed to kill C .tropicalis and C. krusei (Table 4). Many strains of C. glabrata have
been shown to be resistant to histatin 5 and other histatin family members 80, thus the resistance
of C. glabrata to KM-12 was expected. The exact mechanism for this resistance is not fully
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understood, however recent research has shown that it might be due to the reduction of histatin 5
uptakes into the cell81. This reduction may be explained by the fact that polyamine transporters
(Dur3p and Dur31p) in C. glabrata are uncharacterized which are essential for histatin 5
translocation into the C. albicans cell. The overexpression of Dur3p and Dur31p in C. glabrata
strains increased the susceptibility to histatin 5 by two-folds81. It’s important to mention that
although C. glabrata and C. albicans belong to the same genus, C. glabrata is more
phylogenetically related to S. cerevisiae than C. albicans82. Also the composition of the cell wall
is different as C. glabrata has higher surface levels of β-1,3-glucans as compared with C.
albicans81.
KM-12 primarily adopted a random coil structure; however there was some local structure. In
the presence of DMPC liposome mimicking a neutral cell membrane, KM-12 gained a
propensity to form an alpha helix, while in SDS micelles it showed a tendency to form a betaturn structure (Figure 11). It is likely that the short length of KM-12 prevents the formation of a
strong secondary structure. In all cases, KM-12 is too small to cross a yeast cell membrane in an
α-helix structure, which requires at least 20 amino acids 28. This result suggests that KM-12 as
well as histatin 5 may use the carpet model to cross the membrane, where no secondary structure
and specific size are required 83, 84. In the carpet model, the peptides bind and align in parallel to
the surface of the yeast membrane, and then the membrane is permeabilized and/or is
disintegrated into micelle-like structures at high concentrations of peptides85. So how do KM-12
and histatin 5 differentiate between human and yeast cells? Until now the answer is unclear but
the selectivity may be related to the fact that histatin 5 has the ability to bind to laminarins (betaglucans), yeast cell wall polysaccharides, before translocation into the cytosol86. KM-12 may
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also bind to the cell wall before it interacts with the cell membrane. Since humans lack cell
walls, KM-12 selectively binds to fungal cells.
After characterizing the in vitro activity of KM-12, the stability in human fluids was evaluated.
Because Candida infections can be local (oral and vaginal) or systemic (blood) and the route of
drug administration varies (topical, mouth and intravenous), the stability of KM-12 was
examined in saliva, gastric juice and serum.
Human saliva contains a pool of protease enzymes, more than 13, with various activities such as
trypsin-like, chymotrypsin-like and histidine peptidases 87, 88. These enzymes are mostly
secreted from white blood cells and microflora, but some are produced by the salivary glands 89,
90

. The main target cleavage sites of salivary proteases are lysine and arginine residues for

trypsin-like enzymes, aromatic amino acids for chymotrypsin-like enzymes, and histidine is the
primary target for histidine proteases 87, 88. KM-12 is unstable in human saliva with a T1/2 of 26
minutes (Figure 12). The stability of histatin 5 in saliva has been evaluated in multiple
publication and the kinetics of histatin proteolysis in saliva have also been measured87, 91. The
rate of histatin 5 degradation in saliva was found to be 17.8 µg/ml/h and the T1/2 was around 8 h
87

. However these studies did not use whole saliva, instead they used a 1:10 diluted version, so

the data are not directly comparable. The difference in stability between KM-12 and histatin 5
may relate to the fact that histatin 5 can be adsorbed to the teeth 31. This feature prolongs histatin
5 life via protecting it from proteolysis enzymes. The stability of other AMPs has been evaluated
in saliva and in several cases they were degraded completely with less than 60 min90, 92. For
example, the T1/2 for the KSL peptide, a deca-AMP , in saliva was less than 5 minutes and the
peptide was totally degraded within 10 minutes 18. The problem of KM-12 stability can be
solved using D-amino acids and this idea has been confirmed in multiple AMPs 18, 90, 92-95.
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We also examined the stability of KM-12 in simulated gastric juice which becomes important
when considering oral administration of an antifungal compound. Pepsin, an enzyme found in
simulated gastric juice, cleaves peptides and proteins before and after hydrophobic residues, such
as phenylalanine, tryptophan, and tyrosine18. KM-12 is unstable in simulated gastric juice with a
T1/2 of 7.8 min (Figure 14). Using the mass spectrometry, we identified phenylalanine as the
only cleavage site in KM-12 (Figure 15). Therefore, the stability in gastric juice could be solved
by simply replacing the phenylalanine for D-phenylalanine. In fact, this idea was tested and the
peptide containing D-phenylalanine was stable over for over 60 min in artificial gastric juice
(Akkam, unpublished observation).
The stability of KM-12 in serum as well as the binding to serum proteins was evaluated to study
the possibility of using KM-12 intravenously. These results showed KM-12 has a tendency to
bind to serum proteins and the peptide was found to be unstable in serum (Figure 16). Although
20 % FBS was used in the assays, approximately 50% of KM-12 was either bound to serum
proteins or was reduced to monomer. Binding to serum protein has benefits as it increases the
volume of distribution and the duration of action. The serious problem was the reduction of KM12 because the activity will be reduced. The only solution is to remove the cysteine and dimerize
the peptide using a different method such as lysine-lysine covalent bond, or to produce a 10
amino acid peptide without dimerization.
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4.5 Conclusions
KM-12 is a novel antimicrobial peptide designed utilizing two KM motifs dimerized via a
disulfide bond. The activity of KM-12 on C. albicans is approximately fifteen times more potent
than the monomer and ten times more active than histatin 5 or the C-16 peptide. KM-12
possesses potent antifungal activities on most common Candida species, including those resistant
to fluconazole. The results of this study suggest that the mode of action for KM-12 may be
similar to histatin 5 as the activity was inhibited in the presence of common histatin 5 inhibitors.
Unlike histatin 5, C-16 and KM-5 peptide, KM-12 exhibits the ability to kill S. cerevisiae on
fermentable medium. Structurally, KM-12 retains a random coil structure in aqueous solution,
DMPC liposomes, and SDS micelles. KM-12 was evaluated for use as an oral, topical and
intravenous compound. The T1/2 was 26 and 7.8 minutes in saliva and simulated gastric juice,
respectively. In serum, a portion of KM-12 was reduced to the monomeric form; however, KM12 has shown a tendency to bind serum proteins. In conclusion, KM-12 is promising antifungal
peptide and may serve as a candidate drug for pharmaceutical applications against Candida
infections. KM-12 is a prototype design in which additional modifications may be required to
achieve maximum benefits.
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Table 1: KM peptides synthesized in this study.
Name
Sequence1
Molecular weight (g/mol)
KM-11
CFKRKY
855
KM-13
CWKRKW
947
KM-15
FKCRKY
855
KM-17
CFKRKYC
988
KM-25
CFHRKY
894
KM-27
CFRRRY
941
1
Underlined letter represents the cysteine and the italic represents the variable amino acid.
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Table 2: MIC assay for KM-12 activity against Candida albicans.
The concentration of RPMI

MIC value (µg/ml)

1X

>176.8

0.5X

176.8

0.25X

44-88

0.125X

5.5-11
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Table 3: MIC assay of KM-12 analogs against Candida albicans.
Peptide name

Sequence1

KM-12

CFKRKY
CFKRKY

CWKRKW
CWKRKW
FKCRKY
KM-16
FKCRKY
KRK
KM-18
F
Y
C C
CFKRKYC
KM-19 & KM-20
CFKRKYC
CFHRKY
KM-26
CFHRKY
CFRRRY
KM-28
CFRRRY
1
Red line indicates a disulfide bond.
KM-14

3

MIC3
µg/ml

Mean
Hydrophobic2
moment
0.40

5.5 - 11

0.12

118 – 23.6

0.40

44 - 88

0.35

8 - 16

0.35

197.2

0.37

44.65

0.39

11.16

Mean hydrophobic moment was calculated using the Kyle and Doolittle scale96 .

3

MIC assay was performed in 0.125X RPMI-1640 medium.
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Table 4: MIC assay for comparison of the activity of fluconazole and KM-12 on different
Candida species.
Candida strain1

Fluconazole

KM-122

C. albicans

1.4 -2.8

5.5 - 11

C. dublinesis

1.95 -3.9

11- 22

C. glabrata

37.5

88.4

C. kefyr

1.35 – 2.34

2.75-5.5

C. krusei

75-150

5.5-11

C. lucitaniae

0.29 – 0.58

1.38-2.75

C. tropicalis

>150

2.75-5.5

C. parapsilosis

15

5.5

1

Specific clinical isolate and assay are described in the Materials and Methods

2

Assay was performed in 0.125X RPMI-1640 medium
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KM-11

C

0

KM-11 + 58

5
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Time (min)

15

20

25

Figure 1: HPLC profiles for three different protocols of KM-11 cleavage from the Rink
resin. (A) A cocktail composed of 85% TFA, 5% dH2O, 5% triisopropylsilan, and 5% phenol was
incubated with KM-11 for 3 h and peptides were precipitated in 1:1 v/v methyl-t-butyl ether/hexane. (B)
A cocktail composed of 90% TFA, 5% thioanisol, 3% ethandithiol, and 2% anisole was incubated with
KM-11 for 4 h and the peptide precipitated in 1:1 v/v methyl-t-butyl ether/hexane. (C) The same cocktail
as in panel B but the peptide was precipitated in diethyl ether.
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KM-13

KM-13

0

2.5

7.5

10

12.5

15

20

Time (min)5

Figure 2: HPLC profiles for different protocols of KM-13 cleavage from the Rink resin.
(Upper panel) A cocktail composed of 85% TFA, 5% dH2O, 5% triisopropylsilan, and 5%

phenol was incubated with KM-11 for 3 h and peptides were precipitated in 1:1 v/v methyl-tbutyl ether/hexane. (Lower panel) A cocktail composed of 90% TFA, 5% thioanisol, 3%
ethandithiol, and 2% anisole was incubated for 4 h and the peptides precipitated in diethyl ether.
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0 hours

Monomer

12:27

13:75

4 hours

Dimer

Dimer

Monomer

24 hour
Dimer

Monomer

Figure 3: HPLC profile of the kinetics of KM-11 dimerization. The peaks containing the
monomer (KM-11) and dimer (KM-12) are indicated. The procedure for dimerization and HPLC
are outlined in the Materials and Methods.
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Figure 4: Mass spectrometry of KM-12 dimerization. Mass spectrometry was performed on
the KM-12 peptide purified by HPLC as shown in Figure 3 using: (a) MALDI-TOF and (b) ESI
spectrometry.
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13:6
KM-17
Before Dimerization

KM-17
2 hours

KM-19, KM-20

13:2
KM-18
15:2

15:7

KM-18
24 hour

13:6

KM-17

In DTT

Figure 5: The HPLC profile of the kinetics of KM-17 dimerization. The peaks containing
the linear monomer (KM-17), the circularized monomer (KM-18) and two dimer peptides (KM19 and KM-20) are indicated. The procedure for dimerization and HPLC are outlined in the
Materials and Methods. The addition of dithiothreitol (DTT) to the oxidized peptide sample was
used to confirm the peaks were derived from KM-17 (Bottom panel).
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A

B

Figure 6: Mass spectrometry profile of KM-17 following oxidation of the peptide. MALDI
data for the dimerization of KM-17 at initial concentration of 1mg/10 ml. (Panel A) After
dimerization and (Panel B) before dimerization.
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Figure 7: Effect of KM-11 dimerization on the antifungal activity. The KM-12 peptide (2.5
µM) was incubated with C. albicans (1.8×105 cells/ml) for 2 h at 37oC in 10 mM sodium
phosphate buffer pH 7.4 or in the same buffer containing 5 mM DTT. The percentage of viable
cells was calculated as (viable colonies in the presence of peptide / viable colonies without
peptide) × 100. The data represents the mean of three independent experiments with the error
bars representing the standard deviation.
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Figure 8: Dose-dependent fungicidal activity of KM-12. (A) Dose-dependent fungicidal
activity of KM-12 against C. albicans. (B) Linear regression used for calculating the LD50 of
KM-12 against C. albicans. Different concentrations of KM-12 were incubated with C. albicans
(1.8×105 cells/ml) in 10 mM sodium phosphate buffer for 2 h at 37oC. The percentage of viable
cells was calculated as (viable colonies in the presence of peptide / viable colonies without
peptide) × 100. The data represents the mean of three independent experiments with the error
bars representing the standard deviation.
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Figure 9: Kinetics of KM-12 fungicidal activity. The KM-12 peptide (2.5 µM) was incubated
with Candida albicans (1.8×105 cells/ml) in 10 mM sodium phosphate buffer for different time
periods (15, 30, 60 and 120 min). The percentage of viable cells was calculated as (viable
colonies in the presence of peptide / viable colonies without peptide) × 100. The data represents
the mean of three independent experiments with the error bars representing the standard
deviation.
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Figure 10: Characterization of KM-12 antifungal activity. The effect of: (A) Salt, (B)
temperature, (C) respiratory activity, and (D) the fungicidal activity on Saccharomyces
cerevisiae were examined by fungicidal activity assays. For each assay, 2.5 µM KM-12 was
incubated with C. albicans or S. cerevisiae (1.8×105 cells/ml) in 10 mM sodium phosphate buffer
for 2 h at 37oC. The percentage of viable cells was calculated as (viable colonies in the presence
of peptide / viable colonies without peptide) × 100. The data represents three independent
experiments and the error bar represents the standard deviation.
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Figure 11: Circular dichroism spectroscopy of KM-12. CD spectra of KM-12 peptide in
sodium phosphate buffer pH 7 as well as in the presence of SDS micelles and DMPC liposome
were determined as outlined in the Materials and Methods. The calculated percentage of α-helix
and β-turn is indicated. CD spectra are displayed in mean residue ellipticity [θ].
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Figure 12: Stability of KM-12 in human saliva. A) HPLC profile of KM-12 following
incubation with human saliva for the indicated times as outlined in the Materials and Methods.
B) The determination of the half-life of KM-12 in human saliva.
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Ac-CFK
Ac-CFKRKY-Am

Figure 13: Mass spectrometry of KM-12 after exposure to human saliva. KM-12 was
incubated with human saliva for 60 min, the reaction was terminated and subsequently mass
spectrometry was performed to identify the cleavage site within the peptide. The putative
cleavage product is shown.
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Figure 14: The stability of KM-12 in artificial gastric juice. A) HPLC profile of KM-12
following incubation with artificial gastric juice for the indicated times as outlined in the
Materials and Methods. B) The determination of the half-life of KM-12 in artificial gastric juice.
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(KM-12)+4
Ac-CFKRKY-Am
Ac-CFKRKY-Am

Fragment 2
(Fragment 1)+2

KRKY-Am

Ac-CFKRKY-Am
Ac-CF

Figure 15: Mass spectrometry of KM-12 in artificial gastric juice. KM-12 was incubated
with artificial gastric juice for 0 min and 60 min, the reaction was terminated and subsequently
mass spectrometry was performed. The two samples were analyzed using ESI, and the data were
merged together to identify the proteolytic fragments. The putative cleavage product is shown.
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Figure 16: Stability of KM-12 in serum. KM-12 was incubated in 20% fetal bovine serum for
5 min, processed as described in Materials and Methods, and analyzed by HPLC. The KM-11
(monomer) and KM-12 (dimer) peaks are indicated.
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Candida species are the most common fungal pathogens that affect humans 1. Although
Candida species are primarily considered commensal microorganisms of the gastrointestinal,
urinary, and vaginal tracts of healthy individuals, they are also opportunistic pathogens and can
be associated with high levels of mortality2, 3. The incidence of Candida infections are
dramatically increased in immune compromised patients. For instance, research has shown 90%
of HIV patients had oral candidiasis. In terms of the economic burden to the health care system,
systemic Candida infections in the United States alone cost about 1.8 billion dollars and that
accounts for 70% of the overall fungal infection costs 4. Among all fungi, Candida albicans is
the major cause of both mucosal and systemic human infections.
Currently there are four categories of antifungal drugs: azoles, polyenes, echinocandins, and
antimetabolites. Each class has some limitations, and multiple cases of drug-resistant Candida
have been identified for each category. At therapeutic concentrations, azole compounds are
fungistatic and only a few members of this family of drugs can be used to treat systemic
infections. There are multiple genes that have been identified that affect resistance to azole
compounds in C. albicans (MDR1, CDR1, CDR2) 5, 6, C. glabrata (CDR1, CDR2)7, 8, and C.
dubliniensis (MDR1 , CDR1)9.
The polyene compounds, such as amphotericin B, while highly effective in killing fungi, have a
narrow therapeutic index, limiting clinical use to only the most severe cases where other
antifungals are not useful. Renal failure and nephrotoxicity are common consequences of
polyene treatment, and it has been reported that the rates of acute renal failure in patients on
polyenes are between 49% and 65% 10. Although fungal resistance to polyenes has not been a
major clinical problem, multiple cases have been reported in Candida species, including C.
albicans11, C. krusei12, C. lusitaniea13, C. glabrata 14 and C. tropicalis15.
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Echinocandins are the most recently discovered class of antifungal drugs introduced for clinical
use. Because of the relative high risk of acquiring resistance, echinocandins are not
recommended to be used as an initial therapy 16, 17. Echinocandin resistant strains of C. albicans
18

, C. krusi19, C. glabrata 20, C. lusitaniae21 and C. parapsilosis 22 have been observed in

patients.
Antimetabolites, such as 5-flucytosine, are considered fungistatic and the acquisition of
resistance occurs at a high rate. Thus, their use as a monotherapy is restricted, but can be
combined with other antifungal agents such as amphotericin B 23 to effectively treat patients as
needed. Again, several cases of resistant Candida species have been reported 24-26.
The limited arsenal of antifungal drugs coupled with the growing number of drug resistant
clinical isolates of Candida species stresses the need for the development of new antifungal
agents with new mechanisms of action 27, 28. The resistance to current drugs has, in part, resulted
from the excessive use of antifungals as an approach to prevent fungal infections in immune
compromised patients 29. In addition, some Candida species exhibit inherent resistance to the
current fungal drugs. For example, the majority of Candida glabrata clinical isolates are
resistant to fluconazole at therapeutically permissible concentrations, and Candida lusitaniae is
known to be resistant to amphotericin B30.
The average length of time for a drug to reach the market and get FDA approval is
approximately 15 years31. Therefore, the current focus on developing new antifungal drugs is a
logic step before our current arsenal of drugs fail. Additionally, designing new drugs with novel
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mode of action is essential. Antifungal drugs with novel mechanisms of action are less likely to
be affected by current resistance mechanisms and subject to the possibility of cross-resistance.
This research has focused on designing, developing and characterizing a novel family of
antimicrobial peptides which may serve as a model for new antifungal drugs. This family,
named Kumar-McNabb antimicrobial peptides (KM), was developed utilizing natural
antimicrobial peptide models. The KM peptides were developed in a multistep process: selecting
histatin 5 as a natural model, studying the structural requirement for histatin 5 activity,
identification of KM motif as the minimum functional domain of histatin, and finally utilizing
the KM motif to design a family of new peptides.
Histatin 5 as a model for a naturally occurring peptide. Besides their role in innate
immunity, antimicrobial peptides (AMPs) serve as promising candidates for new therapeutics.
AMPs are attractive models because they possess unique features such as broad activity, rapid
action, low microbial resistance and high selectivity 32. In general, the major source of new
AMPs is natural 33. Therefore, the search for a model peptide began by searching for AMPs that
exist in a common infection site for Candida species such as mucosal tissues, especially the oral
cavity 34. In the oral cavity, five different AMPs were identified; however, only three of them
exhibited significant antifungal activity: HNP1-4 , histatins and β-defensins 35. The histatins are
a family of histidine-rich cationic peptides produced by salivary glands 36, 37 and are considered
to be the first line of defense against Candida infections of the oral cavity 36. Histatin 5, a
member of the histatin family, has the most potent fungicidal activity among oral AMPs, and has
been studies extensively for several years 38, 39.
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Structural requirement of histatin 5 fungicidal activity. Histatin 5 is a histidine-rich peptide
composed of twenty amino acids. Several studies have shown that the full length peptide is not
required for fungicidal activity since an N-terminal truncated peptide, termed C-16 (a 16 amino
acid fragment of histatin 5), retains the full activity 40. Since histidine is the most abundant
amino acid in histatin, it would be presumed that the antimicrobial activity of the peptide would
be strongly affected by the pH of the environment. In fact, changing the pH from acidic to basic
is enough to shift the net charge from +14 to +5. Surprisingly, histatin 5 and C-16 retain the
same activity against C. albicans over a wide range of pH (5 - 9) which strongly suggests that the
histidine residues may not be involved in the antifungal activity.
The optimal number of positive charges and their role in histatin 5 fungicidal activities, as well
as the structural requirements for the fungicidal activity (represented by C-16 fragment) were
studied in this dissertation. Initially, four C-16 analogs were synthesized, referred to as C-16
(W), retro-C-16 (R) and two additional peptides containing only D-amino acids. The fungicidal
activities of the four peptides were examined against Candida albicans, as well as the effects of
temperature, EGTA (a chelator of divalet cations), sodium chloride, pH and sodium azide. The
stability in saliva and artificial gastric juice were also evaluated.
Our results have shown that all four peptides exhibited the same activity against C. albicans, and
the results of killing assays in the presence of common histatin 5 inhibitors (NaCl, sodium azide,
EGTA and low temperature) support the hypothesis that the analog peptides have the possibility
to work through the same pathway as histatin 5. Furthermore, the results suggested that the
mode of action doesn’t involve any receptor-mediated activity as the retro peptide and the Damino acid-containing peptides exhibited the same activity. Surprisingly, the four peptides were
also structurally similar and contained the same percentage of alpha helix in the presence of 50%
237

of TFE). The secondary structure studies of the retro and wild peptides using CD spectroscopy
showed that the retro and wild peptide largely adapt a random coil structure in aqueous solution.
The only difference observed between these peptides was the stability in gastric juice where the
C16 peptide was more stable than the retro peptide.
These initial studies yielded several important results. First, the antifungal activity of histatin 5
is likely to be related to the spatial relationship of the amino acids within the peptide rather than
the specific N-to C-terminal sequence or stereospecificity. Secondly, the antifungal activity was
shown to be dependent on the positive charges that come from arginine and lysine residues, but
not likely histidine. Thirdly, the characteristics of peptide’s killing activity and mode of action
imply that the four derivatives achieved the activity via same mechanisms pathways. Finally, our
studies and other’s indicate that a smaller region within histatin-5 derivatives may have potent
antifungal activity.
Identification of the KM motif, the functional domain of histatin 5. One of the general
problems utilizing therapeutic peptides as therapeutic agents is cost effectiveness. In order to
utilize a peptide as a commercial drug it must economically feasible to prepare. Over the past
two decades, several attempts have been carried out to optimize histatin 5 and attain the smallest
active fragment. P-113, a12 amino acid peptide, is the most effective and smallest fragment of
histatin 5-derived peptide developed to date.
After our studies with the retro C-16, we noted the presence of a small symmetrical sequence
within C-16 peptide that would not be affected by the orientation of the amino acid sequence
(retro or normal), and this fragment was (-YKRKF- , referred to as Kumar-McNabb or KM
motif). Furthermore, this sequence contained three positively charged residues that were
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required for the activity. The role of this KM fragment in histatin 5 anti-fungal activity was
investigated by establishing a sequence comparison using published histatin 5 fragments and
known analogs. The result revealed that the KM motif is found in every active fragment and any
change in KM sequence lead to the abolishment or a decrease in the activity.
The function of the KM motif in antifungal activity was evaluated with two pentameric peptides,
KM-5 and KM-6. Both peptides contained the same amino acid composition as the KM motif;
however, KM-5 had the retro amino acid sequence (FKRKY) while KM-6 (YKRKF) had the
normal sequence found in histatin 5. It is important to mention that those pentamer peptides were
acetylated and amidated to improve the stability. The activity of the pentamers against C.
albicans was evaluated and compared to C-16 peptide. Later, the similarities in the mechanism
of action were compared to the histatin 5 C-16 peptide by evaluating the effect of sodium
chloride, sodium azide, low temperature, as well as the activity against S. cerevisiae. Finally, the
general characteristics of KM-5 activity were measured by determining the LD50, the kinetics of
fungicidal activity, and the effect of pH.
Our results show that the KM motif is the shortest active fragment in histatin 5, and is less than
half the size of P-113. The activity of KM-5 is not affected in the retro orientation (KM-6) and
that may explain why the retro C-16 peptide retained full activity as C-16. The characteristics of
KM-5 fungicidal activity were similar to C-16 peptide and histatin 5. Moreover, like histatin 5,
active respiration is also required for optimal KM-5 activity. By synthesizing several KM-5
analogs, it was found that any interference with the positively charged amino acid residues
reduces the anti-fungal activity.
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Although KM-5 (LD50=5.5 µM) is less active than the C-16 peptide (LD50=3 µM), it is much
smaller and would be more economically efficient. Our results, supported by published data,
suggest that the KM motif might be the functional motif of histatin 5 and the C-16 peptide.
This study is not the first to report the presence of a common sequence in some histatin 5
fragments. KRKFHE has been reported as a common motif in the active fragments but its
activity has not been evaluated 41. Also KM-5 is not the only antimicrobial peptide with five
amino acid in sequence , several small anti-fungal42-44, antibacterial45, 46and antiviral 47peptides
have been reported including the antifungal drug family, the echinocandins.
Utilizing KM motif to design a new family of antimicrobial peptides. In this study, we
developed the KM-12 peptide, a potent antifungal peptide, utilizing KM-5 as a model. KM-12 is
a homodimeric peptide composed of two KM motifs, where a cysteine residue was introduced to
the N-terminus of KM-5 to facilitate dimerization through disulfide bond formation. It is
important to mention that the addition of cysteine didn’t interfere with activity as the monomer,
which retained the same activity as KM-5. With dimerization we achieved several targets.
Firstly, KM-12 peptide has a high probability to work via the same mechanism like histatin 5 as
the dimerization did not interfere with KM motif sequence. Secondly, from a cost effectiveness
point of view, KM-12 is cheaper to make than any other 12mer peptide because only a six amino
acid peptide (monomer) is required. Finally, the dimerization improved the activity
approximately 10-fold over the naturally occurring histatin 5.
Although several analogues were synthesized to improve fungicidal activity and salt tolerance,
it was found that the KM-12 sequence was the optimal. The studies of KM-12 antifungal
characteristics support the theory that KM-12 might work through the same mechanism of action
as histatin 5. KM-12 activity was inhibited by histatin 5 inhibitors such as sodium azide, sodium
240

chloride and low temperature. However, there were some differences noted. The kinetics of
yeast killing is faster with KM-12 than histatin 5 as KM-12 achieved 95% loss of viability in one
hour while histatin 5 achieved the same percentage killing after two hours. Furthermore, 2.5 µM
KM-12 had the ability to kill 95 % of S. cerevisiae on fermentable media while histatin 5 has
failed, as it required 25µM histatin 5 C-16 peptide to achieve 50% killing activity.
Focusing on the potential of KM-12 in the fungal drug market, the spectrum of KM-12 activity
against various Candida species was evaluated. KM-12 was tested against C. glabrata, C.
parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, C. kefyr and C. dubliniensis. Except for C.
glabrata, KM-12 exhibited a potent activity against all Candida species, including those that
displayed fluconazole resistance (C. tropicalis and C. krusei).
Regarding the possibility of manufacturing KM-12 peptides on a large scale, the synthesis
protocol and dimerization procedure were optimized. The optimal resin cleavage conditions were
achieved using a cleavage cocktail of 90% TFA, 5% Thioanisol, 3% Ethandithiol, and 2%
anisole. The optimal incubation time for cleavage was 4 hours and the optimum precipitation
buffer after cleavage was diethyl ether.
Because we sought an antimicrobial peptide for pharmaceutical application, the stability in
human fluids was evaluated using KM-12. As all AMPs, KM-12 was unstable in simulated
gastric juice and saliva. The t1/2 of KM-12 in gastric juice and saliva was 7.8 and 26 minutes,
respectively. We used mass spectrometry to identify the cleavage sites within KM-12 when
exposed to saliva and gastric enzymes, creating the possibility of resolving this problem via the
use of D-amino acids at the cleavage sites.
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The negative aspects of KM-12 are the fact that the disulfide bond linking the dimer is liable in
serum and the peptide is highly sensitive to salt concentration. One solution for resolving the
instability of the peptide in serum is to remove the cysteine residues and generate a ten amino
acid peptide. Salt sensitivity is a general problem in all cationic antimicrobial peptides. The
effect of salt was obvious using RPMI-1640 medium to simulate physiological conditions. The
fungicidal activity of KM-12 was improved by diluting the RPMI-1640 medium to reduce the
salt content. Although KM-12 is salt sensitive, it’s still more active in the presence of salt than
histatin 5. The salt sensitivity and instability in serum may narrow the usage of KM-12 to topical
application.
After we designed the KM-11 peptide (CFKRKY), a search on the database using the sequence
revealed that a similar sequence is found in multiple peptides, such as the C-terminus of MtDef4
peptide (FRRRCF) and the N-terminus of Lactoferricin B (FKCRRW). In spite of MtDef4
containing 46 amino acid, any interference with the C-terminal region inhibits the activity
against plant fungi Fusarium graminearum
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. Research on Lactoferricin B has shown that the

N-terminal sequence has the ability to suppress Candida cell growth 49 . Interestingly in both
peptides, the disulfide bond is not essential for the activity.
In summary, this study focused on developing a new family of antimicrobial peptides, later
referred to as Kumar-McNabb (KM) peptides, utilizing the histatin 5 peptide model. This family
is designed to serve as a model for the development of additional peptides that serve as
therapeutic agents for the treatment of Candida infections. Although a promising prototype
peptide was designed and evaluated, future research is needed to achieve maximum benefits and
solve problems associated with the prototypic peptide, KM-12.
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